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ABSTRACT 
 
Pharmacists as members of health care teams, have a central role to play with respect to 
medication. The pharmaceutical care and cognitive services which pharmacists are able to 
provide can help prevent, ameliorate or correct medication-related problems. There are however 
many barriers to the provision of these services and one of the barriers commonly cited by 
pharmacists is the lack of remuneration for their expert services. 
 
The aim of this study is to ascertain if patients in South Africa are willing to pay for pharmacist-
provided services which may reduce medication related problems, and thereby determine the 
perceived value of the pharmacist-provided services, by patients. The study will also seek to 
determine factors that influence willingness to pay (WTP), including financial status, gender, 
race, age and level of education. In addition the perceived value of the pharmacist‘s role in 
patient care, by third party payers (SA Medical Aid providers) and their WTP for pharmacist-
provided services (such as DSM) on behalf of patients through their monthly premiums will also 
be investigated. 
The study was conducted as a two-phase process: the first phase focused on the opinions of 
patients and the second phase on the medical aid companies. In phase-1 a convenience sample of 
500 patients was recruited by fifty community pharmacies distributed throughout the nine South 
African provinces. Data collection, consisting of telephonic administration of the questionnaires, 
was conducted and the survey responses were captured on a Microsoft Excel® spreadsheet. All 
the captured information was analyzed using descriptive statistics, box and whisker plots, 
analysis of variance (ANOVA) and regression analysis. In phase-2, medical aid schemes that are 
registered with the Council of Medical Schemes (CMSs) of South Africa were included in this 
research. A fifteen point questionnaire was completed electronically via e-mail by willing 
medical aid participants. Data was analyzed using descriptive statistics only. 
Only 233 or 88.6%, of the 263 participating respondents, were willing to pay at least one rand 
towards pharmacist-provided services. On average respondents were willing to pay R126.76 as 
out-of-pocket expenses. Respondents‘ WTP increased as the risk associated with medication-
related problems was reduced due to pharmaceutical care intervention. 
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Of the 263 respondents who took part in this research, fifty percent were willing to pay at least 
R100 for a risk reduction of 30%, R120 for a 60% reduction and approximately R150 for a 
greater than 90% risk reduction. It was also found that the respondents‘ willingness to pay was 
influenced by their age, earnings, racial grouping, employment status, medical aid status and 
their level of satisfaction with pharmacist-provided care services. 
Of the thirty-one open medical aid schemes only eight (25.8%) participated in the study. 
Findings indicate that all the participating medical aid respondents were unwilling to pay for 
pharmacist-provided care services, although they perceived pharmacists as very influential 
healthcare providers and as having a significant role to play in reducing medication-related 
problems. 
In conclusion it was found that majority of participants were willing to pay for pharmacist-
provided services directed towards reducing risks associated with medication-related problems. 
Until pharmacists are able to prove pharmaceutical care‘s utility and cost-effectiveness to third-
party payers, pharmacists must look to the patient for reimbursement. 
 
KEYWORDS: Pharmaceutical care, Pharmacist-provided services, medication-related problems, 
Contingency valuation method, Willingness to pay, Cost-benefit analysis 
 
 
 
 
 
 
 
 
Patients’ WTP for Pharmacist-Provide Services towards reducing risks of Medicine-Related Problems, in SA. Irvine Mushunje  xiv 
  
1 
1. CHAPTER ONE: INTRODUCTION 
 
1.1. BACKGROUND TO THE STUDY 
 
The efficient delivery of quality health care in society is dependent upon teamwork. The 
delivering team comprises, amongst others, doctors, nurses, dentists, psychiatrists, 
physiotherapists, dietitians as well as pharmacists. The contribution of each team member is as 
important as the other, with each group of health care professionals possessing a unique set of 
skills that are essential for the delivery of quality health care to the patient. 
 
Pharmacists as members of the health care team, have a central role to play with respect to 
medication. As defined by the Pharmaceutical Society of South Africa (PSSA), pharmacists are 
the custodian of medicines (Pharmaceutical Society of South Africa, 2010). They typically take a 
request for medicines from a prescribing health care practitioner in the form of a medical 
prescription and dispense the medication to the patient, counseling them on the proper use and 
any adverse effects the medication may have. 
 
The pharmacist, by virtue of their comprehensive education, plays a unique and important role 
pertaining to the health care needs of society. Pharmacists can offer a variety of useful and 
important health care services in the community, including consultation about medication 
therapy, detection and resolution of medication-related problems, therapeutic monitoring, patient 
education and disease state management (DSM). The pharmacist, by offering a comprehensive 
pharmaceutical care service, thus helps improve patient-care and quality of life. 
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1.2  MOTIVATION FOR THE STUDY 
 
Over the last two decades there has been an increase in over the counter medication and more 
frequent use of pharmacies. There has also been an increase in poly-pharmacy. Poly-pharmacy 
refers to ―the use of a number of drugs, possibly prescribed by different doctors and dispensed in 
different pharmacies, by a patient who may have one or several health problems (Anonymous, 
2000). Such practices expose patients to a higher degree of potential adverse drug reactions 
which could prove to be fatal in some cases. The longer patients use medication without proper 
management, the higher the risk of them experiencing medication-related problems. Since an 
increasing number of potent drugs is being prescribed for the management of disease states, 
some of which have a narrow therapeutic index, the potential for serious medication errors, 
adverse reactions and drug interactions has increased (Barner, 2004). 
 
The patients‘ need for acute and chronic medication is highly variable and individualized, but 
often patients are treated with standardized regimens that do not meet their individual needs. 
Standardized therapy may lead to flaring up of symptoms of the disease state, lack of compliance 
and discontinuing the regimen which, in turn may have detrimental effects. Many patients may 
also experience increased side-effects of their chronic medication as a result of inappropriate 
administration or incorrect dosage or drug regimens (Barner, 2004).  
 
In today‘s health care system, physicians often do not have sufficient time with each patient to 
provide an in-depth consultation (Anonymous, 2000). The onus is upon the pharmacist to take 
co-responsibility for the patient‘s medicine-related needs, an opportunity to make a difference in 
the community and improve the patient‘s quality of life. Besides the traditional provision of 
pharmaceutical products, pharmacists have a social responsibility to deliver pharmaceutical care, 
which includes cognitive pharmaceutical care services (CPCs) by identifying, preventing, and 
correcting medication-related morbidity and mortality. Cognitive services are those services 
provided by the pharmacist to or for a patient or health care provider that are educational in 
nature, such as disease state management (DSM) (Donald, 2000). 
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As indicated above, there is a need for the patient to consult regularly with a health care 
professional who is able to help to reduce medication-related risks and to improve the patient‘s 
quality of life. Studies have shown that, for many years, patients have been turning to the 
pharmacist for medical advice (Smith, Fasset, & Christensen, 1999; Hailemeskel, 2001). In some 
countries pharmacists have been providing specialized disease state management (DSM) 
programs to patients who suffer with asthma, diabetes, hyperlipidemia, hormone replacement 
therapy (HRT) and osteoporosis. According to studies undertaken in the United States of 
America (US) (Pauley et al.., 1995; Kelso et al., 1995; Smith et al., 1999; Gillespie & Rossiter, 
2003), a number of pharmacists have been providing asthma disease management programs. 
 
However, only a few of them actually offer their services to the general public for a fee. Many 
significant benefits have been observed with asthma DSM programs, which entailed educating 
the patients by providing them with a better understanding of their condition and symptoms. 
These benefits include reduction in the number of visits to emergency departments; decreased 
hospitalization due to asthma flare-ups; decreased days of work missed due to asthma symptoms; 
improvement in asthma symptoms, and improvement in overall quality of life (Suh, 2000).  
 
Although there seems to be opportunity and interest in the provision of cognitive pharmaceutical 
care services such as DSM and patient-counseling, there are several barriers that hinder the 
provision of these services in the South African context. One of the challenges for the pharmacy 
profession in South Africa has been the change in the pricing regulations of medicines. 
Traditionally the pharmacist was remunerated for their cognitive services and expertise offered 
to the patients through profit on the sale of medicines. However the new South African pricing 
regulation (Single-Exit-Pricing or SEP system) enforces a transparent pricing system, which does 
not allow any profit on sale of medications (Government Gazette 25872 and 26304). Changes in 
pharmacy ownership laws have also seen the emergence of corporately owned pharmacies and 
have put immense pressure on the independent community-pharmacist in South Africa. In order 
for the community pharmacist to survive these changes they have to consider charging their 
patients for consultation and for the provision of CPCs. 
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The South African Pharmacy Council (SAPC) has been involved in the development of rules, 
and guidelines relating to the services for which a pharmacist may levy a fee and the guidelines 
for levying such a fee. The rules relating to such services were published in the Government 
Gazette in 2004 (29463). 
 
Legislative changes including the introduction of the SEP, although considered to be detrimental 
to the profession, may subsequently have become the driving force for positive change. The 
focus has now shifted from retailing medicinal products to the provision of professional 
pharmaceutical services. In the past a pharmacy‘s revenue had been based on the total number of 
prescriptions a pharmacist could dispense in a day and investing in high levels of patient care 
reduced dispensing time (Larson, 2000).    
 
Pharmacists now have to look to the patients and third party payers (medical aid schemes) for 
remuneration for the cognitive services they render. However there are obstacles to this, 
including: the fact that these services were provided free of charge in the past, thus making it 
difficult to initiate a payment system. Besides the reimbursement obstacle, other barriers to the 
provision of cognitive pharmaceutical care services have been researched. Barriers often cited 
include: not enough time to talk to patients, no private counseling area in the pharmacy, not 
enough training, misperception by pharmacists of a lack of demand for pharmaceutical care, and 
trepidation regarding the reaction of physicians (Lourie & Robertson, 1993; Shepherd, 1999; 
Oparah & Eferaleya, 2005; Babiker, 2008). 
 
It is imperative to elicit and understand the patients‘ willingness to pay (WTP) for 
pharmaceutical services rendered to them. Thus patients‘ willingness to pay is a good indicator 
of the value of utility placed on the therapeutic benefits of services rendered to them by 
pharmacists (Larson, 2000). 
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2. CHAPTER TWO: PROVISION OF PHARMACEUTICAL CARE SERVICES 
 
2.1. INTRODUCTION AND DEFINITION OF PHARMACEUTICAL CARE 
 
Over the past decades, the pharmacy profession has experienced significant changes worldwide, 
particularly regarding the philosophy of practice, educational requirements and ethical codes 
(Schneider & Nickman, 1994). The philosophy of pharmaceutical care has been accepted as the 
mainstay and primary mission of pharmacy into the twenty-first century. Pharmaceutical care 
mandates that practitioners not only dispense medicines, but also assume responsibility for 
improving the quality of patient‘s outcomes (Hepler & Strand, 1990). Traditionally professional 
services provided by pharmacists were exclusively drug-orientated. The role of a pharmacist has 
evolved since the nineteenth century, from compounding medicines from raw materials to 
dispensing pre-packed medicinal products (Higby 1990). The traditional role of the pharmacist 
that is preparing, dispensing and selling of medication is no longer adequate for the pharmacy 
profession to survive in the evolving healthcare environment. 
 
With development of the philosophy of pharmaceutical care, Hepler and Strand (1990) have 
provided the impetus for a change in the model of pharmacy practice and pharmaceutical care 
that has become the dominant practice for thousands of pharmacists around the world. Currently 
pharmaceutical care is understood as the pharmacist‘s intervention to obtain maximum benefit 
from the pharmacological treatment of patients, with the pharmacist taking responsibility for the 
pharmacotherapy outcomes (Berenguer, La Casa, de la Matta, & Martin-Calero, 2004). 
 
Pharmaceutical care is defined as the direct, responsible, provision of medication-related care for 
the purposes of achieving definite outcomes that improve the patient‘s quality of life (Hepler and 
Strand 1990). Although the concept of pharmaceutical care has been accepted worldwide, it is 
still a relatively new concept to be implemented in most developing countries (Berenguer, et al. 
2004). There has also been much debate on the definition of pharmaceutical care as a result of 
the differences in pharmacy systems and health care structures in different countries (Berenguer, 
et al. 2004). 
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Under the ―Pharmaceutical Care‖ model, the patient delegates decision-making authority to the 
pharmacist; with the perception that the pharmacist has a better knowledge of the patient‘s 
medication-related needs and is in the best positon to make a therapeutic decision in their  best 
medical interests to achieve definite results that improve their quality of life (QoL) (Hepler & 
Strand, 1990). The epicenter of pharmaceutical care is genuine provision of care to the patient 
rather than merely product provision. Although a conducive environment for the provision of 
such care is necessary, pharmaceutical care does not only entail attractive private consultation 
areas, it also requires detailed patient records, adequate computer systems, performing 
pharmacokinetic calculations and responding to drug-related queries (Rovers, Currie, Hagel, 
McDonough, & Sobotka, 1998). 
 
Although the above procedures are integral to the provision of pharmaceutical care, the emphasis 
of this new practice-philosophy promotes and demands more direct interventions and 
involvement on the part of the pharmacist, in the overall patient care, beyond the supply of 
medications (Carter & Barnett, 1996). 
 
Pharmaceutical care is about caring and having a genuine concern for patients and spending the 
time and effort to assist them. For pharmaceutical care to actualise, pharmacists need to co-
operate with patients and other healthcare providers in designing, implementing, and monitoring 
a care plan aimed at preventing and resolving medication-related problems (Rovers, et al. 1998; 
Babiker, 2008). 
 
Pharmacists need to be the driving force behind the transformation and implementation of 
pharmaceutical care practices. Thus, the pharmacists‘ own perception, attitude, knowledge and 
skills pertaining to the philosophy and practice are the cornerstone to the realisation of the 
philosophy into a practice. 
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2.2. THE EVOLUTION OF PHARMACY PRACTICES 
 
Summers (1996) suggested that, by tracing the path of pharmacy through recorded history, by 
analyzing the current function of the pharmacist and by examining the basic requirements we can 
show the importance of pharmacy in healthcare. 
 
Pharmacy practice is a slowly-evolving and ongoing professional movement, which has evolved 
from zero and minimum patient contact to a higher degree of provision of direct patient-oriented 
services as depicted in Figure 2.1 shown below (Babiker, 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Evolution of Pharmacy Practice. (Babiker, 2008) 
*(PC = Pharmaceutical Care) 
 
The practice of pharmacy has evolved and transformed in three substantial phases as depicted 
above, namely: the drug distribution era; the clinical pharmacy phase, and the pharmaceutical 
care era. 
 
 
 
1990s 
1960s 
Drug distribution 
Clinical Pharmacy 
*PC 
Product-oriented        
service 
Disease-oriented        
service 
Individual patient 
oriented service      
service 
Zero patient contact     
Physician contact > patient 
contact or minimal 
Higher degree of patient contact     
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2.2.1. Drug distribution era (prior to the 1960s): 
 
Prior to the 1960s pharmacists were known as apothecaries since most of the drug-related 
formulations in those days required compounding from raw materials. The apothecaries‘ role 
entailed supplying, preparing and compounding medicinal products. The pharmacist‗s primary 
responsibility was to assess that the products sold were pure, and prepared according to the 
internationally-accepted standards as described for example in the British Pharmacopeia (BP). 
The pharmacist‘s role gradually faded as the pharmaceutical industry emerged. In the US, in 
1951, an amendment to the Food, Drug and Cosmetic Law effectively relegated the retail and 
hospital pharmacist to a dispenser of pre-formulated drugs. Industrial pharmacists however, were 
in great demand to craft the formulations for the drug manufacturer (Berenguer, La Casa, de la 
Matta, & Martin-Calero, 2004). 
 
2.2.2. Clinical Pharmacy Phase: 
 
The clinical pharmacy phase emerged, and was pioneered, in the mid-1960s in American 
hospitals. It expanded the scope of practice and laid a foundation for a modern patient-oriented 
profession. This practice may also have been known as the Drug Use Control, which entailed the 
provision of structured services by pharmacists to meet the drug-related needs of patients, 
physicians and nurses within hospital and institutional environments, for the optimization of drug 
therapy. Unfortunately outpatients were neglected in the process. Regardless of the positive 
contribution to professionalism afforded by clinical pharmacy, the skewed approach and 
outcomes stimulated the further evolution of pharmaceutical practice towards pharmaceutical 
care (Berenguer, et al. 2004). 
 
2.2.3. Pharmaceutical Care (PC) Phase 
 
This is the more patient-focused stage that began to emerge in the 1990s and is still evident 
today. In the patient-care era, pharmaceutical care has become the mainstream function of 
pharmacists, as the therapeutic advisors and gate keepers for rational drug usage (Babiker, 2008). 
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Table 2.1 summarizes and describes some of the key events, legislation, conferences and 
literature which have contributed to the evolution of professional services in pharmacy. 
 
Table 2.1: The evolution of the professional services in pharmacy 
YEAR SUBJECT 
(event/article/held conference) 
Comments 
1951 Food, drug and cosmetics Amendment of Durham-Humphrey to the 
law of Food, Drug and Cosmetics resulted in 
the relegation of the pharmacist to a mere 
dispenser of drugs 
 
1960 Clinical Pharmacy Pioneered in some American hospitals 
Authors: Hepler 
Aim: to expand the professional practice of 
the pharmacist to a more patient oriented  
service 
 
1975 Millis Report ―Pharmacist of the 
future‖ 
Authors:American Association of College 
of Pharmacies (AACP) 
Aim:the need to involve pharmacists in the 
control of rational drug use. 
 
1979 Standards of Good Pharmaceutical 
Practice 
Formulated by the AACP and the American 
Pharmaceutical Association (APA) 
Aim:standardization of pharmaceutical 
practice 
 
1984 Pharmacy in the 21
st
 Century 
Conference 
 
Aim: transformation of the community 
pharmacies from product-based practice to 
clinical-based practice 
 
1985 Hilton Head Conference Charles Hepler (1985) first introduced the 
term pharmaceutical care. 
Aim: encouraged pharmacists to take 
responsibility for their own profession and 
take responsibility of the patients‘ drug-
related needs for a better therapeutic 
outcome. 
 
1988 PWDT (Pharmacist Workup of Drug 
Therapy) 
Authors: Cipole, Strand & Morley (1988)  
Aim:to standardize the documentation of 
clinical pharmacists‘ database, patient-care 
and therapeutic plans. 
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1989 Opportunities and responsibilities in 
the pharmaceutical care 
Authors: (Charles Hepler; Linda Strand, 
1989). 
Aim:emphasized the need for pharmacists to 
deviate from factionalism and adopt patient-
center pharmaceutical care as their 
philosophy of practice. 
In this article they argued that drug-related 
morbidity and mortality were preventable 
and that implementation of pharmaceutical 
care services could reduce the number of 
adverse drug reactions, the length of stays, 
and the cost of care. 
1990 The 1990s‘ mission of the pharmacy 
profession 
ACCP presented the idea of pharmaceutical 
care as the 1990s‘ mission of the pharmacy 
profession. 
Aim: encourage pharmacists to share in 
responsibility for therapeutic outcomes and 
highlighted ways of overcoming the barriers 
to the provision of pharmaceutical care 
1990 Definition and categorization of Drug-
Related problems (DRPs) 
 
Authors: (Strand, et al 1990). 
Aim: define and categorize DRPs; DRPs 
were categorized into eight different 
categories 
1990 The Omnibus Budget Reconciliation 
Act (OBRA 1990) 
Required pharmacists to counsel patients 
after dispensing medications. Implemented 
in 1993 as a prospective drug-use review for 
medical aid recipients. 
1991 First course on ―Research methods in 
pharmaceutical care‖, Hillerod 
(Denmark) 
The Danish college of Pharmacy practice 
organized the first course on pharmaceutical 
care research methods. 
 
1992-95 Minnesota Pharmaceutical Care 
Project 
The project was designed by the Pharmacy 
department of the University of Minnesota 
Aim: was to determine whether an 
innovative professional practice was feasible 
in the community. 
1993 WHO document on Pharmacists‘ role 
in Health care (FIP Conference in 
Tokyo) 
Aim: cementing the implementation of 
pharmaceutical care 
 
1994 Creation of PCNE (Pharmaceutical 
Care Network Europe) 
European research platform created with the 
aim of coordinating activities and 
implementation of pharmaceutical care 
Table 2.1 adopted from (Berenguer, et al. 2004) 
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2.3.   PHARMACEUTICAL CARE IN-RELATION TO MODERN HEALTHCARE 
 
Modern medicines and medical practices have become more advanced, more effective and 
specific in a bid to reduce health care costs, increase availability of medications and improve 
health care outcomes (Nahata 2000). Modern information systems implemented to make it 
possible to define; measure and compare patient outcomes. This technological advancement has 
contributed significantly to the growth of managed care and outcomes management. 
 
These changes in healthcare practices necessitate pharmacists changing to a more collaborative 
pharmacy-managed care. Pharmaceutical care, an aspect of managed care, is an evolving concept 
in which the pharmacist provides services that extend after a physician‘s care has ended, for 
example by reviewing a drug‘s intended use, checking for drug interactions, counseling patients 
on compliance and optimal drug use. Pharmaceutical care necessitates changing role by 
practicing pharmacists, from the traditional product-oriented to a more patient-oriented 
professional practice (Martín-Calero et al, 2004). Figure 2.2 depicts the ideal healthcare mode; 
that is dispensation of pharmaceutical care with patient at the core of inter-professional 
relationship (Martín-Calero et al, 2004). 
Health Care model 
   
 
 
 
 
 
 
 
 
 
 Improved professional 
relationship 
 Patient focused 
 Improved 
understanding of 
disease state and goals 
of therapy 
 Improved adherence to 
therapy 
 Reduced risk of 
medication-related 
problems 
Nurse
s 
Care givers 
Pharmacists 
Other 
Specialist
s 
Patient 
Family physician 
Optimal therapeutic outcome 
Figure 2.2: The ideal healthcare model (Martin-Calero, et al. 2004) 
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Pharmacists, when involved in collaborative managed care, have contributed significantly to 
reductions in adverse drug reactions and improvements in other measurable outcomes (Academy 
of Managed Care Pharmacy, 2008). The evolution of the profession into a more patient-oriented 
practice has helped to maximise contributions  pharmacists have made in reducing the cost of 
healthcare by decreasing the incidence of medication-related problems (MRP) or better termed 
―drug misadventuring‖ (Mannase, 1989). Drug misadventuring or medication related problems 
(MRP) includes, but is not limited to, overdosage, subtherapeutic dosages, improper drug 
selections, drug interactions, adverse reactions, drug non-compliance and untreated conditions. 
Studies have shown that as many as 27% hospital admissions are attributed to medication-related 
problems (McKenney & Harrison, 1976). 
 
Many authors have cited the effectiveness of the implementation of pharmaceutical care 
interventions by pharmacists, through the provision of such cognitive services and diverse 
clinical management of disease states (Shu Chuen Li, 2003). Some of the areas of intervention, 
as cited by Shu Chuen Li (2003), may include asthma-management, rational use of antibiotics, 
cardiovascular risk monitoring, hypertension management, medication review, health promotion 
and disease prevention, pain management, patient counseling, palliative care, geriatric care and 
smoking cessation programs (Shu Chuen Li, 2003). 
 
Table 2.2 is asummary of some of the articles cited on pharmacist-intervention studies discussed 
above. 
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Table 2.2: Outcomes of Intervention by Community Pharmacists  
 
Areas of Intervention Types of Intervention Clinical Outcomes Cost Savings 
Pain Management 
Read & Krska 1998 (UK) 
Medication review for 
patients with Chronic pain 
Pain score using McGill pain 
questionnaire and visual 
analogue scale improved in 
patients re-interviewed after 
pharmacist intervention 
(p<0.001) compared with 
baseline (p<0.001). 
Not presented 
Smoking Cessation 
Crealey et al, 1998 (UK) 
 
Formal counseling on 
smoking cessation  
Higher cessation rate in the 
formal counseling group than in 
the control group (p<0.01) 
£196.76-351.45/life-year 
saved (men); £181.35-
£772.72/life-year saved 
(women). 
Rationale Antimicrobial 
usage 
De Santis et al, 1994 
Australia 
Educational campaign 
targeting general 
practitioners 
Better compliance to guidelines 
in the intervention group than in 
the control group (81.7% vs 
71.7% p<0.05) 
Not reported 
Asthma Management  
Narhl et al; 2000 
(Finland) 
Pharmacist-directed 
therapeutic monitoring 
program 
Patients in the intervention 
group experienced 
improvement in lung function 
(p<0.001) compared with the 
control group. 50%ofpatients 
on the intervention group had 
their medication changed to one 
that best suited them. 
Not reported 
Cholesterol Screening and 
Management 
Simpson et al, 2001 
(Canada) 
Pharmacist-directed lipid 
management program 
10-year risk of cardiovascular 
disease decreased from 17.3% 
before intervention to 16.4% 
after intervention (p<0.0001). 
Incremental costs to a 
government payer and 
community pharmacy 
manager were 
$Can6.40/patient and 
$Can21.76/patient, 
respectively. 
Krska et al, 2001 
(UK) 
Medication review for 
elderly patients with 
multiple drugs 
More pharmaceutical issues 
resolved in the intervention 
group compared to the control 
group at 3months (70 vs 14%: p 
<0.001). 
Not reported 
Zermansky et al, 2001 
(UK) 
Medication reviews for 
patients with repeat 
prescriptions 
The intervention patients had a 
small rise in the number of 
drugs prescribed compared with 
the control group (p<0.02). 
Not presented 
Patient Counseling 
Hammarlund et al, 1985 
(Sweden) 
Counseling sessions about 
drug use after the initial 
assessment 
11% decrease in the number of 
prescriptions filled (p<0.05) 
and 39% decrease in the 
number of medication 
behaviour problems (p<0.001) 
vs baseline. 
Not presented 
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Disease Prevention 
Van Amburgh et al; 
2001 (US) 
Education campaign 
targeting high risk patients 
The influenza vaccination rate 
increased from 28% at baseline 
(before program initiation) to 
54% at program initiation 
(p<0.05) 
Not reported 
Proactive Pharmaceutical 
Care 
Munroe et al; 1997 (US) 
Targeted patient education 
and systematic monitoring. 
Assisting behavior 
modification, and interaction 
with physicians to initiate 
early intervention of drug-
related problems 
 
 
Not reported 
Saving ranged from 
$US143.95/patient/month 
(conservative estimate) to 
$US293.95/patient/month 
(when accounting for the 
possible influence of age, 
co-morbid conditions, and 
disease severity). 
Benrimoj et al; 2002 
(Australia) 
Proactive clinical 
intervention and patient 
counseling 
Not reported Savings of $A85.35 per 
thousand prescriptions. 
Medication Review 
Hanlon et al; 1996 
(US) 
Evaluation of drug regimens Significantly greater reductions 
inappropriate prescribing scores 
in the intervention group than in 
the control group (reductions of 
24 or 6% in 3months 
[p<0.0006] and 28 or 5% at 
12months [p<0.0002]. Fewer 
patients with adverse drug 
reactions in the intervention 
group than in the control group 
(30.2%vs 40% p<0.019).  
Not reported 
Benrimoj et al; 2002 
(Australia) 
Proactive clinical 
intervention and patient 
counseling 
Not reported Savings of $A85.35 per 
thousand prescriptions. 
 
 
 
The table above is neither exhaustive nor comprehensive. It provides some examples of 
pharmacist interventions, which have demonstrated positive clinical outcomes in variable 
degrees and also reports cost-savings. 
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2.4.      THE PRACTICE PRINCIPLES OF PHARMACEUTICAL CARE 
 
2.4.1. The principal goals of pharmaceutical care 
 
The principal elements, of pharmaceutical care, are medication related; it is care that is directly 
provided to the patient; and its goal is to optimize the patient‘s health-related quality of life and 
to produce definite clinical outcomes. In pharmaceutical care the provider accepts co-
responsibility with the patient for the outcomes. These outcomes may include: reduced 
medication-related problems, cure of a disease, improved adherence to chronic treatment, 
elimination or reduction of symptoms and arresting or slowing a disease process (Hepler and 
Strand, 1990). 
 
In order to attain the goals of pharmaceutical care a holistic structured approach is required, 
which includes: 
 established patient-pharmacist relationship; 
 patient-specific information to be collected, organized, recorded, monitored and 
maintained; 
 patient-specific medical information to be evaluated and a therapeutic care plan to be 
established involving the patient and the prescriber; 
 linking each medication to an appropriate indication; 
 identifying actual or potential drug therapy problems; 
 resolving and/or preventing drug therapy problems; 
 the pharmacist should ensure that the patient has all supplies, information and 
knowledge to carry out the therapy care plan; 
 documenting appropriately and; 
 monitoring and modifying the therapeutic plan, by the pharmacist, in consultation 
with the patient and healthcare team (Rexy and Shruti, 2006). 
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2.4.2. The Principal elements of Pharmaceutical Care 
According to Rexy and Shruti (2006) elements required to effectively provide pharmaceutical 
care may include: 
 knowledge and skills of  trained personnel; 
 systems for data collection, documentation, and transfer of information; 
 efficient workflow processes; 
 references, resources and equipment; 
 good communication skills and; 
 Commitment to quality improvement and assessment procedures. 
The provision of pharmaceutical care necessitates teamwork which is a collaborative effort 
between the prescriber, the nurse, the pharmacist and the patient. The pharmacist should be able 
to communicate effectively with the healthcare team as well as with the patient. Pharmaceutical 
care is also dependent on the establishment of a therapeutic relationship between the pharmacist 
and the patient (Hepler & Strand, 1990). Within the context of a therapeutic relationship the 
pharmacist is required to assess the patient‘s drug-related needs from the perspective of each 
patient‘s unique medication experience (Strand & Cipolle, 2004). Medication experience has 
been defined as the sum of all events in a patient‘s life that involve medication use, these may 
include: patient‘s expectations, wants, preferences, values, attitudes and beliefs, cultural, ethical 
and religious influences (Strand & Cipolle, 2004). 
According to Strand and colleagues (2004), the patient care process entails three steps, namely: 
the assessment, the care plan and the follow-up evaluation as shown in Figure 2.3. 
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Components and objectives of providing patient-care 
 
 
 
 
 
 
 
 
Figure 2.3: Adopted from; Current pharmaceutical design, (Strand, et al. 2004). 
Although the pharmacist takes full responsibility, the patient is considered an active participant 
in care planning and is the ultimate decision maker. Pharmaceutical care creates a therapeutic 
bond between the pharmacist and the patient (Cipolle, Strand, & Morley, 2004). Effective 
communication does not only warrant a good pharmacist-patient symbiotic relationship, but 
establishes a good patient counseling platform, consequently promoting adherence and reducing 
dispensing errors. 
In order to adopt a pharmaceutical care approach, the pharmacist requires advanced counseling 
skills, sound clinical knowledge including disease states, drug-related knowledge, and 
information concerning the patient (Rexy & Shruti, 2006). The pharmacist has to possess 
sufficient skills and experience to gather all this information and integrate it appropriately. In the 
provision of pharmaceutical care, the role of the pharmacist does not only involve the traditional 
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dispensing methods or supplying of medication, but entails decision-making about medication 
use by patients. 
The philosophy of pharmaceutical care clearly states that the pharmacist has to accept 
responsibility for the patient‘s drug-related needs, to identify, resolve and prevent each patient‘s 
medication-related problem (Strand and Cipolle, 2004). Medication-related problems (MRPs), as 
shown in Figure 2.4 may include untreated indications, improper drug selections, wrong dosage 
(either too low or too high), adverse drug reactions, drug interactions and poly-pharmacy. 
Categories of Medication-related Problems (MRP)/Drug-related Problems(DRP) 
 
 
 
 
 
 
 
Continuous Professional Development (CPD) is important to increase a pharmacist‗s knowledge 
(Awad, Al-Ebrahim, & Eman, 2006). Pharmaceutical societies and associations, managed care 
organizations, government health institutions and educational institutions should participate in 
the continuous development of pharmacists‘ knowledge and advanced skills. The institutions 
need to understand patient care and pharmaceutical care and the benefits thereof, in order to 
formulate a unit standard of pharmaceutical care implementation (Awad, Al-Ebrahim, & Eman, 
2006), enabling professional re-modeling. 
Indication Drug Product Dosage Regimen Outcome 
MRP 
Unnecessary drug therapy 
Needs additional drug therapy 
MRP 
Effectiveness: Ineffective drug 
Safety: Adverse drug reaction 
MRP 
Effectiveness: dosage too low 
Safety: dosage too high 
MRP 
Compliance issues 
SAFETY 
EFFECTIVENESS 
MR
MR
MR
MR
Figure 2.4: Adopted from; Current pharmaceutical design, (Strand,et al.2004). 
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The pharmacy curriculum should have a patient-centered focus, preparing practitioners with 
extensive clinical knowledge and skills, enabling them to develop as critical thinkers, problem 
solvers, good communicators, empathetic practitioners capable of respecting their patients and 
working collaboratively with other healthcare professionals. 
Strand and Cipolle (2004) proposed a set of Professional Behavioral Practice Standards (Table 
2.3) which are consistent with pharmaceutical care service delivery (Strand & Cipolle, 2004). 
Table 2.3: Professional Behavior Practice Standards for PC Practice 
Category Standard 
Quality of Care The practitioner evaluates his/her own practice in relation to 
professional practice standards and relevant statutes and 
regulations. 
Ethics The practitioner‘s decisions and actions on behalf of patients are 
done in an ethical manner. 
Collegiality The pharmaceutical care practitioner contributes to the 
professional development of peers, colleagues, students and 
others. 
Collaboration The practitioner collaborates with family, and/or caregivers, and 
healthcare providers in providing patient care. 
Education The practitioner acquires and maintains current knowledge in 
pharmacology, pharmacotherapy, and pharmaceutical care 
practice. 
Research The practitioner routinely uses research findings in practice and 
contributes to research findings when appropriate. 
Resource Allocation The practitioner considers factors related to effectiveness, safety, 
and cost-in-planning and delivering care. 
Adopted from; Current pharmaceutical design, (Strand,et al.2004). 
 
Provision of pharmaceutical care entails a systematic approach to the dispensation of care, and a 
defined set of practice standards can help to ensure this across the profession (Rexy & Shruti, 
2006). 
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Once a therapeutic relationship has been established, the pharmacist designs and implements a 
care plan. In the process he or she collaborates with other healthcare providers and the patient to 
identify and evaluate the most cost-effective intervention. The patient should be involved in the 
decision-making to ensure commitment and adherence to the pharmaceutical therapy plan. After 
the data collection and planning, the pharmacist needs to document the pharmaceutical therapy 
plan and the desired outcomes of each problem identified (Rovers, Currie, Hagel, McDonough, 
& Sobotka, 1998; Rexy & Shruti, 2006). 
Documentation does not only serve as a legal record of care that is provided but also provides 
evidence of pharmacist intervention and can also be used as a future reference point. It is also an 
essential reference point for reimbursement purposes (Simpson, 1997; American Society of 
Hospital Pharmacists, 1993). To ensure positive outcomes the pharmacist regularly reviews the 
patient‘s progress and communicates with other appropriate healthcare providers. 
Pharmaceutical Care (PC) can be considered as medication-related care since pharmacists have 
the widest knowledge in the science and use of medicines, and pharmaceutical care focuses on 
empowering and protecting patients (Rexy & Shruti, 2006). 
Pharmaceutical care is therefore a healthcare need associated with any drug therapy and is a 
shared responsibility for healthcare professionals and health workers (King & Fomundam, 2010). 
Pharmacists can serve as a key mechanism in the global healthcare machine, since they are the 
legal custodians of medicines and often the first point of contact for provision of primary health 
care (Commonwealth Pharmaceutical Association, 2005). Pharmaceutical care interventions 
have the potential to be cost-effective, in other words interventions benefit patients whilst 
reducing healthcare utilizations and costs associated with medication-related problems. 
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2.5. BARRIERS TO THE PROVISION OF PHARMACEUTICAL CARE 
 
The implementation of pharmaceutical care has been progressing worldwide since its adoption in 
the 1990s when it became more patient focused; however there have also been several barriers 
and challenges to its implementation. The barriers that hinder the provision of pharmaceutical 
care have been cited in multiple journal articles; these barriers include: insufficient time to 
counsel patients, dispensary counseling area not conducive for a one-to-one interface with the 
patient, insufficient training, misconception on the role of the pharmacist in healthcare, 
trepidation regarding the reaction of the physician, pharmacists‘ misperception of the lack of 
demand for pharmaceutical care, and reimbursement for pharmaceutical care (Al Shaqua & Zairi, 
2001; Shu Chuen Li, 2003). 
 
The barriers to implementation of pharmaceutical care which must be overcome by pharmacists 
can be categorized as environmental, attitudinal and economic in nature. 
 
2.5.1. Environmental barriers to provision of Pharmaceutical Care 
 
These may include the nature and structure of the healthcare systems and the lack of access to 
drug-therapy related information (Shu Chuen Li, 2003). The dispensing areas and designated 
counseling areas in most pharmacies are not conducive to one-on-one counseling with the 
patient, thus creating a physical barrier between the pharmacist and the patient. This physical 
barrier inhibits the pharmacist-to-patient relationship; it also inhibits the exchange of essential 
information and ultimately pharmaceutical care outcome (Al Shaqua & Zairi, 2001). 
Furthermore the structure of the healthcare system often deprives the pharmacist of the primary 
clinical data necessary to participate in the initial drug therapy decision-making process. 
 
The lack of such information and isolation from the place of primary diagnosis not only hinders 
the pharmacist from making any meaningful contribution but also limits the pharmacist to 
secondary drug therapy management. This places a pharmacist in a position of problem-solving 
as opposed to problem-preventing. Therefore the secondary information utilized by pharmacists 
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mostly limits their ability to ensure an effective rational drug therapy outcome (Al Shaqua & 
Zairi, 2001). 
 
2.5.2. Attitudinal barriers 
 
The attitudes of physicians, pharmacists, patients and other healthcare payers significantly hinder 
the implementation and provision of pharmaceutical care (Shu Chuen Li, 2003). Owing to 
constrained relationships between physicians and pharmacists there is a misconception of the 
role played by the pharmacist in the healthcare delivery system. This often results in the 
perception by patients that doctors are the sole providers of care and pharmacists are simply the 
providers of drug products (Al Shaqua & Zairi, 2001; Strand & Hepler, 1997). The root of this 
misconception however may even lie with the pharmacists. 
 
First and foremost, it is important that pharmacists change their attitudes about their abilities to 
participate in patient care. The pharmacist needs to gain confidence in their ability to deliver 
pharmaceutical care and present themselves as the capable professionals they are. They need to 
convey the message that they are willing providers of healthcare to patients, to other healthcare 
professionals, to third-party payers and to healthcare administrators (Shu Chuen Li, 2003). 
According to the practice philosophy of pharmaceutical care this requires that a good therapeutic 
relationship be established with patients (Strand & Hepler, 1997). 
 
A survey conducted in California, US, which included 2600 physicians, showed that physicians 
did not know what to expect from the pharmacist as a partner in the healthcare team (Smith, Ray, 
& Shannon, 2002). Pharmacists need to communicate, define and market their pharmaceutical 
role to physicians and dispel their own fears of role duplication. Pharmaceutical care is not 
intended to replace the role of the physician or any other practitioner but it is rather directed at 
caring for and improving the quality of life of a population. Owing to the increase in 
consumption of drug-related products, poly-pharmacy and an increase in drug related morbidity, 
the pharmaceutical role only complements the roles of other healthcare professionals, whilst 
addressing the needs of a society (Gonzalez-Martin, Joo, & Sanchez, 2003). 
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2.5.3. Economic barriers 
 
Economic barriers to the provision of pharmaceutical care include limited resources such as time, 
money and trained personnel, as well as reimbursement issues. The economic barriers are 
considered the most difficult impediments to overcome internationally (Shu Chuen Li, 2003). 
Most pharmacists claim they do not have sufficient time to provide pharmaceutical care, 
although they are investing ample time in de-skilled traditional activities that are product-
oriented activities (Rovers, Hagel, McDonough, & Sobotka, 1998; Al Shaqua & Zairi, 2001). 
The supply of drugs is considered the core of the business and the cognitive provision of care 
will only be considered if one has extra time and staff available. Inorder for pharmacists to be 
available for patient care they need to be freed from their technical role and make use of the 
assistance of pharmaceutical technical assistants. 
 
Although delegation of their technical function will allow for more time to provide 
pharmaceutical care, it also means the pharmacy has to incur extra costs to invest in the extra 
labour required (Shu Chuen Li, 2003). However, according to a study considering costs of 
implementing pharmaceutical care, and the turnaround revenue, conducted by Norwood and 
colleagues (1998), it has been shown that those pharmacies that spent more on capital converting 
from traditional practices to modern practices were more successful in generating revenue in 
pharmaceutical care (Norwood, Sleath, Caiola et al, 1998). 
 
In South Africa, increased emphasis is being placed on the role of pharmaceutical technical 
assistants in order to meet the growing needs of pharmaceutical services and, thus, to free the 
pharmacist from the technicalities of dispensing drugs. The pharmacist is then better able to 
carry out cognitive drug management functions, which are so important when providing 
pharmaceutical care. 
. 
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Economic barriers can only be overcome if pharmacists are fully reimbursed for their cognitive 
interventions. Full reimbursement by either patients or medical schemes for pharmaceutical care 
services would allow the pharmacist to acquire the necessary resources such as technical 
assistants, pharmacist assistants, and sufficient space to perform their function more effectively 
(Shu Chuen Li, 2003). 
Reimbursement for pharmaceutical care services is by far the biggest hurdle for the 
implementation and provision of pharmaceutical care. The question being asked is where does 
the pharmacist look for reimbursement? Despite several studies that have been published about 
benefits provided by pharmaceutical care, there is limited recognition by the health systems, 
patients and third-party payers of the services pharmacists provide (Rovers, Hagel, McDonough, 
& Sobotka, 1998; Shu Chuen Li, 2003). The pharmacist is reluctant to spend time on services 
they are not paid for. On the other hand the third-party payers are not willing to provide 
reimbursement for a service that has not yet been established (Krska & Veith, 2001). 
Furthermore since pharmacy services have traditionally been free of charge pharmacists are also 
reluctant to charge patients for the provision of pharmaceutical care services for the fear of 
driving patients away. 
 
In 2004, the South Africa Pharmacy Council, in consultation with many stakeholders, committed 
to new medicine pricing regulations when the objectives were to lower the prices of medicines 
and to make them more accessible to the public (Hill and Dowse, 2007). In the new legislation 
that was promulgated, pharmacists are forced to sell prescription medicine to the consumer at the 
price they pay to the wholesaler, known as the single-exit price (SEP), while charging a 
professional fee, rather than a profit mark-up (Gray, 2009). The implementation of pricing 
regulations, among other challenges, has created economic challenges for the community 
pharmacist, as discussed in detail in Section 2.8.2. Some pharmacies have closed doors as a 
result of lack of profitability since they could not make profit on dispensed medicines, and 
consequently failed to break even (Hill & Dowse, 2007). 
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2.6.  PHARMACEUTICAL CARE IN MAJOR DEVELOPED COUNTRIES 
 
The philosophy and practice of pharmaceutical care is subject to various interpretations around 
the globe. These different interpretations lead to dissimilar applications of the philosophy in 
practice from one continent to the next. The term pharmaceutical care is sometimes used when 
clinical pharmacy services are described or evaluated. Hepler is cited as saying; ―Pharmaceutical 
care studies are difficult to set up and impossible to sustain‖ (Pioneer, 1997). Internationally 
various synonyms are used to describe pharmaceutical care practices and services, such as 
―clinical pharmacy services‖, ―cognitive services‖, ―medication management‖, ―disease state 
management‖ and ―medication review‖ (Roughead, Semple, & Vitry, 2002). Although these 
services are not always interchangeable with pharmaceutical care services, they share the same 
philosophy and objectives, namely ―responsible provision of drug therapy for the purpose of 
achieving defined outcomes that improves a patient‘s quality of life‖ (Martín-Calero et al, 2004). 
 
Pharmaceutical care is slowly becoming a part of daily community pharmacy practice in 
developed countries such as the US, Canada, Australia and some European countries. 
Pharmaceutical care practice in the United States is influenced by forces from within both the 
pharmaceutical care movement and the managed care movement. Pharmacy in the US is driven 
by the academic sector, the American Pharmaceutical Association (AphA), individual 
pharmacists and pharmaceutical companies. The professional body of pharmacists in the US, the 
AphA, created the American Center of Pharmaceutical Care (ACPC) which works toward there-
engineering of the profession into the future, by proliferation of pharmaceutical care integration 
and research into the practice setting. 
 
Although the first definition of pharmaceutical care emerged in the United States, around 1988, 
the progression and implementation of pharmaceutical care appears to have been relatively slow. 
Maine and Pathak (1996) reported that the vast majority of pharmacists in the United States were 
still in the drug distribution model of pharmacy practice. And in the same year Carter and 
Barnett (1996) concluded that there were few pharmacists in the US who were providing the full 
scope of pharmaceutical care. 
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Although the US is where most of the studies on pharmaceutical care implementation have taken 
place, this service has not yet been introduced on a broad scale and hence is still considered a 
relatively new form of practice (Martín-Calero et al, 2004).  
 
Canadian pharmacy practice seems to be less driven by the managed care than in the US. In 1996 
the Canadian Medical Association and the Canadian Pharmaceutical Association published a 
joint statement on enhancing quality of drug therapy. The goal of the statement was to promote 
optimal drug therapy by enhancing communications and working relations amongst physicians, 
patients and pharmacists (Anonymous, 1997). It is a pre-requisite for pharmacists involved in 
such practices to undergo continuous educational professional development programs with the 
designated approved colleges (Pearson, 2007). 
 
In some jurisdictions of Canada, such as the Alberta province, pharmacists have adopted 
collaborative drug therapy management and supplementary prescribing models (dependent 
prescribing model) in partnerships with physicians. In the dependent prescribing model, the 
patient is examined by the physician or other healthcare professional and the pharmacist who has 
obtained the patient‘s informed consent can make changes to the prescription (Pearson, 2007). 
Where it has been implemented, pharmacist-prescribing has improved drug therapy, optimized 
patient outcomes, and increased synergy and collaboration between pharmacists, physicians and 
other healthcare providers (Pearson, 2007). 
 
In Europe pharmaceutical care practice is as variable as it is in the rest of the world. Throughout 
most European countries, pharmaceutical care studies have been conducted in different fields. 
However, despite the positive outcome of most studies and acceptance by most pharmacy 
associations, implementation on a large scale seems to be deficient. There is yet to be 
harmonization in the field of primary healthcare in Europe, there are major differences in the 
policies and practices hence it is difficult to get a clear picture of the pharmacy and 
pharmaceutical care practices (Foppe van Mil & Schulz, 2006). 
 
Similar to the US, Clinical pharmacy was the foundation to the development of pharmaceutical 
care principles in most European countries (Foppe van Mil & Schulz, 2006). 
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Since most pharmaceutical societies and associations and pharmacy faculties within universities 
have committed to the provision of pharmaceutical care it is expected that there will be an 
increase in pharmaceutical care practice in the future. 
 
2.7. PHARMACEUTICAL CARE IN DEVELOPING COUNTRIES 
 
In most developing countries the pharmacy is often highly accessible to patients for healthcare 
advice and services. Pharmacy practice comprises of public and private sectors, with private 
services mostly being offered in the more affluent urban areas. The urban areas tend to be 
wealthier than the rural areas thus attracting pharmacists and other professionals to work in the 
cities (Anderson, 2002). 
 
Pharmacy practice models in developing countries vary significantly from one country to 
another, although they may experience similar challenges. This is a reflection of different social, 
political and economic characteristics, as well as differences in customs and traditions 
(Anderson, 2002). Some of the challenges encountered include lack of appropriate and good 
quality medicines, weak regulatory enforcement of drug sales, irrational use of medicines and 
shortages of trained pharmacists (Azhar, Hassaliet al, 2009). 
 
According to WHO recommendations, a ratio of one pharmacist per 2000 population is needed 
for optimal healthcare to be delivered. Although pharmacists are regarded as medication experts 
in most developing countries, they are not the sole dispensers as medical practitioners are 
allowed to dispense as well (Anderson, 2002). 
 
In a country such as Malaysia, which is considered to have one of the leading growing 
economies in South-east Asia, data for 2006 showed that one pharmacist was serving 6207 
people. In African countries, the shortage of pharmacists is even greater, for example in great 
Accra, Ghana, in 2006, only 619 pharmacists were serving a population of 2.9 million, which is 
equivalent to one pharmacist per 4685 people (Frances, Felicity & Rita, 2008). In 2001, Eriteria 
in East Africa, was reported to have a ratio of one pharmacist per 60 000 population. 
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Table 2.4 provides 2001 figures for the ratio of pharmcists to population in middle to lower 
income developing countries. 
 
Table 2.4: Ratio of pharmacist to population in some developing countries 
Country Number of registered 
pharmacists 
Population 
(millions) 
Pharmacist per 
population 
Slovenia 695 1.988 2 860 
Jamaica 860 2.576 2 995 
Belarus 3 230 10.187 3 154 
Azerbaijan 2 505 8.041 3 111 
India 300 000 1 008.937 3 356 
Singapore 1 350 4.018 2 976 
Thailand 15 478 62.806 4 058 
South Africa 10 690 43.309 4 051 
Chile 3 000 15.211 5 070 
Bulgaria 1 315 7.949 6 045 
Malaysia 3 560 22.218 6 241 
TFYR Macedonia 320 2.034 6 356 
Georgia 438 5 262 12 014 
Romania 1 600 22 438 14 024 
Russia 9 340 145.491 15 577 
Albania 85 3.314 36 870 
Zimbabwe 335 12.627 37 692 
UR of Tanzania 850 35.119 41 316 
Eritrea 53 3 659 69 038 
Gambia 10 1383 138 300 
*Adapted from Organisation for Economic Co-operation and Development (2001) and World Health 
Organisation (2001). 
 
The implementation of pharmaceutical care services in developing countries may prove to be 
more challenging than in developed countries, since a shortage of pharmacists creates significant 
problems in the delivery of quality health services. 
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2.8.      PHARMACEUTICAL CARE IN THE SOUTH AFRICAN CONTEXT 
 
South Africa, with a population of approximately 49.9 million people, has amongst the most 
extreme disparities of wealth in the world (Statistics South Africa, 2010). There is a mal-
distribution of healthcare in South Africa, with the healthcare system consisting largely of the 
resource-deprived public sector and the privileged private sector. The resource-stricken public 
sectors delivers healthcare to approximately 80% of South Africa‘s population and the remaining 
20% of the population is catered for by the private healthcare sector (SAinfo Reporter, 2010). 
 
There is a fast-growing healthcare expenditure of which medicine consumes a large proportion 
of the healthcare budget. In 2005 about R100 billion was spent on healthcare which was 
approximately 7.7% of the Gross Domestic Product (GDP) (McIntyrei & Thiedei, 2007). 
According to McIntyrei and Thiedei (2007) South Africa‘s expenditure on healthcare is 
relatively high with respect to its economic development; it is similar to that of high-income 
countries. In the healthcare budget, drugs and hospitalization costs are the costliest, although the 
cost of drugs has decreased since the introduction of the single-exit-price in 2005 by the SA 
Government in a bid to control the spiraling medication costs. McIntyrei and Thiedei further 
argue that it is important for SA to utilize the available resources equitably and efficiently 
(McIntyrei & Thiedei, 2007). 
 
Increase in the consumption of medicine creates drug-use issues such as misuse or inappropriate 
use of medicines. The establishment of pharmaceutical care practices is necessary in SA to 
ensure the appropriate use of medicines while administering much needed patient care. 
 
Despite the effort by government to ensure the availability of primary health care to every South 
African, by establishing programs and projects that include the supply of essential drugs for 
priority health problems, the nation is besieged with multiple life threatening ailments such as 
tuberculosis (TB), Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS), malaria and chronic malignancies (Mehta, 2011). While much attention has 
been focused on increasing access to drug supply, limited effort has been made on the investment 
and development of the human resources to ensure drug therapy management and patient care. 
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The battle against HIV and AIDS, malaria, tuberculosis (TB) and other common Sexually 
transmitted diseases (STIs) is yet to be won in Africa as a whole. According to the 
Commonwealth Pharmaceutical Association, the pharmacist is an essential component of the 
fight against endemic disease and is the pharmacist as the custodian of medicines 
(Commonwealth Pharmaceutical Association, 2005). The pharmacist is an important team 
member; and often serves as the first point of contact with the patient and should be the primary 
dispenser of care. 
 
Pharmaceutical care is applicable and achievable by pharmacists in all practice settings, 
including both public and private. In SA pharmaceutical care can be practiced in home care 
settings or community care settings, private hospitals‘ inpatients and outpatients, primary health 
care settings (clinics) and government hospitals‘ inpatients and outpatients. There is, however, 
limited literature and research on the benefits and provision of pharmaceutical care in South 
Africa. 
 
The healthcare delivery system in South Africa is undergoing significant transformation. For 
effective transformation to exceed nominal expectations, the attitudes and practices of health 
care providers in SA must change (Gray & Smit, 1998). Pharmacy practice in South Africa has 
been subject to numerous changes since the beginning of the millennium. The ever changing 
South African medical legislation, implemented and governed by the Medicine Control Council 
has had a major influence on the pharmacy profession, both positive and negative. Below are 
some of the major factors which have affected the profession nationally. 
 
2.8.1. Dispensing doctors 
 
In a bid to increase availability of medicines in remote areas without pharmacies, the general 
practitioners were granted dispensing licenses by the Medicine Control Council (MCC). At 
present, in 2011 there are more than eleven thousand dispensing doctors in SA. Whether the 
provision of these licenses served its intended purpose is, as yet, unknown. However, it seems 
certain that granting dispensing licenses has exacerbated the already compromised relationship 
between doctors and pharmacists (Gilbert, 2001).  
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Evidently there has been ongoing conflict between community pharmacists and dispensing 
doctors worldwide. The granting of dispensing licenses has impacted South African retail 
pharmacists negatively (Gilbert, 2001). 
 
Traditionally, the roles of medicine prescribing and dispensing have been kept separate in order 
to avoid conflict of interest and maintain a system of checks and to uphold quality care 
standards. Although pharmacists tried to challenge the trading of medicine by doctors, their 
efforts were fruitless as doctors argued that dispensing was their inherent right (Gilberts, 1998; 
Gilbert, 2001). According to a research conducted by Hill and Dowses (2007), most dispensing 
doctors believed that the provision of medication was the role of the pharmacist. Since 
pharmacy‘s revenues, in South Africa are based on the total number of prescriptions dispensed, 
an increase in the number of dispensing doctors decreases the number of prescriptions 
pharmacists are able to dispense and thus reduces the total revenue available to them. 
 
2.8.2. Single-Exit Pricing system 
 
In an effort to ensure that South Africans have access to affordable, quality medication the 
Medicine Control Council (MCC), a medicine regulating board of the South African 
government, in 2004 introduced new medicine pricing legislation including a SEP (The Free 
Market Foundation of Southern Africa, 2005). 
Single-exit-pricing entails a transparent pricing system for medicines and scheduled substances 
and means that medicinal products exit the manufacturing facility at one single price for all 
authorized purchasers. The medicine pricing regulation banned the provision of discounts on the 
sale of medicines and allowed for the pharmacists to only charge an additional dispensing fee on 
the SEP, essentially removing the possibility to make profit on the sale of medicine. Although 
the medicine pricing regulations were eventually implemented, they were subjected to numerous 
legal challenges and raised widespread general concern on its possible unintended and 
unforeseen consequences to the South African healthcare system (The Free Market Foundation 
of Southern Africa, 2005). 
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In the medium to long-term, price control mechanisms of any form imposed by Governments 
over the past 40 centuries have been known to be more harmful than helpful to the consumer as 
they reduce competition and ultimately impair the quality of service delivered to the consumer 
(The Free Market Foundation of Southern Africa, 2005). 
 
The implementation of SEP has created challenges for the independent retail pharmacy-owner in 
South Africa, with many being forced to close as they struggled to breakeven financially. 
Together with a change in ownership laws, the medicine-pricing laws gave birth to corporate 
pharmacies such as Clicks Pharmacies, Medirite Pharmacies, and pharmacies in Pick and Pay 
(Lowe & Montagu, 2009). 
 
The closure of independent pharmacies may ultimately prove to be costly to the less wealthy 
consumers, since they lose the convenience of purchasing their medication and obtaining advice 
from a locally situated pharmacist and may have to travel to distant shopping malls where the 
corporate pharmacies are situated (Lowe & Montagu, 2009). Coupled with these local challenges 
are the normal barriers to the implementation of pharmaceutical care that are faced by the rest 
world. 
 
The current situation of the profession in South Africa mandates the pharmacist to provide 
pharmaceutical care. Amidst all these changes and challenges it is important for pharmacists to 
apply themselves and be recognized as healthcare team members. Remuneration or no 
remuneration, the community is in need of the pharmacists‘ vigilant and efficient intervention 
towards rational medication usage. Indeed pharmacists are needed to utilize their knowledge and 
expert skills efficiently, and re-define their role in healthcare practice and join the combat against 
medication-related morbidity and mortality. 
 
Studies show that approximately 6.7% of all hospitalizations are as result of medication-related 
problems and more than half of the problems experienced were considered to be preventable 
with improved prescribing, administration, monitoring and adherence. Immune-compromised 
patients, HIV & AIDS patients, were also found to be more vulnerable to adverse drug-related 
problems; possibly due to complex drug regimens they are receiving (Mehta, 2011). 
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Pharmacists as medicine specialists can help reduce the potentially serious consequences of 
irrational drug usage and help diminish the already strained health budgets to earn the respect of 
the community as a trusted and healthcare provider of choice. The time is right for the SA 
pharmacist to take responsibility for patients‘ drug therapy and their outcomes. Pharmacists have 
a key role to play in ensuring improved health gain where ever medicines are utilized (Rexy & 
Shruti, 2006). 
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3. CHAPTER THREE: PHARMACOECONOMICS  
 
3.1. INTRODUCTION TOPHARMACOECONOMICS 
 
Globally, costs of providing healthcare are increasing. Increased costs account for 10% to 15% 
of most national healthcare budgets; and funders such as governments, social security funds and 
insurance companies are strained to contain costs (Walley, Haycox, & Boland, 2004). There is a 
general increase in the understanding of disease state pathologies, thus leading to the 
development of new effective drugs and technologies (Bootman, Townsend, & McGhan, 1998). 
 
The costs of pharmaceuticals and pharmacy services have become an issue for patients, third-
party payers, and governments. Healthcare providers and decision-makers are faced with the 
challenge to implement healthcare policies aimed at controlling ever increasing healthcare costs 
(Shu Chuen Li, 2003). 
In response to increased need for accountability and cost containment, the ultimate aim of 
pharmacoeconomics is to assist decision makers in achieving allocation efficiency in the 
healthcare system (Shu Chuen Li, 2003). ―Efficiency‖ is an evaluation of whether an 
intervention produces the desired beneficial effects with minimum waste of resources (Walley, 
Haycox, & Boland, 2004). 
To understand pharmacoeconomics, it is best to understand the basic disciplines of economics. 
At the basic level economics is about trade-offs and choices between wants, needs, and the 
scarcity of resources to fulfill these wants (Bootman, et al. 1998). Health-economics is a 
discipline of economics concerned with allocation of scarce social resources in health care 
systems. It can help to inform and improve decision-making to maximize welfare within 
constrained resources (Walley, et al. 2004). 
 
Health-economics is a social science assessing the supply and demand of goods and services 
pertaining to healthcare, including their costs and benefits. Central to the economics of health 
care is pharmacoeconomics (Walley, et al. 2004). Figure 3.1 is a representation of 
pharmacoeconomics in the global science of economics. 
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Figure 3.1: The placement of pharmacoeconomics in the context of the global science of 
economics (Wessels, 2002). 
 
 
3.1.1.  What is Pharmacoeconomics? 
 
Pharmacoeconomics (PE) is a relatively new hybrid health science, with less than five decades of 
existence, which borrows from other disciplines such as health-economics, social sciences, 
decision analysis and evidence-based medicine (Shu Chuen Li, 2003). Pharmacoeconomics 
refers to a scientific discipline that systematically describes and analyses the costs and 
consequences of pharmaceuticals and pharmaceutical services and their impact on individuals, 
health systems, and society (Townsend, 1987). Pharmacoeconomic research identifies, measures, 
and compares costs (that is, resources consumed) and consequences (clinical, economic, and 
humanistic) of pharmaceutical products (for instance, drugs) and services such as pharmaceutical 
care interventions (Bootman, et al. 1998). 
 
Although PE is a relatively new discipline of pharmacy with respect to clinical pharmacy, 
pharmacokinetics and pharmaceutics, increasingly it is becoming a critical and integral part of 
the pharmaceutical sciences and consequently pharmacy education (Bootman, Townsend, & 
McGhan, 1998). Pharmacoeconomics emerged in the 1970s at the University of Minnesota, 
when McGhan, Rowland and Bootman introduced cost-benefit and cost-effective analyses 
(McGhan, Rowland, & Bootman, 1978). The actual term ―pharmacoeconomics‖ was pioneered 
by Townsend in 1986 (Townsend, 1986). 
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In the fulfillment of a pharmacoeconomic evaluation, essential methodologies are utilized to 
define the costs and consequences of an intervention. The essential methodologies for the 
economic evaluation of healthcare services may include: cost-effective analysis (CEA), cost-
minimization (CMA), cost-utility analysis (CUA) and cost-benefit analysis (CBA) (Walley, 
Haycox, & Boland, 2004). 
 
Pharmacoeconomic evaluations can be performed to analyze the effectiveness of an intervention, 
assessing costs and benefits, so that the greatest amount of benefit can be bought with the 
available limited money or resources (Walley, et al. 2004). All economic evaluations have a 
common structure which involves explicit measurement of inputs (costs) and outcomes (benefits) 
as shown in figure 3.2. 
 
Structure of Economic Evaluation 
 
Inputs Outputs 
 
 
 
 
 
 
Figure 3.2 illustrating the structure of an economic evaluation 
 
 
 
 
 
 
 
 
 
 
 
Intervention 
Costs of delivering the 
treatment in monetary 
terms 
CEA, CMA, CUA 
and CBA outcomes 
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3.2. PHARMACOECONOMICS EVALUATION METHODOLOGIES 
 
The four types, of economic evaluation summarized in the table below, differ in the manner that 
outcomes are measured. 
 
Table 3.1 Pharmacoeconomic Methodologies 
 
Methodology Cost Measurement 
Unit 
Outcome Unit 
Cost-Minimization Analysis 
(CMA) 
Monetary value Assume to be equivalent in 
comparative groups 
 
Cost-Effective Analysis (CEA) Monetary value Natural units (life years gained, 
mmol/L blood glucose, mm Hg 
blood pressure) 
 
Cost-Utility Analysis (CUA) Monetary value Quality adjusted life-year or other 
utilities 
 
Cost-Benefit Analysis (CBA) Monetary value Monetary value 
 
 
The above four basic methodologies central to pharmacoeconomic evaluations will be briefly 
discussed in the following sections. 
 
3.2.1. Cost-Minimization Analysis (CMA) 
 
This type of analysis is used to compare interventions in which outcomes are demonstrated or 
assumed to be equivalent in other words outcomes have identical efficacy/efficiency and safety 
profiles (Walley, et al. 2004; Bootman, et al. 1998). The costs of the interventions are then 
compared. For example CMA can be used to compare two generically equivalent drugs in which 
the outcome has been proven to be equal. The acquisition and administration costs of the two 
drugs may differ significantly and these are compared using CMA methodology (Bootman, et al. 
1998). However, in practice this analysis is hardly ever used (Fleurence, 2003). 
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3.2.2. Cost-Effective Analysis (CEA)  
 
Cost-effective analysis is a technique that utilizes a series of analytical and mathematical 
procedures, aimed at assisting decision-makers in identifying a preferred choice among possible 
treatment alternatives with different efficacy/effectiveness and safety profiles (Bootman, et al. 
1998; Venturini & Johnson, 2002). As with other methodologies, CEA intervention inputs 
(costs) are measured in monetary terms, whilst the outputs are measured in natural unit measures. 
Therefore, for interventions to be captured using CEA the outcome must be able to be measured, 
or scored, in a common natural unit. These natural unit measures may include: heart attacks 
avoided, disability days avoided and quality of life scores. Quality of life scores are obtained 
from health-related quality of life (HRQoL) instruments, which can be used to measure the 
quality of life of a patient in a number of domains (for example physical, emotional and social) 
and provide scores for each (Fleurence, 2003; McGhan, Rowland, & Bootman, 1978).  
 
For example, the cost-effectiveness of treating an ulcer with drugs from two different classes can 
be analyzed using CEA. The desired outcomes, ulcer alleviation can be measured in common 
natural units and the input costs for each drug per natural outcome unit can then be compared. In 
CEA, costs and consequences of two treatment alternatives can also be compared in terms of the 
additional cost incurred in-relation to the additional beneficial effects achieved known as 
incremental CEA. 
 
3.2.3. Cost-Utility Analysis (CUA) 
 
Cost-utility analysis is a method that is used to measure benefits in outcomes in terms of both 
quantity and quality of life. The unit of measurement is quality adjusted life years (QALYs). In 
health economics, a ―utility‖ is the measure of the preference or value that an individual or 
society places on a health state (Fleurence, 2003). 
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For cost-utility analysis there is a defined outcome and the cost to attain a unit of the outcome is 
measured in monetary terms (Bootman, et al. 1998; Walley, et al. 2004). Cost-utility analysis can 
be applied in a variety of cases such as: to aid in making decisions regarding alternative 
healthcare programs (for example surgery versus chemotherapy), when both mortality and 
morbidity are affected by intervention and a combined unit of outcome is preferred; and when 
the quality of life is the vital outcome. 
 
3.2.4. Cost-Benefit Analysis (CBA) 
 
Cost-benefit analysis is a methodology in which a monetary value is assigned to both the 
implementation of the service and or drug (inputs) and the benefits (outputs) in-order to 
determine the net cost of the intervention (Venturini & Johnson, 2002; Fleurence, 2003). Cost-
benefit analysis is used to evaluate either single or multiple interventions with different 
outcomes, such as diagnostic, screening or therapeutic interventions. The net economic value of 
an intervention can be defined as a loss or gain. However some benefits are difficult to measure, 
especially in monetary terms, such as improved patient quality of life, and improved patient-
satisfaction with healthcare systems. These benefits are deemed ―intangible benefits‖ and are left 
to the decision-makers to include in their final deliberations (Bootman, et al. 1998). 
 
There are two main methods to measure health gains in a CBA: the human capital approach and 
the willingness to pay (WTP) approach. The human capital approach values a health 
improvement on the basis of the future productive worth to society as a consequence of being 
able to return to work. In a WTP approach, the utility an individual gains from an intervention is 
valued as the maximum amount they would be willing to pay for an intervention. 
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3.2.4.1. Human Capital (HC) Approach  
 
In accounting principles, capital is defined as an asset available for use in the generation of 
another prospective asset (Association of Chartered Certified Accountants, 2009). The financial 
value of the asset can be ascertained from its anticipated earnings. In the human capital approach 
people are treated as an asset or an investment to society. The human capital approach values 
benefits attained by society by avoiding premature death of a human being, thus loss of human 
capital results in reduced productivity (Bootman, et al. 1998). 
 
Future productivity is based on health improvement results in being able to return to work and 
earn wages. Death due to ill-health, is considered a loss to others (society) and thus forgone 
earnings can be determined and quantified (Bootman, et al. 1998; Fleurence, 2003). However the 
human capital approach has been greatly criticized as being unethical since, for example, the life 
of non-working people, such as the elderly or children, is considered to be of zero value, if not 
negative (Walley, et al. 2004). 
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3.3. WILLINGNESS TO PAY (WTP) APPROACH 
 
3.3.1. Introduction and definition of Willingness to Pay 
 
In the evaluation of non-market related commodities and services such as pharmaceutical care, 
where consumers‘ preferences for trade-offs between costs and benefits need to be assessed, 
cost-benefit analysis (CBA) is often the most applicable methodology (O'Brien, Torrance, & 
Streiner, 1995). 
 
Willingness to pay is a pharmacoeconomic parameter used to measure the perceived value by the 
patient, of the services rendered to them, and is the maximum amount of money a patient is 
willing to forgo or sacrifice so as to receive a healthcare program (Barner, 2004). 
 
A WTP study is a form of cost-benefit analysis (CBA) (Donald, 2000) in which the inputs and 
outputs are converted into monetary values, based on utility. Willingness to pay requires 
valuation of both the cost of intervention (pharmacist-intervention) and the value of benefits 
(VOB); health gain and sources of wellbeing (Suh, 2000). The VOB or utility gained from a 
particular intervention by a respondent is correlated to the maximum amount of money they are 
willing to pay for it. It has been suggested that something is of value if a person is willing to pay 
for it, thus WTP can ascertain the perceived value of a service to patients (Barner, 2004). 
 
3.3.2. Methods used to measure Willingness to Pay 
 
As discussed in section 3.3.1, WTP is a means of evaluating preferences of outputs in a CBA 
study (Donald, 2000). In CBA, benefits are valued in the same unit as costs, that is, in monetary 
or rand value. However, although theoretically appealing, CBA can be practically difficult 
especially in assigning monetary value to the process and outcomes of care (Bootman, et al. 
1998). 
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There are two main approaches in WTP studies and the two main methodologies are listed 
below: 
1. ―Revealed preference‖ benefit; 
2. ―Stated preference‖ measures – Contingent Valuation (CV) and discrete choice modeling 
(sometimes referred to as conjoint analysis). 
 
3.3.2.1. Revealed preference 
 
Although rarely used revealed preference is one of the methods used to measure WTP. Revealed 
preference infers the benefits of an intervention based on making observations of subjective 
choices of individuals; these choices may include obtaining low or high risk services (Walley, et 
al. 2004). 
 
The revealed preference approach, commonly applied to labour or environmental economics 
where wage premiums are offered to incentivize workers to accept more risky jobs. This 
approach assumes workers are familiar with risks they take in the workplace and any additional 
wages they receive reflect their choices, thus also known as the compensation-wage approach 
(United States Department of Agriculture (USDA), 2009).  
 
Risks preferences can be inferred based on actions devised to avoid them. The compensation 
differential approach assumes that workers are willing to accept exposure to a certain level of 
job-related risk in return for a certain level of compensation (United States Department of 
Agriculture (USDA), 2009).  
 
Although the revealed preference approach has an advantage of measuring WTP based on real 
market data rather than hypothetical data, it has its shortcomings as well. 
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3.3.2.2. Stated Preference - Contingent Valuation Method (CVM) 
 
Contingent valuation (CV) is a survey-based economic technique for evaluating non-market 
goods and services like environmental preservation or healthcare interventions such as 
pharmaceutical care services. Contingent valuation is often referred to as a stated preference 
model. Contingent valuation, a utility-based approach, constructs a hypothetical market for the 
healthcare intervention in question by asking respondents to state the maximum amount of 
money they would be willing to pay (WTP) in compensation for it or willingness to accept 
(WTA) compensation for not having it (Bootman, et al. 1998). 
 
Survey techniques that may be used in the CVM include open-ended questions and close-ended 
questions. In a closed-ended technique respondents are required to respond with a simple yes or 
no to the presented questions.  
 
In a CV approach, researchers collect respondents‘ socioeconomic and demographic 
characteristics in order to draw inferences about the entire population of beneficiaries and 
aggregate demand for provided or proposed services. The observations attained from the 
respondents can be presented as a frequency distribution, where maximum WTP can be 
determined (as shown below) (Bootman, et al. 1998; United States Department of Agriculture, 
2009). 
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 Figure 3.3 Illustrating respondents’ willingness to pay (WTP) 
 
If the researcher can show that observations obtained from respondents‘ stated preferences are 
not random, but vary systematically, with respect to defined demographic characteristics, then 
population information such as age, sex and income can be utilized to infer willingness to pay for 
proposed services (United States Department of Agriculture (USDA), 2009). However, a CV 
method can be subject to bias as discussed in the following section. 
 
3.3.2.3. Limitations of the Contingent Valuation Method in the measurement of 
willingness to pay 
 
Although widely used in research, the contingent valuation approach has been subject to 
controversy in adequately determining consumers‘ willingness to pay (Journal of Pharmaceutical 
Association, 2000).  
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First and foremost, although the hypothetical nature of the contingent valuation method is 
defined as its strength, it is also considered to be its weakness. Hypothetical bias is potentially a 
problem in contingent markets where respondents are assumed to understand the market goods 
and services in question. Respondents are unfamiliar with assigning monetary value to 
environmental goods (for example, electricity and water) as opposed to everyday household 
goods (e.g. bread and butter), thus determining their true utility, on unfamiliar hypothetical 
goods, is uncertain. In a hypothetical market respondents do not engage in cash transactions and 
are asked what they would be willing to pay without any trade-off; hence they may not be able to 
sufficiently determine the true demand (Journal of Pharmaceutical Association, 2000). 
 
Respondents‘ attitude towards the object under investigation can result in a biased response; 
sometimes respondents accept or refuse to pay, based on emotions. In the case of determining 
willingness to pay for pharmacist-provided services, the respondents‘ attitude towards drug 
pricing may affect the true response towards the services in question. The pharmaceutical drugs 
may be perceived by the respondents to be over priced; hence they might not be willing to pay 
for proposed hypothetical services although considered to be of value. Thus follow-up questions 
might be necessary to avoid biased responses (Journal of Pharmaceutical Association, 2000). 
 
Respondents usually indicate a WTP based on a reference value rather than on its true value. The 
stated WTP usually depends on the starting point (starting point bias) and the response to the 
question following can be influenced by the previous question (question order bias).  
 
Elicited response is dependent upon wording of the presented questions, thus the respondents 
might perceive the hypothetical scenario differently from the researcher‘s intentions resulting in 
a biased response (United States Department of Agriculture (USDA), 2009). 
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Despite the aforementioned limitations, contingent valuation survey methods have yielded 
plausible theoretical results. It is important that the researcher puts measures in place so as to 
minimize the level of bias. To minimize errors and thus bias it has been recommended that 
hypothetical scenarios must be readable, understandable, meaningful and plausible to the 
respondents. It has been recommended that the WTP questions posed to respondents must be 
clear and unambiguous; the respondents should be familiar with the assumed commodity or 
amenity being explained; and ideally the respondents should have had prior valuation and choice 
experience with respect to consumption levels of the commodity (United States Department of 
Agriculture (USDA), 2009).   
 
Other methods not discussed above which have been previously employed in the measurement of 
WTP may include a hedonic approach as well as household health production. The hedonic 
approach extends the health-production through the observation that often only specific 
characteristics of goods or service contribute to health, with other characteristics serving other 
functions. The final price of goods or services will reflect the desirability of all its characteristics 
or attributes (United States Department of Agriculture (USDA), 2009).   
 
The household health-production function method for measuring WTP is built on the observation 
that households continually make decisions involving the allocation of income and time between 
health-enhancing goods and activities or other goods. The household health-production approach 
recognizes that individuals can and do make decisions attempting to influence their own health 
status. However, this method has limited usefulness (United States Department of Agriculture 
(USDA), 2009).   
 
The WTP approach reflects the observation that individual preferences are unique and the 
demand for risk reduction is derived from expected value of benefits. Although the demands for 
risk reduction vary, due to individual preferences, some of the variances are best explained by 
income differences (United States Department of Agriculture (USDA), 2009).   
 
 
 
  
47 
3.4. PATIENTS’ WILLINGNESS TO PAY FOR PHARMACIST-PROVIDED 
SERVICES 
 
It is important to elicit and understand the patient‘s willingness to pay (WTP) for pharmaceutical 
services rendered to them (Blumenschein & Freeman, 2004; Barner, Manson, & Murrray, 1999). 
Several factors may influence a patient‘s WTP including the ability to pay that is determined by 
their wealth and income status and their health status (Barner, 2004). 
 
Various pharmacoeconomic studies have been carried out worldwide in order to investigate 
patients‘ willingness to pay for pharmacy-related services. Below is a table summarizing some of 
the studies that were conducted between 1999 and 2010 to elicit patients‘ willingness to pay for 
pharmacist care services provided in community pharmacies. 
 
Table 3.2: Published Studies Addressing Consumer Willingness to Pay for Pharmacist 
Care Services (1999–2010) 
 
Author(s) Number of 
respondents 
 
Proportion of respondents who 
were willing to paymore than $0 
Average WTP 
 
Conclusion from Study 
Author(s) 
Larson 
RA (2000) 
175 55% were willing to pay for a 
"one time comprehensive 
evaluation of medication use"; 
56% would pay for a one time 
evaluation of medication use plus 
"a year's worth of follow-up" 
 
 
US$12.91 for a "one time 
comprehensive evaluation 
of medication use"; 
US$27.87 for a one time 
evaluation of 
medication use plus "a 
year's worth of follow-up" 
"A majority of patients are 
willing to pay for 
pharmaceutical care 
services" 
 
 
Suh DC 
(2000) 
316 60% were willing to pay for a 
service that would provide a risk 
reduction from 40% to 20%; 
35.7% were willing to pay for a 
service that would provide a risk 
reduction of 10% to 5% 
 
 
US$5.57 for a 6.5 minute 
counseling 
 
 
"Respondents were willing 
to pay for pharmacists' 
services that reduce the 
risk of mediation related 
problems" 
Daftary 
MN, Lee 
E, Dutta 
AP, et al 
(2003) 
90 40% were willing to pay more 
than $10 for a single 
"pharmaceutical care evaluation"; 
63% were ―willing to pay for a 
pharmaceutical care evaluation 
with a year of monitoring by the 
pharmacist‖ 
Not estimated 
 
―Many patients would be 
willing to pay for this type 
of service and they would 
pay more for long-term 
services" 
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Cerulli J, 
Zoella M. 
(2004) 
140 41% indicated a willingness to 
pay US$20 or more 
 
 
 
Not estimated 
 
―Patients are willing to pay 
for this service; feasibility 
varies depending on 
available resources and 
patient population served" 
 
Côté I, 
Grégoire 
J-P, 
MoisanJ,et 
al. 
(2003) 
41 Pre intervention: 17.1% were 
willing to pay more than Can$0 
Post intervention: 4.9% were 
willing to pay more than Can$0 
Pre intervention: 
Can $3.29 
Post intervention: 
Can $0.54 
―The lack in willingness to 
pay post intervention may 
be due to the fact that 
participants 
did not see much change in 
the way their disease had 
been managed" 
 
Barner 
JC, 
Branvold 
A. 
(2005) 
203 At least 85% of women surveyed 
were willing to pay a minimum of 
20 US dollars for pharmacist-
provided menopause therapy and 
hormone replacement therapy 
services. 
Not estimated ―This study showed that 
most women surveyed 
were willing to pay for 
pharmacist-provided 
hormone replacement 
therapy and menopause 
counseling services‖ 
Shafie AA, 
Hassali 
MA. 
(2010) 
100 At least 67% of the participants 
were willing to pay for the 
pharmacists‘ dispensing service, 
and the median willing to pay was 
2.86USD. 
Not estimated ―Generally, the public 
valued the  pharmacist‘s 
dispensing service‖ 
 
 
 
 
Suh (2000), in New Jersey USA, found that consumers were willing to pay for pharmacist- 
services that reduce the risk of medication-related problems and that WTP was influenced by the 
patient‘s age, health status, and the perceived level of reduction in the risk of having medication-
related problems. Of the 316 interviewed respondents, 60% were willing to pay for a service that 
would provide a risk-reduction of between 40% to 20% and 35.7% were willing to pay for a 
service that would provide a risk reduction of between 10% and 5% (Suh, 2000). 
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In the State of Kentucky, USA, Blumenschein and Freeman (2004), suggested that one in five 
consumers were willing to pay for pharmacist-provided disease state management (DSM) 
services. However the price that they were willing to pay was less than the actual cost of 
providing the service. One of the reasons provided by the researcher for this apparent lack of 
willingness to pay included, patients already receiving the rendered services from another 
healthcare provider (Blumenschein & Freeman, 2004). 
 
Barner (2004) investigated patients‘ willingness to pay for pharmacist-provided asthma 
management services and diabetes disease state management (DSM) services. On both occasions 
patient were willing to pay for the provided services (Barner, Manson, & Murrray, 1999). 
 
Hanna and colleagues (2010), investigated if and how much patients were willing to pay for 
diabetes DSM services in Australian-community pharmacies. Hanna (2010) found that patients 
were willing to pay a median of AUS$30 for fifty percent improvement and AUS$40 for one 
hundred percent improvement per 30-minute initial consultation. For a 30-minute follow-up 
consultation, patients were willing to pay a median of AUS$20 for fifty percent improvement 
and AUS$30 for one hundred percent improvement (Hanna, White & Yanamandram, 2010). 
 
Hanna (2010) found that, for a 30-minute initial consultation, patients were willing to pay a 
median of AUS$30 for 50% improvement and AUS$40 for 100% improvement; whereas, for a 
30-minute follow-up consultation, patients were willing to pay a median of AUS$20 for 50% 
improvement and AUS$30 for 100% improvement (Hanna, et al. 2010). 
Patients‘ WTP increased with an increase in income greater than AUS$150,000 and with a 
frequency of diabetes-related hospitalizations of between two and four. The value of pharmacist 
provided DSM for diabetes was perceived by patients to be high and necessary (Hanna, et al. 
2010). 
The studies described above suggest that patients have a willingness to pay and, to an extent, are 
willing to compensate pharmacists for their expertise. 
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Although WTP for pharmacist provided services has been explored in many countries 
worldwide, including Canada, Australia and America, this present study serves to investigate 
patients‘ WTP for pharmacist-provided services in the South African context. Although there is a 
dearth of South African studies in this field, Munyikwa (2008) carried out a study to determine 
patients‘ WTP for pharmacist-provided asthma care services. Results from that study suggest 
that patients are willing to compensate the pharmacist for their services. (Munyikwa, 2008). 
 
Munyikwa explored the WTP for a hypothetical community-based pharmacist-provided asthma 
care service of a sample of one hundred asthma patients across South Africa. Demographic 
factors, medication usage, patients‘ level of satisfaction and perceived levels of intervention of 
healthcare professionals on the monitoring and management of asthma were determined using a 
telephonically-administered questionnaire. In her study, Munyikwa used a mini-AQLQto 
determine patients‘ quality of life and a contingent valuation method to measure WTP. She 
found out that, of the respondents, 91.4% were willing to pay an average of ZAR68.00 for a 
hypothetical DSM service provided by a pharmacist. The maximum that respondents were 
willing to pay was ZAR300, with a median WTP of R63. She also determined that WTP was 
strongly influenced by the time spent during consultation visits, the presence of co-morbid 
disease states and participants‘ perceived quality of life (Munyikwa, 2008). 
. 
This study utilizes a contingency valuation methodology to measure patients‘ willingness to pay 
for pharmacist-provided services, to reduce risks of medication-related problems, in South 
Africa. In a bid to assist decision-makers, the respondents‘ level of demand and appreciation of 
pharmaceutical care services was also determined. 
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4. CHAPTER FOUR: RESEARCH METHODOLOGY 
 
This chapter presents an overview of the research design and methodology used in determining 
the willingness to pay for pharmacist-provided services in South Africa. 
4.1. RESEARCH HYPOTHESIS 
In research ―Hypothesis‖ is generally defined as a logical supposition, a theory, a reasonable 
guess, a thought or a statement formulated by the researcher when they speculate upon the 
outcome of a research or an experiment (Antonius, 2003).  
The formulation of a hypothesis is an important step during the course of research as it provides 
an appropriate guide to the researcher. It assists the researcher to adopt the right approach to 
resolving the study problems or sub-problems, and also assists the researcher in identifying 
relevant data for the study (Tustin, Ligthelm, Martins, & Wyk, 2005). 
2.5.3. Study hypothesis:  
The hypothesis underpinning this study is: South African patients are willing to pay for 
pharmacist-provided services aimed at reducing risks associated with medication-related 
problems.  
4.2. RESEARCH AIM AND OBJECTIVES 
The aim of this study is to determine if patients in South Africa (SA) are willing to pay for 
pharmacist provided services aimed at reducing medication related problems. To this end the 
following objectives guide the study: 
 
 Determine if clients of community pharmacies in SA are willing to pay for 
pharmacist provided services aimed at reducing risks associated with medication 
related problems. 
 Ascertain the perceived value of the pharmacist provided services to patients, by 
determining how much they are willing to pay. 
 Determine factors that influence WTP, including financial status, gender, race, and 
age. 
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 Establish the perceived value of the pharmacists‘ role in patient care, by third-party 
payers (SA Medical Aid providers) and their WTP for pharmacist-provided services 
(such as DSM) on behalf of their members. 
 
 
4.3. RESEARCH DESIGN 
Research design is defined and understood as a strategic framework, a plan that guides research 
activity to ensure the realization of the research objectives or hypothesis and sound conclusions 
are reached (Terre Blanche & Durrheim, 1999; Tustin, et al. 2005). The research design should 
provide a plan that specifies how the research is going to be executed in such a way that it 
answers the research questions (Terre Blanche & Durrheim, 1999). 
 To accomplish the goals of this study; a non-experimental cross-sectional, descriptive study 
design was employed. Quantitative methods were also employed in analyzing the data obtained 
from the questionnaires in order to determine patients‘ WTP for pharmacist provided services 
and to determine the correlation between willingness to pay and the socio-demographic factors 
such as age, gender and total household income.  
In descriptive studies the aim is to describe a phenomenon accurately either through narrative-
type descriptions, classification, or through measuring relationships, such as WTP approach. 
Descriptive studies are structured and quantitative and are constructed to answer the ―who‖, 
―what‖, ―when‖, ―where‖ and ―how‖ questions (Tustin, et al. 2005). 
Quantitative design is a structured approach which begins with a series of predetermined 
categories, usually embodied in standardized quantitative measures. Data is measured and 
quantified to determine the relationship(s) between an independent variable and a dependent 
variable in a population (Terre Blanche & Durrheim, 1999; Tustin, Ligthelm, Martins, & Wyk, 
2005).  
This study employed a quantitative descriptive approach to determine and quantify the 
relationship between willingness to pay (WTP/ZAR) for pharmacist provided services and socio-
demographic factors (e.g. gender, age and income). 
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4.4. RESEARCH PROCESS 
The study was conducted as a two-phase process; the first phase (phase-1) focused on the 
opinions of patients and the second phase (phase-2) focused on the medical aid companies. In 
phase-1 a questionnaire containing 38 questions was developed and piloted at a private hospital 
pharmacy before the data collection was initiated. A convenience sample of 500 patients was 
recruited through fifty community pharmacies distributed throughout the nine South African 
provinces. A pharmacist within the participating pharmacy was asked to recruit ten participants 
for the researcher. The questionnaire was then administered telephonically by the researcher at a 
prearranged time. 
In phase-2, medical aid schemes registered with the Medical Aids Scheme Council of South 
Africa were included. The medical schemes were contacted via electronic mail and the principal 
officer was invited to participate. A fifteen point questionnaire was completed electronically by 
the willing medical aid participants. 
The administered responses for both phases were captured in Excel® and analyzed with the use 
of statistical software. 
Below is a diagrammatic illustration of the research process employed in the fulfillment of the 
study objectives, and an in-depth discussion of the process follows. 
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Table 4.1 Summary of the research process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5. PHASE 1 – PATIENTS 
 
4.5.1 Research population and sample 
RESEARCH PROCESS 
PHASE-1 - PATIENTS 
Questionnaire Development 
Pilot Questionnaire 
Recruitment of Pharmacies 
Recruitment of Patients 
Conduction of Interviews 
and data collection 
Data Analysis 
Questionnaire Development 
Pilot Questionnaire 
Recruitment of Medical aids 
Data Collection 
Data Analysis 
PHASE-2 – MEDICAL 
AIDS 
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4.5. PHASE-1 - PATIENTS 
4.5.1 Study sample  
According to de Vos (2002), a sample consists of the elements of the population considered for 
actual inclusion in the study. To accomplish the goals of this study a convenience sample of 500 
patients was recruited from fifty participating pharmacies; with each pharmacy recruiting ten 
patients for the study. 
To ensure the sample chosen for the study was representative of the population, proportional 
stratified sampling methodology was employed. In stratified sampling, the population is divided 
into segments or strata and the sample can then be selected proportionally from each stratum 
(Tustin, Ligthelm, Martins, & Wyk, 2005).  
The numbers of patients were proportionally selected from the nine provinces in South Africa as 
shown in the table below. 
Table 4.2: Calculation of study sample (n=500) 
Proportional Stratified:  
 
 
  
% Y Pharmacies X Study Sample (n=500) = Study sample to be recruited per Province  
 
 
 
 
 
Number of Pharmacy per Province (n-Pp) 
Total number of Pharmacies in SA (T-n-Pp) 
X100% = % Y Pharmacies in each province 
(stratum) 
(Stratum)  
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4.5.2. Questionnaire development  
A questionnaire containing 38 questions was developed by the researcher. For easy patient 
administration the questionnaire was structured into four sections, as follows: 
Section A consisted of 15 questions, to determine the participant‘s demographic information 
such as age, gender, racial group highest level of education, employment status, occupation, and 
monthly household income. In this section the respondents‘ were also asked to indicate their 
willingness to pay for various luxurious items, such as buying a new car, as well as being 
questioned about time spent on their activities.  
Section B consisted of four closed-ended questions pertaining to the doctor‘s consultation. In this 
section the respondents were asked to indicate the number of times they consult with their doctor 
within a year and also to indicate their perception of the level of care dispensed by their doctors. 
Section C contained one open-ended question and 17 closed-ended questions pertaining to 
cognitive pharmaceutical care services.  Respondents were asked to indicate their level of 
satisfaction with the services provided to them by pharmacists on a 4-point Likert Scale; where a 
response of 1 indicated a lack of satisfaction and 4 being very satisfied. The respondents‘ 
perception of the level of importance of the provided-care was also elicited. In this section 
respondents were also asked to indicate if they had previously experienced a medication-related 
problem and the management thereof.  
Lastly, section D presented the patient with an ideal collaborative counseling session with their 
pharmacist. It was a collaborative effort with the prescribing doctor in a quest to maximize 
therapeutic outcomes and minimize any potential risk factors for the patient. The respondent was 
further asked to indicate their willingness to pay for the presented risk reduction levels; that is, a 
risk reduction by 30%, 60% through to 90%, either out-of-pocket and/or through their medical 
aid premiums. 
A full copy of the questionnaire is included in Appendix 6. 
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4.5.3.  Pilot study 
According to de Vos (2002:215), a pilot study is conducted to test the methods, procedures, 
instruments and documentation of the study. The purpose of the pilot study is to improve the 
success and effectiveness of the investigation and to validate and allow for readability of the 
questionnaires to be utilized in the study(De Vos, 2002). 
A pilot study for the developed questionnaire (see Appendix 6) was conducted at a private 
hospital pharmacy in Johannesburg, using a group of pharmacists and pharmacist-assistants. 
Based on initial pilot testing, the study instruments were revised and additional testing was done 
telephonically for final assessment.  Discussion with the pre-test candidates after the telephonic 
interviews revealed that all questions were understood in the manner in which they were 
intended and were therefore not altered and the questionnaire was finalized on that basis.  
 
4.5.4. Recruitment of Pharmacies 
 
Fifty South African community pharmacies were proportionally chosen from a list of pharmacies 
registered with the South African Pharmacy Council. The percentage distribution of pharmacies 
with respect to the ten provinces in SA was initially determined, as shown in Table 4.2 above. 
The participating pharmacies in each province were then chosen with respect to the percentage 
distribution within each province as shown in Table 4.3 below.  
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Table 4.3: Percentage distribution of pharmacies by province 
PROVINCE Number of Pharmacies as a 
percentage (%) of total 
Number of pharmacies to be 
recruited 
Eastern Cape 7.4 5 
Free-State 5 2 
Gauteng 39.4 20 
Kwa-Zulu Natal 14.8 7 
Limpopo 4.3 3 
Mpumalanga 4.7 2 
Northwest 5.3 2 
Northern Cape 2.2 1 
Western Cape 16.6 8 
Total 100% 50 
 
 
4.5.5. Recruitment of Patients 
 
A convenience sample of 500 patients was recruited from the fifty participating pharmacies, with 
each pharmacy tasked to recruit ten patients for the study. The small sample size of ten patients 
per pharmacy was designed to reduce inconvenience to the recruiting pharmacist and provide the 
researcher with a spread of data. 
 
Table 4.4 provides a summary of the proposed number of recruiting pharmacies and participants 
per province. 
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Table 4.4 recruitment of patients by province 
Province Number of Recruiting Pharmacies Number of recruited participants 
Eastern Cape 5 50 
Free-State 2 20 
Gauteng 20 200 
Kwa-Zulu Natal 7 70 
Limpopo 3 30 
Mpumalanga 2 20 
Northwest 2 20 
Northern Cape 1 10 
Western Cape 8 80 
Total 50 500 
 
Eleven research packages were sent to each recruiting pharmacy, ten of which were patient 
specific and one for use by the recruiting pharmacist. Within the pharmacist‘s recruiting package 
was a letter explaining the study (see Appendix 4) and a data collection sheet (see Appendix 8). 
The responsible pharmacist or delegated pharmacist or pharmacist-assistant of the selected 
pharmacy was requested to recruit the ten patients based on the following inclusion criteria.  
The inclusion criteria for patients to participate were: 
 they should be over 21 years of age; 
 patrons of the pharmacy involved in the research;  
 able to read and write (literacy level) and; 
 must have had either their chronic or acute prescription filled at that particular pharmacy 
at least once.  
Within each research package was a letter for the participant (see Appendix 3) explaining the 
study, consent forms (see Appendix 5) and the questionnaire (see Appendix 6). 
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The recruited participants were asked to sign the consent form which they had to sign and submit 
to the recruiting pharmacist as an indication of their willingness to participate. On behalf of the 
researcher, the recruiting pharmacist had to setup an appointment for a telephonic interview with 
the participant and record it appropriately on a provided data collection sheet, which was to be 
conducted by the researcher at the designated time. 
After completing the recruiting procedure, the recruiting-pharmacist provided the researcher with 
a list, by facsimile, containing all the recruited participants‘ details. 
4.5.6. Interviewing of patients and data collection 
 
The data collection, consisting of telephonic administration of the questionnaires, was conducted 
over a period of five months, from June 2010 to October 2010. 
Self-administered questionnaires are known to have a poor response rate and therefore it is 
crucial that the researcher consider ways of improving the response rate (Rossi, Wright, & 
Anderson, 1983).  Rossi and colleagues (1983) introduced the principle of Total Design Method 
(TDM) as a means of improving response rates. This includes the use of a covering letter that 
ascertains confidentiality. Gestures such as signing each cover letter personally can make the 
respondents feel like important contributors to the study (Rossi, Wright, & Anderson, 1983).   
Participants were also given provision to request a copy of the research findings and were 
requested to provide the researcher with their electronic mail address for further communication 
once the research was complete.  
Once the data collection sheet was received from the recruiting pharmacist, the patients were 
contacted to confirm the interview at their preferred time. The questionnaires were administered 
telephonically and the conversations were recorded by the researcher and the data was captured.  
The researcher and supervisor‘s contact details were made available to the participants, if felt 
they needed any queries to be resolved. The questionnaires were coded to allow for 
identification, but in order to protect identity and ensure confidentiality; they did not contain any 
participant‘s identifying features, such as name.   
 
  
61 
4.5.7. Data Analysis  
 
The responses to the questionnaire-based survey were captured on a Microsoft Excel® 
spreadsheet by the researcher and coded for analysis using statistical software (SPSS and 
STATA10).  
Initial data analysis was performed using descriptive statistics with the aid of graphical 
representation where relevant. The main objective of descriptive statistics is to summarize and 
represent obtained observations of time variables (Terre Blanche & Durrheim, 1999). The study 
demographics were tallied and captured with the South African current demographics to 
determine generalizeability. Most of the data was expressed numerically as a percentage of the 
total population involved.  
The data obtained from demographic observations was depicted using frequency distributions; 
for example bar charts, line curves and pie charts, where necessary. A frequency distribution is a 
graphical representation of the pattern of values obtained in a particular observation (Antonius, 
2003). Once the observations had been manipulated into diagrams, the measures of central 
tendencies (mode, median and mean) were easily defined and reported by the researcher.  
To enable the measurement of bi-variate or multivariate relationships between independent 
variables (age, gender, and so forth) and the dependent variable willingness to pay (WTP), and to 
determine the significance of these relationships, additional statistical techniques such as box 
plots, cross-tabulation, chi-square tests, analysis of variance (ANOVA) and linear regression 
were employed under the guidance of a statistician (please refer to acknowledgments).  
4.5.7.1. Box plots or Whisker diagrams 
Box plots or whisker diagrams were used to further describe the data. A box plot is a 
standardized visual description of the most important aspects of an observed variable based on 
the five-number summaries: minimum (lower extreme), first quartile, median, third quartile and 
maximum (upper extreme) as shown in figure 4.1 (Keller & Warrack, 2003).  
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Box plot or Whisker diagram 
 
 
 
 
 
 
 
 
 
Figure 4.1: Illustrating a box plot or a whisker diagram   
4.5.7.2. Cross-tabulation and chi-square test 
Cross-tabulation of chi-square tests were utilized to measure the existence or absence of 
relationships between variables and the significance thereof. A cross-tabulation is a joint 
frequency distribution based on two or more categorical variables. They are usually presented in 
a matrix, called a contingency table. The joint frequency distribution can be analyzed with the 
chi-square statistic to determine the significance in the relationship between the variables (Keller 
& Warrack, 2003; Gujarati, 2003). 
4.5.7.3. Analysis of Variance (ANOVA) 
Analysis of Variance (ANOVA) is a collection of statistical models and their associated 
procedures, useful in comparing means of more than two groups of observations and it is 
sometimes referred to as the test of significant difference between means (Terre Blanche & 
Durrheim, 1999). ANOVA has the advantage that it can be used to analyzed situations in which 
Upper extreme 
Upper Quartile 
Median 
Lower Quartile 
Lower extreme 
Inter-quartile 
Range (IQR) 
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there are several independent variables and can help identify the way in which these independent 
variables interact, as well as the effect these interactions have on the dependent variable in a 
regression analysis (Terre Blanche & Durrheim, 1999). 
4.5.7.4. Correlations 
Correlation statistical techniques indicate the statistical relationship between two or more 
random variables or observed data values (Gujarati, 2003). These techniques are used to measure 
the strength of relationship between two variables. The relationship between two variables can be 
strong or weak and positive or negative (Terre Blanche & Durrheim, 1999). Mathematically, the 
correlation is expressed in the form of a correlation co-efficient, that ranges from -1 (negatively 
dependent), through to 0 (absolutely independent), and 1 (always occur together). A simple 
correlation co-efficient is a statistical measure of degree of linear association, between two 
variables (Gujarati, 2003). Correlation and regression are similar as they are both associated with 
assessment of relationships between variables. In this study the relationship between variables 
was assessed by employing the Pearson correlation coefficient and the significance of the 
relationships was also determined. 
4.5.7.5. Regression Analysis 
Regression analysis is a statistical tool for investigating and quantifying relationship between 
variables, that is, the dependent variable as a function of the independent or explanatory 
variables, through the aid of a mathematical equation (Studenmund, 2000).  
In this study the dependent variable, the respondents‘ willingness to pay (WTP) for pharmacist-
provided services, was expressed as a function of multivariate determinates such as age, gender 
and income, as explained in the following section. The explanatory variables were carefully 
chosen with reference to literature (Donald, 2000; Shu Chuen Li, 2003), and their individual 
relationship with respect to WTP was simultaneously investigated and defined with the 
assumption that other influential factors and independent variables were held constant. The table 
below indicates the independent variables which were regressed against the dependent variable 
WTP. 
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Table 4.5 Explaining and defining the study’s independent variable  
Independent variable  Symbol and expected 
sign 
Explanation 
Geographical location Geo-Loc (+) The participants‘ provincial location in 
South Africa, which included: Gauteng, 
North-west, Limpopo, Mpumalanga, 
Western Cape, Eastern Cape, Northern 
Cape, Free-state and Kwa-Zulu Natal. The 
objective was to ascertain if a participant‘s 
location had a particular effect on WTP. 
Some provinces have a greater contribution 
to the country‘s GDP; hence more economic 
muscle thus possibly influencing 
participant‘s WTP. 
Gender Gender (+) The objective was to ascertain if the gender 
of participants had an effect on WTP. 
Age Age (+) The participants were categorized in to age 
groups. It is expected that different age 
groups have different appreciation for 
pharmaceutical care; hence a possible 
disparity in their WTP across age categories. 
Race Race (+) Consisted of the racial groups representing 
the South African nation, that is, Blacks, 
Whites, Asians and Coloureds. Owing to 
skewed distribution in economic ability 
amongst racial groups in SA, race was 
expected to have an effect on WTP. 
Level of education Education (+) It was expected that the greater the 
education level of a participant the greater 
the appreciation of healthcare, the better the 
economic power and possibly the greater the 
willingness to pay. 
Total household 
income 
Income (+) High income earners were expected to be 
willing to pay more possibly due to ability to 
pay. 
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Employment status  Employment (+) An employed participant should be 
economically able to pay more than an 
unemployed participant. 
Chronic diseases Cronic (+) Participants with a chronic disease were 
expected to be willing to pay more. 
Co-morbidities Co-morbid (+) The more chronic diseases, that is an 
increase in co-morbidities, possibly the 
greater the expected willingness to pay. 
Medical aid status  Medical aid (-) Participants with medical aid are expected to 
be reluctant to pay as they expect their 
medical aid to cover the proposed serviceon 
their behalf. 
Level of Satisfaction  Satisfaction (+) The greater the level of satisfaction the 
greater the likelihood of willingness to pay. 
 
As discussed above, to determine the regressive effect of each individual variable on the 
dependent variable, other variables were held constant. However in reality these variables may 
occur together and hence interfere, consequently producing a combined effect, thus for purposes 
of inference a second regression including all the independent variables was done. 
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4.6. PHASE-2 – MEDICAL AID SCHEMES 
 
4.6.1. Research population and sample 
A list of all registered medical aids and their contact details was obtained from the website of the 
Council of Medical Schemes (CMS) of South Africa (http://www.medicalschemes.com/). The 
Council for Medical Schemes is a statutory body established by the Department of Health in 
South Africa to regulate and provide supervisions over medical schemes. The list is comprised of 
108 medical aids; of which 77 are restricted to the public and 31 are open schemes (see 
Appendix 9). All the medical schemes were sent an e-mail pertaining to the study, requesting 
their willingness to participate in the study.  
4.6.2. Questionnaire development 
A questionnaire containing 15 questions was designed to be administered electronically via 
electronic mail by a medical aid scheme delegate. For easy administration the questionnaire was 
structured into four sections (see Appendix 7), namely sections A, B, C and D.  
 
Section A consisted of six demographic questions, and section B consisted of three closed-ended 
questions. The questions were designed to elicit the participant‘s perception on the effectiveness 
of the information dispensed by doctors during consultations with their member. Section C 
consisted of two closed-ended questions that utilized a 5-point Likert Scale to rate the perception 
of pharmacist-provided services and the importance of care that has been provided. Lastly, 
Section D consisted of two questions assessing willingness to pay for pharmaceutical care 
services provided to patients by pharmacists. 
 
4.6.3. Piloting of questionnaire 
The questionnaire was designed in consultation with two pharmacoeconomics specialists in 
clinical research and clinical risk management at a major medical aid scheme in South Africa. 
The questionnaire was further pre-tested with two pharmacists who acted as respondents to 
  
67 
determine readability and usability. The necessary amendments were made before the 
recruitment of medical-aid participants was initiated. 
4.6.4. Recruitment of medical aid schemes 
An electronic mail communication containing background information to the study was sent to 
the principal officer‘s e-mail address available on the medical scheme‘s website. The principal 
officer was requested to participate in the study on behalf of the medical scheme, or to refer the 
researcher to a suitable scheme representative.  Attached to the electronic mail was the abstract 
to the study, a letter outlining the purpose of the study (see Appendix 10) and a questionnaire to 
be completed by the delegated scheme officer (see Appendix 7). 
 
4.6.5. Data collection 
An initial period of four weeks was allowed for returning the questionnaires. Once the waiting 
period had elapsed without response from the principal officer or delegated officer, a letter of 
reminder, which included another questionnaire, was sent. If no response was received a 
furthertelephonic follow up was made after three weeks to establish the reason for the apparent 
lack of response, as well as to make arrangements to administer the questionnaire in any way 
preferred by the delegated officer. Following participation and return of a questionnaire a letter 
of acknowledgment was sent to the participating officer, thanking them for their contribution to 
the study. 
4.6.6. Data analysis 
The responses to the questionnaire-based survey were captured onto a Microsoft Excel® 
spreadsheet by the researcher and coded for analysis using statistical software (SPSS and 
STATA10).  
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4.7. ETHICAL CONSIDERATION AND OBLIGATIONS 
It is always imperative to adhere to ethical standards before initiating any research work, thus 
ethical approval for the study was sought.  
4.7.1. Research Approval 
 Approval by the Faculty of Health Sciences Research, Technology and Innovations 
Committee (FRTI) and the Nelson Mandela Metropolitan University‘s (NMMU) 
Research Ethics Committee was obtained (Reference number: 204009553). 
 
4.7.2. Researcher’s Obligations to Research-sites 
 Permission was obtained from the participating pharmacies to utilize their pharmacies for 
recruiting participants as well as allowing their pharmacists to be actively involved in the 
data collection. 
 
4.7.3. Researcher’s Obligations to participants (respondents) 
 Recruiting pharmacists obtained consent in the form of a signature (see Appendix 5), 
from potential participants. 
 Interviews were scheduled at the convenience of the participants, as they were requested 
to stipulate on the data collection sheet the most convenient time for the interview to be 
conducted.  
  Participant consent was confirmed by the researcher before the telephonic administration 
of the questionnaire.  
 Participants were not forced to answer any question if they felt uncomfortable. 
 Anonymity and confidentiality was maintained at all times. 
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5. CHAPTER FIVE: RESULTS AND DISCUSSION 
 
5.1.     DESCRIPTION OF STUDY SAMPLE 
As outlined in the methodology, (Section 4.3.2), objectives of the study are to obtain  a 
proportional stratified sample of 500 patients who were to be recruited from 50 participating 
pharmacies; with each pharmacy recruiting ten patients for the study. 
5.1.1 Participating Pharmacies 
To ensure that the sample was representative of the study population, the 50 pharmacies were 
proportionally selected from the respective provinces, relative to the total distribution of 
pharmacies in South Africa, as listed by the South African Pharmacy Council (SAPC). 
Pharmacies were proportionally chosen from the SAPC‘s register and were contacted 
telephonically by the researcher, to request them to participate in the study. 
Five hundred questionnaires were prepared and posted to the recruiting pharmacists in the 50 
participating pharmacies. Of the 50 pharmacists who had agreed to participate, only 37 (74.0%) 
pharmacists managed to recruit at least one participant. Table 5.1 shows a summary of the 
distribution of the participating pharmacies. 
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Table 5.1 Number of pharmacies recruited per province 
PROVINCE Number of 
pharmacies as 
a Percentage 
(%) of total 
Number of 
pharmacies 
recruited 
Number of 
pharmacies who 
recruited at least 
one participant 
Percentage (%) of 
pharmacies who 
recruited at least 
one participant 
Eastern Cape 7.4 5 5 10 
Free-state 5 2 1 2 
Gauteng 39.4 20 18 36 
KwaZulu-Natal 14.8 7 3 6 
Limpopo 4.3 3 3 6 
Mpumalanga 4.7 2 2 4 
Northwest 5.3 2 1 2 
**
Northern Cape 2.2 1 0 0 
Western Cape 16.6 8 4 8 
Total 100% 50 37 74 
**
No participants were recruited from this province 
Thirteen (26.0%) of the pharmacists could not provide the researcher with at least one 
participant. Multiple reasons were given for not being able to recruit participants even after an 
initial indication of willingness to participate, these comments included: 
 “This is a very good study for the pharmacy profession in South Africa; however, our 
retail pharmacy is so busy that we do not even have time to breathe. It would have been 
nice if we could assist you with a few patients, but unfortunately due to time constrains 
we were unable to fulfill our promise.” 
 “The pharmacists that received your documents misplaced them so would you mind 
resending those documents again so that we can see how we can assist you.” 
 “We are experiencing shortages of staff, hence we might find it very difficult to allocate 
someone to recruit patients. We are not promising anything but we will give it our best 
shot.” 
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 “Patients are not willing to provide their contact details so unfortunately there are no 
other means we can assist.” 
 “Although we might be able to recruit these patients for you, I strongly feel this is a 
waste of time for two main reasons: pharmacists will not be able to effectively provide 
this particular service as it requires a lot of input by the pharmacist in a limited amount 
of time and secondly patients are not willing to spend time with the pharmacist as well as 
pay for such a service.” 
According to Hepler and Strand (1990) pharmacists spend most of their time performing 
technical functions such as packing stock, counting pills and possibly pre-packing tablets 
amongst other things, instead of efficiently utilizing their pharmacological knowledge for 
cognitive interventions that would improve therapeutic outcomes. 
Negative attitudes of pharmacists could be a hindrance to the continuous development of the 
pharmacy profession locally and internationally. 
South Africa is a multicultural and multilingual nation, with twelve officially-recognized spoken 
languages in South Africa, thus language is bound to be a barrier in effective communication. 
Data collection proved to be problematic in some provinces as respondents could not speak 
English and therefore could not respond to the questionnaires. Unfortunately due to the 
researcher‗s inability to speak any other South African language but English, participants had to 
be English speaking. This was a limitation to the study, where 68% speak Afrikaans; the other 
languages spoken are Setswana 20.8%, and English 2.5%, thus resulted in no participants being 
recruited in the Northern Cape (Statistics South Africa, 2010). 
5.1.2 Demographic characteristics of respondents 
As discussed in the study objectives (Section 4.3), the demographics of the participants were 
obtained. Demographic information that was assessed includes geographical location, age, and 
gender, and racial group, level of education, employment status, total household occupants, total 
household income, total household expenditure and presence of chronic diseases or co-morbid 
disease states as well as weekly time spent on various activities. 
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5.1.3 Distribution of respondents by geographical location 
Five hundred questionnaires were distributed to 50 pharmacies, of which 37 (74.0%) returned 
lists of patients who were willing to participate. Table 5.2 below provides a summary of 
recruited potential participants and actual respondents. 
Table 5.2 Summary of recruited patients and actual participants 
PROVINCE 
Number of 
patients to 
be recruited 
(n=500) 
Number 
of 
patients 
recruited
(n=313) 
% 
participants 
recruited 
Number of 
participants 
interviewed 
(n=263) 
% 
participants 
Gauteng 200 165 82.5 140 70 
Limpopo 30 20 66.7 18 60 
Eastern Cape 50 37 74 32 64 
Western 
Cape 
80 29 22.5 26 32.5 
KZN 70 26 37.1 23 32.9 
Free State 20 10 50 5 25 
**
Northern 
Cape 
10 0 0 0 0 
North West 20 13 30 11 55 
Mpumalanga 20 13 50 8 40 
TOTAL 500 313 56.4 263 52.6 
**no respondents obtained due to language barrier 
 
Of the 500 intended participants, only 313 (62.6%) patients were successfully recruited from the 
37 participating pharmacies distributed throughout the nine provinces. No respondents were 
obtained from the Northern Cape Province as shown in table 5.2 above. 
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Of the 313 patients recruited from the pharmacies, 263 patients were effectively interviewed 
telephonically. A small percentage of the patients, 10% (n=50), were unable to respond to the 
telephonically-administered questionnaire, for a variety of reasons including: unwillingness to 
participate after being contacted by the researcher; for personal reasons, not being fluent in 
English, and some patient-contact details provided by the pharmacies were incorrect. 
The final 263 respondents were distributed provincially, as shown in table 5.3 below. 
Table 5.3 Summary of recruited patients and actual respondents 
PROVINCE No of respondents 
required 
No of responders 
recruited 
% Recruited of 
required 
Gauteng 200 140 70.0 
Limpopo 30 18 60.0 
Eastern Cape 50 32 64.0 
Western Cape 80 26 32.5 
KZN 70 23 32.9 
Free State 20 5 25.0 
**
Northern Cape 10 0 0 
North West 20 11 55.0 
Mpumalanga 20 8 40.0 
TOTAL 500 263 52.6 
**no respondents obtained due to communication barrier 
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Figure 5.1 below denotes the distribution of respondents by province. 
 
Figure 5.1 Distribution of respondents by province (n=263) 
 
Gauteng was predisposed to have the highest number of participants due to the highest 
proportion of pharmacies, with 39.4% of the pharmacies registered in South Africa (SA), hence a 
higher response rate was expected from Gauteng. Although the smallest province in South 
Africa, Gauteng is the economic hub and contributes 33.9% to South Africa‘s gross domestic 
product (GDP) (Statistics South Africa, 2010). Most businesses in SA, including retail 
pharmacies, thrive in this highly urbanized province although it only occupies 1.4% of the 
country‘s land (Statistics South Africa, 2010). 
5.1.4 Age distribution of respondents 
The inclusion criteria to the study required that respondents be at least 21 years of age, thus the 
age distribution obtained was from 21 years to 83 years. The median age of the sample was 47 
years and the mean was 46 years. The sample population was positively skewed towards the 
younger respondents, with 73.0% of the sample population being less than 50 years of age. The 
group aged between 31 and 40 accounted for 33.1% (n=263) and the middle-aged group 41 to 50 
accounted for 22.8%. The sample consisted of few older respondents with less than 10.0% of the 
12.0% 2.0% 
53.0% 
9.00% 
7.00% 
3.00% 
0.00% 
4.00% 10.00% Eastern Cape
Freestate
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sample being older than 70 years of age. The group aged between 71 and 80 represented 
approximately 3.8% of the study sample and those older than 80 years only accounted for 0.8%. 
 
  
 
Approximately one third (31.0%) of the South African population is less than 15 years of age, 
61.4% is in the age group of 15-60 years and only 7.6% of the population is above the age of 60 
(Statistics South Africa, 2010). 
The age distribution of the study sample therefore appears to represent the South African age 
distribution with the exception of the group younger than 21(Statistics South Africa, 2010). 
 
 
 
 
 
 
Figure 5.2 Age distribution of respondents (n=263) 
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5.1.5 Gender distribution of respondents 
Of the 263 respondents, 67.7% were females and 32.3% males, as shown in Figure 5.3 below.  
 
  Figure 5.3 Gender distribution (n=263) 
According to a community survey conducted in 2007; there are 51.7% females and 48.3% males 
in South Africa (Statistics South Africa, 2010). Therefore the study population contains more 
females than male participates and is not necessarily representative of the South African 
population. Although no statistics are available, it may be representative of the ratio of male to 
female patients frequenting community pharmacies. 
5.1.6 Racial demographic characteristics  
 
Figure 5.4 Respondents’ racial demographic distribution (n=263) 
Racial group 
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There was almost a balanced distribution of respondents in the White and Black racial groups, 
with rates of 46.4% and 36.5% respectively. There was a very low representation from the Asian 
(13.7%) and Coloured groups (3.4%). 
According to government statistics, black Africans are in the majority (79%), divided into 
different ethnic groups such as Xhosa, Zulu, Tswana, Ndebele, Pedi, Sotho, and Swati, as well as 
other immigrants from other countries such as Zimbabwe and Nigeria (Statistics South Africa, 
2010). The study did not however consider the ethnicity of the sample population and data of 
black Africans were all grouped together irrespective of ethnicity and nationality of origin. 
The white population is the second largest group contributing approximately 9.5% of the 
population, the Coloureds, a mixed race, makes up about 8.9% and the remaining population 
consists of Indians or Asians (Statistics South Africa, 2010). 
Racially, the study sample distribution deviates from the South African racial distribution, and 
may  possibly be due to a multiplicity of reasons. The dominancy of the white race (46.4%) in 
the study sample over other races especially blacks (36.5%) as opposed to the actual societal 
norm might be due to the distribution of wealth. The majority of the research sites, that is, the 
privately-owned community pharmacies are situated in the more affluent areas for better 
business outcomes. These areas are still predominately inhabited by whites. Thus, due to 
research site location, the study sample was biased towards the white population. 
5. Highest Level of Education 
Of the 263 respondents, more than three quarters of the study population had obtained at least a 
tertiary qualification (86%). One-third of the sample, 33.5%, had obtained a college diploma. 
There was an equal distribution of respondents with graduate degrees (24.0%) and post-graduate 
degrees (24.7%). The smaller portion of the population had no tertiary qualification; 
approximately 3% had not matriculated and only 14.8% had obtained at least a Matric 
qualification. Figure 5.5 is a summary of the highest level of education attained by respondents. 
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  Figure 5.5 Level of education of respondents (n=263) 
In comparison to the population of South Africa, the above distribution does not tally with the 
current level of education statistics. Approximately 18% of adults above 15 years (about 9 
million) are functionally illiterate and 65% of whites have a higher qualification, while 40% of 
Indians/Asians, 17% of Coloureds and only 14% of Blacks have a higher qualification (SA-Info 
Reporter, 2010). The higher proportion of respondents with a higher qualification could therefore 
be due to the proportionally greater number of Whites included in the study sample. 
5.1.8 Employment Status 
Of the total sample population (n=263), at least two-thirds were employed fulltime and 
accounted for 71.1%; 15.6% were self-employed; 2.7% had retired; 1.9% were on pension; 1.5% 
were still studying and only 2.7% were unemployed (Figure 5.6). 
Pre-Matric 
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  Figure 5.6 Employment status of respondents (n=263) 
The employment status of the study sample is not representative of level of employment and 
unemployment in South Africa. According to Statistics South Africa (2010), 48.3% of the 
population between the ages of 15-24 is unemployed and 28.5% between the age group of 25-32 
are also reported to be unemployed. Of those unemployed, Blacks contribute a greater proportion 
(86.5%), followed by Coloureds (9.7%), whilst Asians and Whites contribute a low proportion of 
1.3% and 2.5% respectively. 
5.1.9 Occupation 
The distribution of respondents‘ occupations varied from the low-paying jobs, such as cashiers 
and caretakers, to executive positions like a Sales Executive Manager. The distribution varied 
from technical, mechanical, engineering, administrative, retailing, sales, service-orientated, and 
health related occupations. Amongst the study sample, ten occupations were recurrent at a 
frequency of at least three times, with the teachers having the highest representation (13), which 
were approximately 4.9% of the total sample. 
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5.1.10 Total Household Occupants 
There was a maximum of nine inhabitants per household and a minimum of at least one 
inhabitant. Of the 263 respondents, most of the households were occupied by at least three 
people accounting for approximately 25.5% of the sample as shown below. 
 
  Figure 5.7 Total household occupants of respondents (n=263) 
 
Of 263 respondents, 37.6% indicated that they had no children under the age of 18 in the house 
and 25.5% had at least two children under 18 years of age. The distribution of children less than 
18 years per household is shown in Figure 5.8. 
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 Figure 5.8 Number of respondents’ children under 18years (n=263) 
 
5.1.11 Total Household Income  
In WTP studies conducted worldwide, respondents‘ willingness to pay has been found to be 
directly related to the ability to pay (Blumenschein& Freeman, 2004). In these studies the 
respondents‘ ability to pay was determined by assessing their total household income as well as 
the respondents‘ willingness to spend money on other commodities such as a new car, a night out 
with friends, a week‘s vacation and monthly household expenditure on food and groceries. In the 
event that some respondents were not comfortable with disclosing their total household earnings, 
the assessment of respondents‘ expenditure on other social commodities was set to provide the 
researcher with a means of determining the ability to pay. However of the 263 respondents, none 
were unwilling to disclose their total household income. A summary of the distribution of 
household earnings of the study sample is provided in Figure 5.9. 
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  Figure 5.9 Total household Income of respondents (n=263) 
 
For analytical purposes the total household income status was further categorized into three 
different groups: Low Income Generating households (LIGhs), Medium Income generating 
households (MIGhs) and High Income Generating households (HIGhs). The table 5.4 below 
shows a summary of the income categories of participants. 
Table 5.4 Summary of total household income categories of respondents 
Category Total monthly household income 
(Rands) 
% of Respondents 
LIGhs <10 000 23.6 
MIGhs 10 001 – 20 000 25.5 
HIGhs >20 000 50.9 
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Although there was almost an even distribution between the low income earning bracket (23.6%) 
and the medium earning bracket (25.5%), the majority of the respondents were in the higher 
income earning bracket (50.9%).. 
As explained previously (Section 5.1.3), participating private pharmacies (research sites) in 
South Africa tend to be situated in relatively affluent areas, hence a relatively high proportion of 
high income earners were included in the study. The affluence and privileged circumstances of 
the majority of the study sample were also reflected by their relative willingness to spend on 
social commodities as shown and discussed below. 
 
 
Figure 5.10 Respondents’ average monthly household expenditure on food and groceries 
(n=263) 
Table 5.5 Respondents’ willingness to pay (WTP) for social activities and commodities 
Respondents’ 
Willingness to pay for: 
Minimum 
(ZAR) 
Maximum 
(ZAR) 
Mean 
(ZAR) 
Standard 
deviation 
New car/month 0 10600 2818.25 2601.227 
Vacation (one week) 0 80000 5830.15 8774.808 
Night out with friends 0 1200 290.46 276.48 
Member at a fitness club 0 750 159.16 276.48 
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Research conducted in 2010, assessing urban consumer patterns reported that an urban 
homestead had an average monthly income of R14 000 (TNS Research surveys, 2010). This 
research was conducted in affluent areas such as: Fourways, Sandton and Bedfordview in 
Johannesburg; Eastern suburbs in Pretoria, Umhlanga and Northern Durban as well as Somerset 
West in Western Cape. It was reported that the lowest income earning households were in 
Evaton (R4384) and Soweto (R5500) in Gauteng (TNS Research surveys, 2010). 
Table 5.6 below shows the average annual income of South African households by population 
group (Statistics South Africa, 2006). 
Table 5.6 average annual income of SA households by population group 
Racial Group Whites Blacks Asians/Indians Coloureds 
Average Income per 
annum (Rands) 
280 870 37 711 134 543 79 423 
 
In light of these statistics and considering the racial composition, and educational levels of the 
study sample, the monthly household income and monthly expenditure of the study sample 
appears to fit. 
As explained previously (Section 5.1.3) most community pharmacies strategically position 
themselves in more affluent areas for better revenue. Since the research was conducted in these 
pharmacies in the more affluent suburbs, hence the observed skewed distribution towards high 
income earners, which is not reflective of the South Africa population. 
5.1.12 Medical Aid Status 
Of the 263 respondents, 60% were reported to have medical aid coverage as shown in Figure 
5.12 below. There is a total of 22 medical aid schemes that represented at least one respondent, 
they are: Bankmed; Bestmed; CAMAF; Clicks; Clientel; Compcare; Discovery; Fedhealth; 
Gems; Ingwe; Liberty Life; Medishield; Medihelp; Netcare; Pick n Pay; Polmed; Profmed; 
Protea; Sizwe; University of Witwatersrand; Woolworths and Xstrata. Of the 157 participants 
who had medical aid, most belonged to the Discovery medical scheme (29.5%), followed by 
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Bestmed (15.4%), Netcare (11%), Pick ‗n‘ Pay (4.5%) and Bestmed and CAMAF were equally 
represented by 3.2%. 
 
 
The monthly medical aid premiums varied, ranging from a minimum contribution of R750 to a 
maximum of R7000 with a mean premium of approximately R2263. 
5.1.13 Chronic diseases 
Of the 263 respondents, approximately one third of the patients (32.3%) suffered from at least 
one chronic disease (Figure 5.12). Chronic diseases experienced by respondents included 
hypertension, asthma, hay-fever, eczema, hypercholesterolemia, diabetes mellitus, 
hypothyroidism, depression, insomnia, panic disorders, ischaemic heart disease, and osteoporosis 
among others. Figure 5.12 is a representation of the number of respondents who experienced at 
least one chronic disease. 
Figure 5.11 Medical Aid Membership of respondents (n=263) 
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Figure 5.12 Chronic diseases experienced by respondents (n=263) 
 
The co-existence of multiple chronic diseases (co-morbidities) was also assessed to determine if 
it had any influence on respondents‘ willingness to pay. Table 5.7 provides a summary of 
respondents with respect to co-existing (co-morbidities) chronic diseases. Respondents with no 
chronic diseases (178) were represented with zero co-morbidity. 
Table 5.7 Co-morbidities of respondents 
Co-morbidities Number of Respondents Percentage 
0 178 67.7 
1 25 9.5 
2 34 12.9 
3 15 5.7 
4 8 3.0 
5 3 1.2 
Total 263 100 
 
Of the 263 respondents, 12.9% presented with two co-morbidities and 9.9% presented with three 
or more. 
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5.1.14 Respondents’ perception of medical care received from doctors 
The respondents‘ perception of care received during doctors‘ consultations was elicited, as 
discussed in Section 4.2 of the methodology. The respondents were asked to respond with either 
yes or no, to a set of questions that may have been asked and explanations that may have been 
given to them during consultations with their doctor. Table 5.8 summarizes the responses 
obtained. 
 
 % Response 
Description of Care Component during consultation NO YES 
Assessment of the presence of allergies 50.6 49.4 
Assessment of the presence of other medical conditions 37.6 62.4 
Assessment of administration of other medication 64.6 35.4 
Explanation of the nature of condition present 5.7 94.3 
Explanation of the diagnosis 3.8 96.2 
Explanation of the reasons for prescribed medicines 59.3 40.7 
Explanation of how the medication was expected to work 52.9 47.1 
Explanation of how the medication was to be administered 45.2 54.8 
Explanation of possible side-effects 44.9 55.1 
Opportunity for patient to ask questions 28.9 71.1 
 
Of the 263 respondents, 37.3% visited the doctor at least once a year, with 30.4% and 21.3% 
visiting the doctor two and three times respectively. Less than 50% of the respondents visited the 
doctor more than four times a year. The maximum number of visits was 12 times in a year by 
one respondent (0.4%). 
Table 5.8 Respondents’ perception of medical care received from doctors 
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Of the respondents interviewed (n=263), 50.6% could not recall having been asked for the 
presence of allergies and 64.6% had not been asked if they were using any other medication. 
Only 55.1% of respondents had the possible side effects of medication explained to them by their 
doctors. Respondents generally had been provided with more explanations with regards the 
nature of their condition (94.3%) and the diagnosis (96.2%). 
5.1.15 Respondents’ Experience of Pharmacy and Pharmaceutical care services 
The cornerstone of re-professionalization of the pharmacy profession has been identified as 
pharmaceutical care, and the provision of pharmaceutical care services, as explained in Section 
2.1 of the literature review. 
In keeping with the study objectives participants‘ experience of pharmacy and pharmaceutical 
care services were determined and these findings follow. 
5.1.16 Patronization of community pharmacy 
Respondents‘ patronization of their community pharmacy, their opinions, behaviours, and 
attitudes particularly towards their pharmacy and pharmacists generally were determined. 
 Pharmacy of Choice 
The participants were asked if the pharmacy that had recruited them for the study was their 
pharmacy of choice, and 224 of the participants (85.2%) indicated that it was, with only 14.8% 
indicating   that it was not. 
 Frequency of visit to pharmacy of choice 
The respondents were asked to approximate their monthly number of visits to the pharmacy to 
fill their acute and chronic prescriptions and to make pharmacist-assisted medication purchases. 
Table 5.9 shows the respondents‘ frequency of visitation to the pharmacy, to obtain pharmacist-
provided pharmaceutical services. 
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Table 5.9 Respondents’ frequency of visitation to the pharmacy (n=263) 
Number of visits per month Number of respondents % of respondents 
1 33 12.6 
2 86 32.7 
3 94 35.7 
4 43 16.4 
5 3 1.1 
6 3 1.1 
7 0 0 
8 1 0.4 
TOTAL 263 100 
 
The frequency of pharmacy visitation varied from a minimum of one a month to a maximum of 
eight visits in a month. 
 Frequency of visitations to other pharmacies other than pharmacy of choice 
Poly-pharmacy has been defined as ―the use of a number of drugs, possibly prescribed by 
different doctors and filled in different pharmacies, by a patient who may have one or several 
health problems (Anonymous 2000). Poly-pharmacy and self-diagnosis creates risk of 
medication-related problems for the patient. The pharmacist as the custodian of medicines can 
minimize this risk by advising the patient about rational medication usage and monitoring 
medication use by the patients. Patients often use different pharmacies, for reasons such as 
convenience of location, availability of certain product lines and availability of care services. 
In this study the researcher determined the frequency with which participants visited pharmacies 
other than their preferred pharmacy.These results are presented in Figure 5.13. 
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Figure 5.13 Respondents’ frequency of visitations to other pharmacies other than the 
pharmacy of choice (n=263) 
Approximately 30.4% of the study participants were loyal to their pharmacy of choice as they 
did not use other pharmacies to obtain their medications. The majority of the participants, 
however used at least one other pharmacy to obtain their medications. Participants obtained their 
medications from a maximum of four pharmacies and a minimum of one pharmacy including 
their pharmacy of choice. 
 Respondents’ awareness of pharmacy services 
Knowledge of patient medical history and personal details such as age, gender and weight are 
important for pharmacists to make informed decisions regarding medication. Effective 
communication between professionals with regards to patient medication is also necessary for 
provision of good healthcare. 
In this study participants were asked about their awareness of the pharmacy, which they last 
frequented, having a record of their personal and medical information. They were also asked if 
they were aware of their pharmacist having had to communicate with their medical doctor with 
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reference to their medication, and if they had been provided with feedback in the event of that 
happening. 
The majority of the participants were aware that the pharmacy had a record of their medication 
history (93.9%). However a smaller percentage of participants (35.4%), were aware of their 
pharmacists having to communicate with their doctor with regard to their medication. 
Of the 35.4% of the respondents who were aware of the pharmacist communicating with their 
doctors, 95.4% (n=93) had been given feedback by their pharmacists about their discussion with 
their doctors. 
 
Figure 5.14 Respondents’ awareness of the communication between pharmacists and doctors 
5.1.17 Respondents’ perceived Pharmaceutical Care Components 
The delivery of pharmaceutical care (PC) involves several activities which may include aspects 
such as obtaining patient medical history, determining allergies and concomitant administration 
of medications, the presence of other medical conditions, explaining the appropriate 
administration of dispensed medications and possible side effects as well communicating with 
patients‘ doctors.  
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In this study the researcher asked the participants for their perception of the delivery of basic 
components of pharmaceutical care delivered by pharmacists and the results are summarized in 
Table 5.10. 
 
 % Response 
Description of Pharmaceutical Care Component NO YES 
Assessment of the presence of allergies 76.4 23.6 
Assessment of the presence of other medical conditions 67.3 32.7 
Assessment of administration of other medication 57.4 42.6 
Explanation of how the medicines are supposed to be used 8.8 91.3 
Explanation of how the medicines are to be administered 4.9 95.1 
Explanation of how the medication are expected to work 55.5 44.5 
Explanation of possible side-effects 27.8 72.2 
Opportunity to ask questions 24.7 75.3 
 
Considering these responses from participants it would appear that they had not received 
adequate basic components of pharmaceutical care, such as being assessed for the presence of 
allergies, the concomitant use of medication and a comprehensive explanation of the purpose of 
medication dispensed to them from pharmacists. Of the 263 participating patients, a relatively 
low proportion had been screened for medication risk factors such as allergies (23.6%), 
concomitant medication administration (42.6%), and the presence of other medical conditions 
(32.7%). Screening for potential risk factors is essential to the prevention of medication related 
problems. 
Table 5.10 Respondents’ perceived delivery of certain components of PC 
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Only 44.5% of the participants were given an explanation on how the medication was expected 
to work (n=263). With respect to other information about medication 72.2% of participants had 
been given a comprehensive explanation of expected side-effects and 75.3% had an opportunity 
to ask questions if they had any, whilst 91.3% had been told how to use their medication and 
95.1% had been advised about administrating their own medication. 
It would appear that although pharmacists are providing some information to their patients about 
medication use, pharmacists are not obtaining sufficient information from patients in order to 
provide comprehensive pharmaceutical care and to help prevent medication-related problems. 
5.1.18 Satisfaction with Pharmaceutical Care Services 
Respondents were asked about their satisfaction with care services received and were asked to 
indicate their responses between 1 and 4 based on a Likert scale. Level 1 represented 
dissatisfaction with services being delivered by pharmacists and level 4 represented the 
maximum level of satisfaction. A summary of responses is provided below in Table 5.11. 
Table 5.11 Level of satisfaction with pharmaceutical care 
Level of Satisfaction with PC 
(Likert scale) 
Description Number of 
respondents 
% of 
respondents 
1 Not satisfied  0 0 
2 Slightly Satisfied 40 15.2 
3 Satisfied 118 44.9 
4 Very Satisfied 105 39.9 
Total  263 100 
 
Contrary to the obvious shortfalls in delivery discussed in the previous section, of the 263 
participants, 44.9% appear to be satisfied with the current delivery of pharmaceutical services by 
the pharmacist, whilst 39.9% are very satisfied. Thus in total 84.8% appear to be satisfied. No 
participant had shown any indication of lack of satisfaction (0%) and only 40 participants 
(15.2%) indicated a slight level of satisfaction. 
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5.1.19 Perceived demand for Pharmaceutical Care Services (PCS) 
One of the pharmacists‘ barriers to the implementation of PCS includes the perception that 
patients do not need pharmacist-provided services (May, 1993). The researcher in this study 
therefore sought to investigate this particular aspect further by trying to assess the demand from 
patients. 
5.1.20 Patients’ perceived demand for Pharmaceutical Care Services (PCS) 
Using a Likert scale, with 1 being not important and 4 very important, the patients were asked to 
indicate if it was necessary for the pharmacist to spend time providing pharmaceutical care. 
Table 5.12 summaries the responses obtained. 
Table 5.12 Patients’ perceived demand for Pharmaceutical Care Services 
Level of Satisfaction with PC 
(Likert scale) 
Description No. of 
respondents 
% of 
respondents 
1 Not Important 0 0 
2 Slightly Important 6 2.2 
3 Important 63 24 
4 Very Important 194 73.8 
Total  263 100 
 
Not one respondent indicated that they felt that pharmaceutical care was not important. Of the 
total response rate, 24% indicated that pharmaceutical care was important whereas 73.8% 
considered pharmaceutical care very important. Only 2.2% thought that pharmaceutical care was 
of slight importance. 
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5.1.21 Medication-Related Problems (MRPs) experienced by respondents 
When a prescription drug is given to a patient, medication-related problems may result, which 
may include untreated conditions, improper drug selection, doses too low, overdose, adverse 
drug reactions and medication interactions (Suh, 2000). Medication-related problems can be very 
costly to the patient, third-party payer and the employer. 
 
Patients were asked whether they, or any member of their family, had experienced a medication-
related problem. If they responded positively, they were further asked to specify from which 
healthcare practitioner they had sought assistance to resolve the problem: their medical doctor, a 
nurse, a pharmacist or any other responsible professional care-giver. In addition, the researcher 
asked patients to specify which healthcare practitioner they considered more suitable to manage 
and to resolve their medication therapy. Figure 5.15 and Table 5.13 summarizes the responses 
obtained. 
 
 
 
 
 
 
 
 
 
Figure 5.15 Respondents’ prior experience of Medication-Related Problems (MRP) (n=263) 
Of the 263 participating respondents, 39.3% reported that they or one of their family members 
had experienced medication-related problems in the past. 
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Table 5.13 Respondents’ preferred healthcare professional to resolve MRP 
Method of resolution of MRP No. of respondents % of respondents 
Medical Doctor 54 52.9 
Nursing Practitioner 3 2.9 
Pharmacist 41 39.3 
Pharmacist and Doctor 3 2.9 
***Other 2 2.0 
Total 103 100 
 ***Respondents read the package insert 
At least half of the respondents had their medication-related problems resolved by their medical 
doctor (52.9%, n=103), and 39.3% discussed these problems with their pharmacist. A few 
patients (2.9%) approached both the doctor and the pharmacist with their problems, with an 
equal number also approaching the nursing practitioner. Only 2% of the 103 respondents had 
other means of resolving their drug-related problems, that is, by reading the provided package 
insert. 
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5.2. WILLINGNESS TO PAY FOR PHARMACIST-PROVIDED SERVICES 
 
The patients‘ willingness to pay (WTP), for pharmacist-provided services in South Africa, was 
measured for three different hypothetical risk reduction levels of medication-related problems 
(MRP). The hypothetical risk reduction of MRPs through pharmacist interventions was varied 
from 30%, through to 60% and 90%. Of the 263 participating respondents only 233 (88.6%) 
were willing to pay at least one rand towards the pharmacist-provided services. On average 
respondents were willing to pay R126.76 as out-of-pocket in-order to avoid risk of medication-
related problems through pharmacist interventions. The respondents‘mean willingness to pay 
(WTPtot), for risk reduction of MRPs at three levels, was calculated and utilized to ascertain the 
relationship between WTPtot and the independent variables. Figure 5.16 below is a graph 
representing the percentage willingness to pay of research participants, from a minimum of R0 to 
a maximum of R367 out of pocket. 
 
Figure 5.16 Willingness to pay from minimum to maximum mean WTP (n=263=100%) 
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At Lower WTPtot more respondents could afford to compensate the pharmacist for their 
services, with 50% of respondents willing to forego approximately R100. Less than 5% of the 
population could afford to or were willing to forgo more than R280. Thus demand for 
pharmaceutical care services fell significantly as the price exceeded R100. The maximum sum of 
money that respondents were willing to pay out of their own pockets was R367. 
In other studies undertaken on WTP, it was found that for different pharmacist-provided 
services, such as for hormone-replacement therapy, asthma, and pharmacist-assisted therapy, 
monies that patients were willing to pay varied. In a study conducted in 2008, pertaining to 
willingness to pay for asthma interventions provided by pharmacists in SA, the mean willingness 
to pay for asthma services was reported to be R68 per month (Munyikwa, 2008). 
In a study conducted in America by Suh (2000), which included 316 respondents, the 
respondents‘ mean WTP out-of-pocket for pharmacy services ranged from $4.02 to $5.48 per 
prescription and $28.79 to $36.29 from the medical aid premiums (Suh, 2000). In another similar 
study consisting of 2500 adult participants in the US, it was found that although the majority of 
the respondents were receiving pharmaceutical care services they were willing to pay the 
pharmacist on average of $13 for a once-off consultation fee(Larson, 2000). 
The findings of the US-related study, are consistent with the present study‘s findings in that more 
than 50% of patients are willing to pay for services provided by pharmacists in South Africa. 
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5.2.1. Proportion of Respondents’ willingness to pay at various Risk Levels 
The respondents‘ willingness to pay varied as the risk associated with reducing MRPs was also 
varied. 
 
 
 
Figure 5.17 above shows respondents‘ willingness to pay in response to the different levels of 
reduction in the risk of having medication-related problems (MRPs) as outlined in this study. As 
the risk associated with MRPs was varied, the willingness to pay also varied significantly. Out of 
the 263 respondents, 50% were willing to pay at least R100 for a risk reduction of 30%, R120 for 
a 60% reduction and approximately R150 for greater than a 90% risk reduction. Thus it is 
evident that respondents‘ WTP increased as the risk, associated with medication-related 
problems, was reduced due to pharmaceutical care intervention. 
 30% 
 60% 
 90% 
Figure 5.17 Willingness to pay (out-of-pocket) for pharmacist intervention at 
various risk levels 
RISK REDUCTION 
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Figure 5.18 presents respondents‘ WTP for a risk reduction of medication-related problems 
through medical aid premiums. 
 
Figure 5.18 Willingness to pay (medical premiums) for pharmacist intervention at various risk 
levels 
As seen and discussed above WTP increased as absolute risk was reduced; however, 
respondents‘ indicated a greater willingness to pay by using their Medical aid benefits as 
opposed to paying out-of-pocket. Not all respondents belonged to a medical aid; out of the 263 
respondents only 157 belonged to a medical aid. Of the 157 respondents, 50% were willing to 
pay approximately R160 for a 30% risk reduction, R180 for a 60% reduction and approximately 
R230 for a greater than 90% risk reduction. The results obtained from this present study are 
similar to those obtained by Suh (2000), which also indicated that respondents‘ WTP varied with 
risk, although the risk levels elicited between the two studies were different (Suh, 2000). 
 
 
 RISK REDUCTION 
30% 
60% 
90% 
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5.3. FACTORS INFLUENCING RESPONDENTS’ WILLINGNESS TO PAY 
In fulfillment of the study objectives the relationships between dependent variable (WTP) and 
other independent variables (geographical location, age, gender,) were assessed. The results of 
the associations between the variables are represented with the aid of box plots as shown and 
discussed below. 
5.3.1. The effects of geographical location on WTP and their correlation 
Figure 5.19 below is a box and whisker diagram depicting willingness to pay of 263 respondents 
with respect to their geographical location. 
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Figure 5.19 Respondents’ WTP with respect to geographical location (n=263) 
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The whiskers‘ distribution results were positively skewed for most provinces except for the 
North West (NW) and Kwa-Zulu Natal (KZN), which were negatively skewed. The median and 
inter-quartile ranges are similar for all depicted provinces, with some variation, possibly 
indicating similarities in willingness to pay between provinces. Inter-quartile ranges were from 
R50 to R200, with an average median of approximately R120 across the box and whiskers. The 
GP (Gauteng) province had the largest inter-quartile range, ranging from R50 to R200 and 
Mpumalanga (Mp) had the least inter-quartile range of between R60 and R140. 
5.3.1.1 Analysis of Variance (ANOVA) of WTP with respect to respondents’ geographical 
location 
The null hypothesis is that geographical location has no effect on willingness to pay or implying 
that the mean amount of willingness to pay (WTPtot) of respondents across different provinces is 
not significantly different from each other. Using analysis of variance (ANOVA) testing the null 
hypothesis is rejected if the p-value [Sig. (2-tailed)] is less than 0.05. 
The ANOVA results are provided in Table 5.14. It compares the mean WTPtot between 
respondents from different geographical provinces namely; Mpumalanga (Mp), Free-state (Fs), 
Limpopo (Limp), Northwest (NW), Western Cape (WC), Kwa-Zulu Natal (KZN), Eastern Cape 
(EC), and Gauteng (GP) provinces. There is no evidence of mean differences (all p-values were 
> 0.05) therefore null hypothesis cannot be rejected. It can then be concluded that respondents‘ 
mean willingness to pay across provinces does not differ significantly, in other words 
respondents‘ mean willingness to pay was not influenced by their geographical location. 
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Multiple Comparisons
Dependent  Variable: WTPtot
LSD
-70.950 49.483 .153 -168.40 26.50
-7.806 36.882 .833 -80.44 64.83
-60.386 40.332 .136 -139.81 19.04
-22.135 35.093 .529 -91.24 46.97
-5.707 35.627 .873 -75.87 64.45
-30.781 34.310 .370 -98.35 36.79
-27.557 31.552 .383 -89.69 34.58
70.950 49.483 .153 -26.50 168.40
63.144 43.879 .151 -23.27 149.56
10.564 46.815 .822 -81.63 102.76
48.815 42.386 .251 -34.66 132.29
65.243 42.829 .129 -19.10 149.59
40.169 41.740 .337 -42.03 122.37
43.393 39.504 .273 -34.40 121.19
7.806 36.882 .833 -64.83 80.44
-63.144 43.879 .151 -149.56 23.27
-52.581 33.218 .115 -118.00 12.84
-14.329 26.614 .591 -66.74 38.08
2.099 27.315 .939 -51.69 55.89
-22.976 25.573 .370 -73.34 27.39
-19.752 21.734 .364 -62.55 23.05
60.386 40.332 .136 -19.04 139.81
-10.564 46.815 .822 -102.76 81.63
52.581 33.218 .115 -12.84 118.00
38.252 31.220 .222 -23.23 99.73
54.680 31.819 .087 -7.98 117.34
29.605 30.337 .330 -30.14 89.35
32.829 27.179 .228 -20.70 86.35
22.135 35.093 .529 -46.97 91.24
-48.815 42.386 .251 -132.29 34.66
14.329 26.614 .591 -38.08 66.74
-38.252 31.220 .222 -99.73 23.23
16.428 24.846 .509 -32.50 65.36
-8.647 22.917 .706 -53.78 36.48
-5.423 18.536 .770 -41.93 31.08
5.707 35.627 .873 -64.45 75.87
-65.243 42.829 .129 -149.59 19.10
-2.099 27.315 .939 -55.89 51.69
-54.680 31.819 .087 -117.34 7.98
-16.428 24.846 .509 -65.36 32.50
-25.075 23.728 .292 -71.80 21.65
-21.851 19.529 .264 -60.31 16.61
30.781 34.310 .370 -36.79 98.35
-40.169 41.740 .337 -122.37 42.03
22.976 25.573 .370 -27.39 73.34
-29.605 30.337 .330 -89.35 30.14
8.647 22.917 .706 -36.48 53.78
25.075 23.728 .292 -21.65 71.80
3.224 17.007 .850 -30.27 36.72
27.557 31.552 .383 -34.58 89.69
-43.393 39.504 .273 -121.19 34.40
19.752 21.734 .364 -23.05 62.55
-32.829 27.179 .228 -86.35 20.70
5.423 18.536 .770 -31.08 41.93
21.851 19.529 .264 -16.61 60.31
-3.224 17.007 .850 -36.72 30.27
(J) GeoLocation
FS
Limp
NW
WC
KZN
EC
GP
Mpu
Limp
NW
WC
KZN
EC
GP
Mpu
FS
NW
WC
KZN
EC
GP
Mpu
FS
Limp
WC
KZN
EC
GP
Mpu
FS
Limp
NW
KZN
EC
GP
Mpu
FS
Limp
NW
WC
EC
GP
Mpu
FS
Limp
NW
WC
KZN
GP
Mpu
FS
Limp
NW
WC
KZN
EC
(I) GeoLocation
Mpu
FS
Limp
NW
WC
KZN
EC
GP
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
Table 5.14 Multiple comparisons on mean willingness to pay for different provinces 
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5.3.1.2. Regression analysis of geographical location on mean willingness to pay 
Table 5.15 below shows the regression coefficient between the independent variable 
geographical location and the dependent variable willingness to pay (WTPtot). 
 
 
Table 5.15 Regression coefficient between geographical location and WTPtot 
 
Dependent variable: WTPtot 
Independent variable: Geographical Location 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 120.580 16.063 7.507 0.000 
Geo-Location 1.109 2.719 0.408 0.684 
 
 
Since p > 0.05 (p-value = 0.684) it can be inferred that there is no regression effect between 
geographical location and willingness to pay. The regression parameter is significant when p < 
0.05; hence willingness to pay is not influenced by respondents‘ geographical location, which 
corresponds with the ANOVA analysis discussed above.  
 
5.3.1.3 Discussion 
Although many studies have investigated the willingness of patients to pay for pharmacist-
provided care services (Larson, 2000; Suh, 2000; Munyikwa, 2008), there are some studies 
which sought to describe the effect of geographical location on WTP. Although urbanized 
provinces in South Africa have been reported to have a significant influence on viability of 
business (Statistics SA, 2010), there was no evidence to show any influence that respondents‘ 
geographical location affect their willingness to pay.  
 
 
 
 
  
104 
5.3.2. The effects of respondents’ age on willingness to pay 
Figure 5.20 shows the relationship between the respondents‘ age and their willingness to pay for 
pharmacist-provided services. 
 
 
 
 
The median, of each box and whisker, generally increases according to age. For the 21-30 age 
group category respondents present with the lowest median of about R90 but in the 81 and above 
category respondents present with the highest median of around R260. Thus, it would appear 
that, respondents‘ willingness to pay generally increases with age. With the exception of the two 
older age groups there was the same minimum willingness to pay of R0. The category 41-50 age 
group had the highest willingness to pay, as depicted by their upper maximum WTPtot of 
approximately R360.  
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Figure 5.20 Respondents’ WTP with respect to age (n=263) 
61-70 
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5.3.2.1.  Analysis of Variance of WTP with respect to respondents’ age groups 
5.3.2.2. 
5.3.2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of Age on WTP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple Comparisons
Dependent  Variable: WTPtot
LSD
-36.136* 14.736 .015 -65.16 -7.12
-56.959* 15.841 .000 -88.16 -25.76
-76.972* 17.361 .000 -111.16 -42.78
-75.179* 22.944 .001 -120.36 -30.00
-142.226* 28.204 .000 -197.77 -86.68
-180.326* 58.388 .002 -295.31 -65.34
36.136* 14.736 .015 7.12 65.16
-20.823 13.565 .126 -47.54 5.89
-40.836* 15.313 .008 -70.99 -10.68
-39.043 21.435 .070 -81.25 3.17
-106.090* 26.991 .000 -159.24 -52.94
-144.190* 57.812 .013 -258.04 -30.34
56.959* 15.841 .000 25.76 88.16
20.823 13.565 .126 -5.89 47.54
-20.013 16.379 .223 -52.27 12.24
-18.220 22.210 .413 -61.96 25.52
-85.267* 27.610 .002 -139.64 -30.89
-123.367* 58.103 .035 -237.79 -8.95
76.972* 17.361 .000 42.78 111.16
40.836* 15.313 .008 10.68 70.99
20.013 16.379 .223 -12.24 52.27
1.793 23.318 .939 -44.13 47.71
-65.254* 28.510 .023 -121.40 -9.11
-103.354 58.536 .079 -218.63 11.92
75.179* 22.944 .001 30.00 120.36
39.043 21.435 .070 -3.17 81.25
18.220 22.210 .413 -25.52 61.96
-1.793 23.318 .939 -47.71 44.13
-67.047* 32.215 .038 -130.49 -3.61
-105.147 60.427 .083 -224.15 13.85
142.226* 28.204 .000 86.68 197.77
106.090* 26.991 .000 52.94 159.24
85.267* 27.610 .002 30.89 139.64
65.254* 28.510 .023 9.11 121.40
67.047* 32.215 .038 3.61 130.49
-38.100 62.614 .543 -161.40 85.20
180.326* 58.388 .002 65.34 295.31
144.190* 57.812 .013 30.34 258.04
123.367* 58.103 .035 8.95 237.79
103.354 58.536 .079 -11.92 218.63
105.147 60.427 .083 -13.85 224.15
38.100 62.614 .543 -85.20 161.40
(J) Age
(31-40)
(41-50)
(51-60)
(61-60)
(71-80)
81
(21-30)
(41-50)
(51-60)
(61-60)
(71-80)
81
(21-30)
(31-40)
(51-60)
(61-60)
(71-80)
81
(21-30)
(31-40)
(41-50)
(61-60)
(71-80)
81
(21-30)
(31-40)
(41-50)
(51-60)
(71-80)
81
(21-30)
(31-40)
(41-50)
(51-60)
(61-60)
81
(21-30)
(31-40)
(41-50)
(51-60)
(61-60)
(71-80)
(I) Age
(21-30)
(31-40)
(41-50)
(51-60)
(61-60)
(71-80)
81
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant at the .05 lev el.*. 
Table 5.16 Multiple comparisons on mean willingness to pay for different age groups 
21-30 
31-40 
41-50 
51-60 
51-60 
61-70 
71-80 
>80 
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The null hypothesis is that respondents‘ age has no effect on willingness to pay implying that the 
different age group categories do not differ in their mean willingness to pay (WTPtot). 
First category: It compares the average WTPtot for respondents aged between 21-30 (category-I) 
with that of other age groups (category-J); 31-40, 41-50, 51-60, 61-70, 71-80 and those above 80 
years of age. The p-values for the categories in comparison were less than 0.05 and thus differ 
significantly and evidently affect respondents‘ mean willingness to pay. Since the mean 
difference in WTPtot between category-I and category-J is negative in all cases, the conclusion is 
that respondents‘ who were between the ages of 21-30 were willing to pay less with respect to 
other age categories. 
Second category: Although the mean WTPtot between respondents who were in the 31-40 age 
category (I) with that of the 41-50 (p-value = 0.126) and 61-70 (p-value = 0.07) age categories 
does not differ significantly, that of (category-I) with that of categories 51-60 (p-value = 0.008), 
71-80 (p-value = 0.000) and 81years and above (p-value = 0.013) differs significantly. 
Third category: The mean WTPtot comparison between participants aged 41-50 (category-I) and 
those that were aged between 51-60 as well as 61-70, does not differ significantly, as shown by 
their respective p-values of 0.223 and 0.413. However, in contrast the mean willingness to pay 
between respondents in category-I (41-50) and those who were senior citizens aged 71-80 and 
those above 80 years of age, does differ significantly, both with p-values less than 0.05 that is 
0.002 and 0.035 respectively. Thus most senior participants were willing to pay 123.67 units 
more than those who were in the 41-50 age categories. 
Fourth category: The mean WTPtot comparison between participants in category-I who were 
aged 51-60 and category-J with those that were aged 61-70, as well as above 80 years, do not 
differ significantly, as shown by their respective p-values of 0.939 and 0.079. However in 
contrast, the mean willingness to pay between respondents in category-I (51-60) and those who 
were aged 71-80 does differ significantly, with a p-value 0.023. 
Fifth category: Although the mean WTPtot between respondents who were among the 61-70 age 
category-I with that of the 71-80 (p-value = 0.038) age categories differs significantly, that of 
(category-I) with that of most senior citizens, 81years and above (p-value = 0.083) does not 
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differ significantly. Hence it was quite evident, that the participants who were aged 71-80 were 
willing to pay 67.05 units more than their immediate junior age group of 61-70. 
Sixth category: The mean WTPtot comparison between participants in category-I aged 71-80 
and category-J with those that were aged above 80 years, does not differ significantly, as shown 
by their p-value of 0.543. 
5.3.2.2. Regression analysis of age on willingness to pay 
Table 5.17 below shows the regression coefficient between the independent variable age and the 
dependent variable willingness to pay (WTPtot). 
Table 5.17 Regression coefficient between age and WTPtot 
Dependent variable: WTPtot 
Independent variable: Age 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 23.438 16.786 1.396 0.164 
Age 2.378 0.369 6.444 0.000 
 
There is a positive relationship between age group categories and respondents‘ willingness to 
pay, which tallies with the box and whiskers‘ analysis and the ANOVA shown above. The 
interpretation is that assuming all other factors are held constant, for every unit increase in age 
group, mean willingness to pay increases by 2.38 units. 
5.3.2.3. Discussion 
The effect of age on willingness to pay has been found to be very inconsistent; some studies have 
reported no evidence of a significant influence of age on WTP (Larson, 2000; Shafie & Hassali, 
2010), while other studies have similar findings  to the present study. Suh (2000) reported a 
decreased tendency of willingness to pay by respondents over the age of 30, which was negative 
with regards to the current findings in which an increase in WTP was found with increase in age. 
As expected, as respondents age they are more likely to appreciate pharmacist interventions as 
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they are at greater risk of experiencing MRPs due to their likelihood of suffering from co-
morbidities. 
5.3.3. The effects of respondents’ gender on willingness to pay 
The box and whiskers diagram below is a representation of the relationship between gender and 
willingness to pay of respondents. 
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Figure 5.21 Respondents’ WTP with respect to gender (n=263) 
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The results of both male and female participants‘ willingness to pay were positively skewed, 
presenting the same median of R100. The males had a larger range of willingness to pay; as 
shown by their lower quartile range of R40 and their upper quartile range of R240, which is 
larger than that of females. Although male respondents had a greater maximum willingness to 
pay, both male and female participants were willing to pay the same minimum amount of R0. 
 
5.3.3.1. Analysis of Variance of WTP with respect to respondents’ gender 
 
The male participants were willing to pay R130.08, a mean which is slightly more than that of 
the females (R125.17), both with a maximum willingness to pay of R367. 
5.3.3.2. Regression analysis of gender on willingness to pay 
Table 5.19 below shows the regression coefficient between the independent variable gender and 
the dependent variable willingness to pay (WTPtot). 
 
 
 
 
 
 
 
Descriptives
WTPtot
85 130.08 103.722 11.250 107.71 152.45 0 367
178 125.17 77.438 5.804 113.72 136.63 0 300
263 126.76 86.635 5.342 116.24 137.28 0 367
Male
Female
Total
N Mean Std.  Dev iation Std.  Error Lower Bound Upper Bound
95% Conf idence Interv al for
Mean
Minimum Maximum
Table 5.18 summaries respondents’ mean willingness to pay with respect to gender 
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Table 5.19 Regression coefficient between gender and WTPtot 
Dependent variable: WTPtot 
Independent variable: Gender 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 130.082 9.412 13.821 0.000 
Gender -4.908 11.440 -0.429 0.668 
 
The hypothesis tested is that there is a regression effect of gender on willingness to pay (WTPtot) 
or alternatively that gender has an effect on WTPtot. The p–value (0.668) is greater than 0.05 
and therefore the null hypothesis cannot be rejected. It can be concluded that gender thus has no 
effect, thus respondents‘ willingness to pay is not influenced by gender. 
5.3.3.3.Discussion 
Previous studies, (Larson, 2000; Munyikwa, 2008; Shafie & Hassalie, 2010), have found gender 
to have no significant influence on respondents‘ willingness to pay. Those findings are consistent 
with the current findings. 
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5.3.4. The effects of respondents’ racial groupings on willingness to pay 
Figure 5.22 below, a box and whisker graphical representation, of how the racial groupings of 
study participants affect willingness to pay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The minimum and maximum amount of respondents were willing to pay was approximately the 
same across all races with the exception of Coloured participants who had a higher minimum 
WTP of about R25 and a lower maximum WTP of about R110. The minimum amount Black, 
White and Asian/Indian participants were willing to pay was R0. Although a few Black 
participants were willing to pay a relatively higher amount than others (outlier scores of WTP), 
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Figure 5.22 Respondents’ WTP with respect to their racial classification (n=263) 
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most white and Asian participants had a similar upper extreme WTP of approximately R300, 
thus were willing to pay more. There is a similar higher variability in WTP amongst the whites 
and Asians with respect to other races, as shown by their greater inter-quartile ranges of R100-
R250 and R40-R180 respectively. 
5.3.4.1. Analysis of Variance of WTP with respect to racial categories 
 
 
The null hypothesis is that race has no effect on willingness to pay. This implies that the different 
race categories do not differ in their willingness to pay (WTPtot) and the mean amount of 
WTPtot, across different racial groups, is not significantly. 
First category: Compares the average WTPtot for blacks with that of Whites, Asians and 
Coloureds. The average willingness to pay for Blacks differs significantly from the average 
WTPtot for Whites (p-value = 0.000) with Whites willing to pay more (mean difference Blacks–
Whites being negative); however it does not differ to the average of Asians (p-value = 0.153) and 
that of Coloureds (p-value = 0.768). 
Multiple Comparisons
Dependent Variable: WTPtot
LSD
-61.547* 11.196 .000 -83.59 -39.50
-22.979 16.037 .153 -54.56 8.60
8.465 28.607 .768 -47.87 64.80
61.547* 11.196 .000 39.50 83.59
38.568* 15.564 .014 7.92 69.22
70.013* 28.345 .014 14.20 125.83
22.979 16.037 .153 -8.60 54.56
-38.568* 15.564 .014 -69.22 -7.92
31.444 30.582 .305 -28.78 91.67
-8.465 28.607 .768 -64.80 47.87
-70.013* 28.345 .014 -125.83 -14.20
-31.444 30.582 .305 -91.67 28.78
(J) Race
White
Asian
Coloured
Black
Asian
Coloured
Black
White
Coloured
Black
White
Asian
(I) Race
Black
White
Asian
Coloured
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant  at the .05 lev el.*. 
Tabl  5.20 Multiple comparisons on mean willingness to pay for different racial groups 
 
  
113 
Second category: Compares the average willingness to pay of Whites with that of Blacks, Asians 
and Coloureds. The average willingness to pay for whites differs significantly from Blacks, 
Asians and Coloureds, (p-values 0.000, 0.14 and 0.14 respectively).  
Third category: Compares the average willingness to pay of Coloureds with that of Asians. The 
average WTPtot between Coloureds and Asians does not differ, with a p-value of 0.305 as shown 
in the third row of the table 5.19 above.  
It can be concluded that the White racial participants were willing to pay more than other racial 
participants. 
5.3.4.2. Regression analysis of racial grouping on willingness to pay 
Table 5.21 below shows the regression coefficient between the independent variable racial 
grouping and the dependent variable willingness to pay (WTPtot). 
Table 5.21 Regression coefficient between racial grouping and WTPtot 
Dependent variable: WTPtot 
Independent variable: Race 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 116.372 7.801 14.917 0.000 
Race 12.362 6.792 1.820 0.070 
 
Race has no effect (p-value = 0.07) and this is in contradiction of the ANOVA results where a 
reversal of associations is commonly referred to as Ecological fallacy or Simpson‘s paradox. 
Ecological fallacy is a logical interpretation of statistical data, whereby variability of individual 
groups (for example Whites, Blacks, Coloureds and Asians) is much greater than their variability 
at aggregate level (for example race) (Jargowsky, 2002). 
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5.3.4.3. Discussion 
Although many studies investigated the effect of most demographic factors, such as gender and 
age, on willingness to pay, they however did not investigate the effect of race on WTP (Larson, 
2000; Suh, 2000; Munyikwa, 2008; Shafie & Hassali, 2010). In this study, although whites were 
willing to pay more than any other racial group, the aggregate effect of race on WTP was 
insignificant. 
5.3.5. The effects of respondents’ level of education on willingness to pay 
Figure 5.23 below is a box and whisker distribution, which shows the participants‘ willingness to 
pay with respect to their level of education. 
 
The inter-quartile ranges increase as one moves from the least educated (Pre-Matric) respondents 
to the most educated respondents (P-Graduate), thus post-graduate participants had the highest 
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Figure 5.23 Respondents’ WTP with respect to their level of education (n=263) 
Highest level of education 
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variability in their willingness to pay, ranging from R30 to R210. The pre-matric median was 
R40 and that of post-graduates was depicted as R210, thus the median willingness to pay of 
respondents increased as levels of education increased. The lower minimum median score of all 
categories of education was R0 with the exception of pre-matric respondents. Thus, some 
respondents – across all levels of education - were not willing to pay; the exception being pre-
matriculant participants who were all willing to pay at least one rand towards pharmacist-
provided services. 
5.3.5.1. Analysis of Variance of WTP with respect to respondents’ levels of education 
 
The null hypothesis is that the respondents‘ level of education has no effect on willingness to 
pay, suggesting that the mean amount of willingness to pay across all levels of education is not 
significantly different from each other. 
Multiple Comparisons
Dependent Variable:  WTPtot
LSD
-43.843 32.510 .179 -107.86 20.18
-87.830* 30.931 .005 -148.74 -26.92
-99.046* 31.439 .002 -160.95 -37.14
-102.248* 31.384 .001 -164.05 -40.45
43.843 32.510 .179 -20.18 107.86
-43.987* 16.113 .007 -75.72 -12.26
-55.203* 17.067 .001 -88.81 -21.60
-58.405* 16.966 .001 -91.81 -25.00
87.830* 30.931 .005 26.92 148.74
43.987* 16.113 .007 12.26 75.72
-11.216 13.824 .418 -38.44 16.01
-14.419 13.699 .294 -41.40 12.56
99.046* 31.439 .002 37.14 160.95
55.203* 17.067 .001 21.60 88.81
11.216 13.824 .418 -16.01 38.44
-3.202 14.809 .829 -32.36 25.96
102.248* 31.384 .001 40.45 164.05
58.405* 16.966 .001 25.00 91.81
14.419 13.699 .294 -12.56 41.40
3.202 14.809 .829 -25.96 32.36
(J) Education
Matric
College
Graduate
P. Graduate
Pre Matric
College
Graduate
P. Graduate
Pre Matric
Matric
Graduate
P. Graduate
Pre Matric
Matric
College
P. Graduate
Pre Matric
Matric
College
Graduate
(I) Education
Pre Matric
Matric
College
Graduate
P. Graduate
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant at the .05 level.*. 
Table 5.22 Multiple comparisons on mean willingness to pay for different levels of 
education 
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First category: Compares the average WTPtot for respondents who had not obtained at least a 
Matric pass (Pre-Matric) with that of respondents who had achieved a Matric, a College, a 
Graduate degree and a post-graduate qualification. Although the average willingness to pay for 
pre-matriculants does not differ from Matric respondents (p-value = 0.179), it differs 
significantly with that of respondents who had a College certificate (p-value = 0.005), a Graduate 
degree (p-value = 0.002), and who had a post-graduate qualification (p-value = 0.001). 
Second category: Compares mean WTPtot of participants who had a Matric certificate with that 
of a College certificate, a Graduate degree, and post-graduate degree. The mean willingness to 
pay differs significantly for all levels of education, with p-values of 0.007, 0.001 and 0.001 
respectively. The mean willingness to pay between participants who had a College qualification, 
a Graduate degree (p-value = 0.418) and a post-graduate degree (p-value = 0.294) does not differ 
significantly as depicted in the third row of the table shown above. Finally the mean difference 
between of Graduates and Post-Graduates also does not differ significantly, with a p-value of 
0.829. 
5.3.5.2. Regression analysis of level of education on willingness to pay 
Table 5.23 below shows the regression coefficient between the independent variable education 
and the dependent variable willingness to pay (WTPtot). 
Table 5.23 Regression coefficient between level of education and WTPtot 
Dependent variable: WTPtot 
Independent variable:Level of Education 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 78.808 12.942 6.089 0.000 
Education 18.993 4.695 4.045 0.000 
 
There is a strong positive relationship between levels of education and respondents‘ willingness 
to pay (WTPtot), which corresponds with the box and whiskers‘ analysis as well as the ANOVA 
shown above. 
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5.3.5.3. Discussion 
It was expected that the greater the education level of a participant the greater the appreciation of 
healthcare would be. It was also thought that improved economic power could possibly mean a 
greater willingness to pay. The findings were consistent with expectations; the respondents‘ 
willingness to pay increased as the level of education increased. Although the findings were 
consistent with a similar study by Suh (2000), the results cannot be generalized as the study 
sample‘s levels of education were not a true representation of the South African population‘s 
levels of education as discussed in Section 5.1.7. 
5.3.6. The effects of respondents’ employment status on willingness to pay 
The box and whisker diagram below depicts the willingness to pay of study participants with 
different levels of employment status. 
 
Retired Pensioner Student Part-time Self Full-time Unemployed 
Employment level 
400 
300 
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0 
WTPtot 
55 
151 
206 
Figure 5.24 Respondents’ WTP with respect to their level of employment (n=263) 
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The results obtained from the study observations between WTP and respondents‘ employment 
status depict a positively skewed distribution, with the exception of retired respondents which 
was negatively skewed. There are two main categories of the WTP median: the lower median, of 
approximately R114, represented by respondents employed full-time, self-employed, part-time, 
as well as students; and the upper median, of approximately R218, represented by unemployed 
respondents, pensioners as well retired participants. 
5.3.6.1. Analysis of Variance of with respect to employment categories 
Table 5.24 shows the analysis of variance on the respondents‘ employment categories, thus 
comparing the mean willingness to pay across different employment categories. The null 
hypothesis is that the respondents‘ employment status has no effect on willingness to pay. 
First category: It compares the average WTPtot for unemployed respondents with that of 
respondents who were self-employed, employed full-time and part-time; the mean willingness to 
pay differs significantly, with p-values of 0.000, 0.000 and 0.001 respectively. In contrast, the 
mean WTPtot does not differ significantly between that of students (p-value = 0.079), pensioners 
(p-value = 0.723) and retired participants (p-value = 0.448). Thus strangely, participants who 
were employed full-time were willing to pay 131.04 units less than unemployed participants. 
Second category: The mean WTPtot comparison between participants employed full-time and 
those that were self-employed, employed part-time as well as students, does not differ 
significantly, as shown by their respective p-values of 0.504, 0.802 and 0.336. However in 
contrast, the mean willingness to pay between respondents who were employed full-time and 
those who were on pension and retired, differ significantly, both have a p-value less than 0.05 
that is 0.002. Thus retired participants were willing to pay 97.61 units more than those who were 
employed full-time. 
Third category: Compares the mean willingness to pay of   respondents who were self-employed 
with that of respondents who were employed part-time, students, pensioners as well as retired. 
Although the average WTPtot between self-employed participants with that of part-time 
employed (p-value = 0.576) and student (p-value = 0.478) participants does not differ 
significantly, that of pensioners (p-value = 0.008) and participants who had retired (p-value = 
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0.009) do differ significantly. Thus pensioners and retired participants are willing to pay 104.43 
and 88.12 units more respectively than participants who were self-employed. 
Fourth category: Compares the average willingness to pay between respondents who were 
employed part-time with that of students, pensioners and retired participants. Although the 
average willingness to pay, between respondents employed part-time and WTP of respondents 
who were studying, does not differ significantly, that of part-time and pensioner and part-time 
and retired respondents, do differ significantly, with p-values of 0.007 and 0.009 respectively. 
This means that retired participants were willing to pay R103.20 more than participants who 
were employed part-time. 
Fifth category: Compares the mean willingness to pay between respondents, who were studying, 
with that of pensioners and retired respondents, which does not differ significantly as shown by 
their respective p-values of 0.182 and 0.265. 
Sixth category: The mean willingness to pay of respondents who were on pension does not differ 
significantly with that of respondents who had retired (p-value = 0.735). 
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Multiple Comparisons
Dependent Variable:  WTPtot
LSD
131.040* 31.656 .000 68.70 193.38
121.544* 33.628 .000 55.32 187.77
136.631* 39.108 .001 59.62 213.64
90.964 51.540 .079 -10.53 192.46
17.114 48.148 .723 -77.70 111.93
33.429 43.953 .448 -53.13 119.98
-131.040* 31.656 .000 -193.38 -68.70
-9.497 14.180 .504 -37.42 18.43
5.590 24.487 .820 -42.63 53.81
-40.076 41.552 .336 -121.90 41.75
-113.926* 37.262 .002 -187.31 -40.55
-97.612* 31.656 .002 -159.95 -35.27
-121.544* 33.628 .000 -187.77 -55.32
9.497 14.180 .504 -18.43 37.42
15.087 26.989 .577 -38.06 68.24
-30.579 43.073 .478 -115.40 54.24
-104.429* 38.952 .008 -181.14 -27.72
-88.115* 33.628 .009 -154.34 -21.89
-136.631* 39.108 .001 -213.64 -59.62
-5.590 24.487 .820 -53.81 42.63
-15.087 26.989 .577 -68.24 38.06
-45.667 47.475 .337 -139.16 47.82
-119.517* 43.770 .007 -205.71 -33.32
-103.202* 39.108 .009 -180.22 -26.19
-90.964 51.540 .079 -192.46 10.53
40.076 41.552 .336 -41.75 121.90
30.579 43.073 .478 -54.24 115.40
45.667 47.475 .337 -47.82 139.16
-73.850 55.161 .182 -182.48 34.78
-57.536 51.540 .265 -159.03 43.96
-17.114 48.148 .723 -111.93 77.70
113.926* 37.262 .002 40.55 187.31
104.429* 38.952 .008 27.72 181.14
119.517* 43.770 .007 33.32 205.71
73.850 55.161 .182 -34.78 182.48
16.314 48.148 .735 -78.50 111.13
-33.429 43.953 .448 -119.98 53.13
97.612* 31.656 .002 35.27 159.95
88.115* 33.628 .009 21.89 154.34
103.202* 39.108 .009 26.19 180.22
57.536 51.540 .265 -43.96 159.03
-16.314 48.148 .735 -111.13 78.50
(J) Employ ment
Full Time
Self
Part  Time
Student
Pensioner
Retired
Unemploy ed
Self
Part  Time
Student
Pensioner
Retired
Unemploy ed
Full Time
Part  Time
Student
Pensioner
Retired
Unemploy ed
Full Time
Self
Student
Pensioner
Retired
Unemploy ed
Full Time
Self
Part  Time
Pensioner
Retired
Unemploy ed
Full Time
Self
Part  Time
Student
Retired
Unemploy ed
Full Time
Self
Part  Time
Student
Pensioner
(I) Employment
Unemploy ed
Full Time
Self
Part  Time
Student
Pensioner
Retired
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant at  the .05 level.*. 
Table 5.24 Multiple comparisons on mean willingne s to pay of employment categories 
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5.3.6.2. Regression analysis of employment status on willingness to pay 
Table 5.25 below shows the regression coefficient between the independent variable employment 
status and the dependent variable willingness to pay (WTPtot). 
Table 5.25 Regression coefficient between employment status and WTPtot 
Dependent variable: WTPtot 
Independent variable: Employment status 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 107.608 8.746 12.303 0.000 
Employment 12.983 4.728 2.746 0.006 
 
There is a strong positive relationship between employment status and respondents‘ willingness 
to pay (WTPtot) (p-value = 0.006), which corresponds with the box and whiskers‘ analysis as 
well as the ANOVA analysis in table 5.24 shown above. 
5.3.6.3. Discussion 
It was logically expected that employed participants should be economically able to pay more 
than unemployed participants, retired participants and pensioners. Contrary to logical 
expectations, analysis of variance has shown that unemployed and retired participants were 
respectively willing to pay R131.04 and R97.61 more than employed participants. The study 
sample consisted of 68% (n=263) female participants, thus it is highly likely that the majority 
may have been housewives, full time mothers or retired. Although they were unemployed or 
retired it is assumed that their spouses probably earned sufficient income to support the entire 
family and hence these female participants were able and willing to pay. 
Although other studies did not report any significant influence of employment status on WTP 
(Suh, 2000; Safie & Hassali, 2010), the findings in this study were consistent with another study 
which has been conducted in SA (Munyikwa, 2008). 
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5.3.7. The effects of respondents’ Income category on WTP 
The box and whiskers diagram below depicts the observations on income categories of study 
participants with respect to their willingness to pay (WTPtot) for pharmacist-provided services. 
The results obtained from the observations depict a positively skewed frequency distribution. 
Across all categories of income, respondents had a similar minimum willingness to pay as seen 
by their similar WTPtot minimum score of R0. The upper extreme score, inter-quartile range 
(IQR) and median willingness to pay increased as income category increased from low to high 
income earners, with an approximate IQR of R50-R100 and R100-250 respectively. The higher 
income earners had a greater willingness to pay as seen by their greater upper extreme score 
(R367), with respect to other income categories. 
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Figure 5.25 Respondents’ WTP with respect to income categories (n=263) 
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From this research it is concluded that mean willingness to pay increased from low income 
earning (R83.97) through medium income earning (R109.30), to high income earning (R155.29) 
respondents. 
5.3.7.1. Analysis of Variance of WTP with respect to respondents’ Income categories 
 
The null hypothesis is that the respondents‘ income category: - either low, medium or high has 
no effect on willingness to pay, thus the mean amount of WTPtot across all income earning 
categories is not significantly different from each other. 
First category: Although the mean willingness to pay of low income earners does not differ 
significantly with that of medium earners (p-value = 0.079), it does vary significantly with that 
of high income-earning respondents (p-value = 0.000). Thus high-earning respondents were 
willing to pay R71.32 more than low income-earning respondents. 
Descriptives
WTPtot
62 83.97 55.019 6.987 70.00 97.94 0 300
67 109.30 68.620 8.383 92.56 126.04 0 267
134 155.29 96.090 8.301 138.87 171.71 0 367
263 126.76 86.635 5.342 116.24 137.28 0 367
Low
Medium
High
Total
N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interv al for
Mean
Minimum Maximum
Multiple Comparisons
Dependent  Variable: WTPtot
LSD
-25.331 14.347 .079 -53.58 2.92
-71.323* 12.505 .000 -95.95 -46.70
25.331 14.347 .079 -2.92 53.58
-45.993* 12.182 .000 -69.98 -22.00
71.323* 12.505 .000 46.70 95.95
45.993* 12.182 .000 22.00 69.98
(J) Income
Medium
High
Low
High
Low
Medium
(I) Income
Low
Medium
High
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant  at the .05 lev el.*. 
Table 5.26: Multiple comparisons on mean willingness to pay of income categories 
 
Table 5.26: Mean willingness to pay with respect to income categories 
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Second category: The mean willingness to pay of medium income earners differs significantly 
from respondents who were the highest earners (p-value = 0.000). Thus respondents who were 
earning more were willing to pay R45.99 more than medium earners. 
5.3.7.2. Regression analysis of income categories on willingness to pay 
Table 5.28 below shows the regression coefficient between the independent variable income and 
the dependent variable willingness to pay (WTPtot). 
Table 5.28 Regression coefficient between Income and WTPtot 
Dependent variable: WTPtot 
Independent variable: Income 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 79.967 9.281 8.616 0.000 
Income 36.737 6.129 5.994 0.000 
 
There is a strong positive relationship between income category and respondents‘ willingness to 
pay, which corresponds with the box and whiskers‘ analysis as well as the ANOVA shown in 
Table 5.27 above. The interpretation is that for every unit increase in income category, 
willingness to pay increases by 36.74 units, assuming all other factors are held constant. 
5.3.7.3. Discussion 
As anticipated high income earners were willing to pay more than lower earning participants 
possibly due to ability to pay. The significantly positive effect of income on WTP is consistent 
with previous studies (Suh, 2000; Barner & Branvold, 2005; Shafie & Hassali, 2010). 
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5.3.8. The effects of respondents’ chronic disease state on willingness to pay 
The results obtained from the study observations depicted a positively skewed distribution as 
shown by the box and whiskers diagram below. 
 
This category‘s medians are similar at approxmately R110, irrespective of the absence or 
presence of chronic disease. Although the level of dispersion between the respondents with 
chronic diseases and those without differed as shown by the differences in the inter-quartile 
ranges (IQR), the lower minimum (R0) and upper maxmum (R300) scores on WTP were the 
same, thus respondents were willing to pay the same minimum and maximum irrespective of the 
presence of chronic conditions or not. The IQR of respondents who had chronic diseases ranged 
from R50-R220 and that of those with none ranged from R70-R180. 
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Figure 5.26 Respondents’ WTP with respect to the presence of chronic diseases (n=263) 
Chronic diseases 
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The mean willingness to pay between respondents‘ with chronic diseases (R134.67) or without 
chronic diseases (R122.98) does not vary significantly. 
 
5.3.8.1. Analysis of Variance of WTP with respect to chronic diseases 
 
The null hypothesis is that chronic diseases have no effect on willingness to pay or implies that 
the mean amount of willingness to pay (WTPtot) of respondents with or without chronic diseases 
is not significantly different from each other. The null hypothesis, if p-value [Sig. (2-tailed)] is 
less than 0.05, is therefore rejected. 
According to the comparison, in Table 5.30 where the p-value=0.307, there is no evidence that 
the mean willingness to pay by respondents, with or without chronic diseases, differs 
significantly. Therefore, the null hypothesis cannot be rejected. 
 
 
 
 
ANOVA Table
7858.183 1 7858.183 1.047 .307
1958636 261 7504.351
1966494 262
(Combined)Between Groups
Within Groups
Total
WTPtot * Cronic
Sum of
Squares df Mean Square F Sig.
Report 
WTPtot 
122.98 178 83.411 
134.67 85 93.043 
126.76 263 86.635 
Chronic 
None 
Present 
Total 
Mean N Std. Deviation 
Table 5.29: Respondents’ mean willingness to pay with respect to chronic diseases 
 
Table 5.30: Compares mean willingness to pay of respondents with respect to chronic diseases 
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5.3.8.2. Regression analysis of the presence of chronic diseases on willingness to pay 
Table 5.31 shows the regression coefficient between the independent variable chronic diseases 
and the dependent variable willingness to pay (WTPtot) 
Table 5.31 Regression coefficient between presence of chronic diseases and WTPtot 
Dependent variable: WTPtot 
Independent variable: Chronic diseases 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 122.983 6.493 18.941 0.000 
Chronic 11.687 11.421 1.023 0.307 
 
The hypothesis tested is that there is a regression effect of chronic diseases on willingness to pay 
(WTPtot) or alternatively that chronic diseases have an effect on WTPtot. The p – value (0.307) 
is greater than 0.05 and therefore the null hypothesis cannot be rejected. It can be concluded that 
chronic diseases have no regression effect on respondents‘ willingness to pay. 
5.3.8.3. Discussion 
Participants with chronic diseases were expected to be willing to pay more. It is understood that 
participants with one or more chronic diseases are more likely to experience medication-related 
problems, and might be more inclined to appreciate pharmacist interventions to reduce 
associated risk factors. Contrary to expectations there was no evidence to show any influence of 
presence of chronic disease on WTP. The study went on to investigate the effect of co-existence 
of multiple chronic diseases (co-morbidities) on respondents‘ willingness to pay. 
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5.3.9. The effects of presence of co-morbidities on willingness to pay 
The box and whiskers below depicts the effects of presence of co-morbidities on respondents‘ 
willingness to pay. 
 
The median of willingness to pay increased in categories as the number of co-morbidities 
increased from 0 to 5; the median rose from approximately R100 (0 and 1 co-morbid) to 
approximately R120 (2 and 3 co-morbid) and significantly rose between 4 and 5 co-morbidities 
with a median of approximately R210 and R250 respectively. The respondents who presented 
with 2 or 3 co-morbidities had greater IQR than the others, hence a greater variability. 
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Figure 5.27 Respondents’ WTP with respect to the presence of co-morbidities (n=263) 
Number of co-mor idities 
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5.3.9.1. Analysis of Variance of WTP with respect to co-morbidities 
 
 
The null hypothesis is that the number of co-morbidities a respondent has does not affect 
willingness to pay, thus the mean amount of WTPtot across all co-morbidities is not significantly 
different from each other. 
 
 
Multiple Comparisons
Dependent Variable:  WTPtot
LSD
18.342 18.060 .311 -17.22 53.91
-23.978 15.824 .131 -55.14 7.18
25.737 23.473 .274 -20.49 71.96
-75.728* 30.566 .014 -135.92 -15.54
-126.978* 49.242 .010 -223.95 -30.01
-18.342 18.060 .311 -53.91 17.22
-42.320 22.285 .059 -86.20 1.56
7.394 28.235 .794 -48.21 63.00
-94.070* 34.358 .007 -161.73 -26.41
-145.320* 51.682 .005 -247.09 -43.55
23.978 15.824 .131 -7.18 55.14
42.320 22.285 .059 -1.56 86.20
49.714 26.860 .065 -3.18 102.61
-51.750 33.237 .121 -117.20 13.70
-103.000* 50.943 .044 -203.32 -2.68
-25.737 23.473 .274 -71.96 20.49
-7.394 28.235 .794 -63.00 48.21
-49.714 26.860 .065 -102.61 3.18
-101.464* 37.488 .007 -175.29 -27.64
-152.714* 53.813 .005 -258.68 -46.74
75.728* 30.566 .014 15.54 135.92
94.070* 34.358 .007 26.41 161.73
51.750 33.237 .121 -13.70 117.20
101.464* 37.488 .007 27.64 175.29
-51.250 57.264 .372 -164.02 61.52
126.978* 49.242 .010 30.01 223.95
145.320* 51.682 .005 43.55 247.09
103.000* 50.943 .044 2.68 203.32
152.714* 53.813 .005 46.74 258.68
51.250 57.264 .372 -61.52 164.02
(J) CoMobid
1
2
3
4
5
0
2
3
4
5
0
1
3
4
5
0
1
2
4
5
0
1
2
3
5
0
1
2
3
4
(I) CoMobid
0
1
2
3
4
5
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant  at the .05 lev el.*. 
Table 5.32: Multiple comparisons on mean willingness to pay of co-morbidities 
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First category: Although the mean willingness to pay between respondents who had no co-
mordities and those who had at least 2 and 3 does not differ significantly (p-values > 0.05), the 
disparity between no co-morbidities with 4 and 5 co-morbidities was significant, with p-values or 
0.014 and 0.010 respectively. It was thus evident, that respondents with 5 co-morbidities were 
willing to pay R126.98 more than those who had no co-morbidities (category-I). 
Second category: The mean willingness to pay of respondents with 1 chronic disease and no co-
morbidity does not differ significantly with that of respondents who had up to 3 co-morbidities 
(p-value > 0.05). However in comparison with those who had 4 and 5 co-morbidities, the mean 
willingness to pay differ significantly (p-values < 0.05). 
Third category: The mean willingness to pay between category-I (respondents who had 2 co-
morbidities) and category-J (respondents who had less than 4 co-morbidities) does not vary 
significantly since p-values are greater than 0.05. The mean difference between respondents who 
had 2 co-morbidities and those who had 5 co-morbidities equals a negative with a p-value of 
0.044 and thus respondents who had 5 co-morbidities were willing to pay R103 more units and 
their mean differs significantly.  
Fourth category: The mean willingness to pay between respondents who had 4 co-morbidities 
and those who had 5 co-morbidities does not differ significantly (p-value = 0.372). 
5.3.9.2. Regression analysis of co-morbidities on willingness to pay 
Table 5.33 below shows the regression coefficient between the independent variable co-
morbidities and the dependent variable willingness to pay (WTPtot). 
 
Dependent variable: WTPtot 
Independent variable: Co-morbidities 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 119.654 6.149 19.460 0.000 
Co-morbidities 10.269 4.505 2.280 0.023 
 
Table 5.33 Regression coefficient between presence of co-morbidities and WTPtot 
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There is a positive relationship between the number of co-morbidities and respondents‘ 
willingness to pay (p-value = 0.023). Assuming all other factors are held constant, for every 
additional chronic disease or co-morbidity, respondents were willing to pay R10.27 more. 
5.3.9.3. Discussion 
The more chronic diseases a respondent has (that is an increased co-morbidities), the greater 
WTP. Contrary to the findings in Section 5.3.8, for every additional chronic disease, or co-
morbidity, respondents were willing to pay R10.27 more. Although one would assume a 
similarity between chronic diseases and co-morbidities, the presence of chronic diseases was 
surprisingly not influential on respondents‘ willingness to pay. Although most studies did not 
investigate either the effect of chronic diseases or co-morbidities on WTP, the findings in this 
study were consistent with Munyikwa‘s findings (2008). She reported that participants without 
other morbidities were willing to pay R37.98 less than those who had co-morbidities 
(Munyikwa, 2008). 
5.3.10. The effects of experience of medication-related problems (MRPs) on willingness to pay 
Figure 5.28 below depicts the relationship between respondents who had experienced 
medication-related problems and those who had not with respect to their willingness to pay. 
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Figure 5.28 Respondents’ WTP with respect to the medication-related problems (n=263) 
YES NONE 
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The results obtained from MRP observations were positively skewed. The measure of dispersion 
between the patients who had experienced MRP and those who had not, appeared to be relatively 
similar, as indicated by the similar inter-quartile ranges. Some respondents   across both groups 
were not willing to pay (minimum WTP score of R0), irrespective of having had experienced a 
medication-related problem or not. Although the respondents who had experienced medication-
related problems had a greater willingness to pay (approximately R370), the median willingness 
to pay was approximately the same for both groups. 
 
 
The mean willingness to pay between respondents who experienced medication-related problems 
(R130.65) or had no prior experience with MRP (R124.30) does not vary significantly. 
5.3.10.1. Analysis of Variance of WTP with respect to medication-related problems 
Table 5.35 is a comparison of mean WTP respondents with respect to experience with MRPs. 
 
The null hypothesis is that prior experience with medication-related problems has no effect on 
willingness to pay or implies that the mean amount of willingness to pay (WTPtot) of 
respondents with or without prior experience of medication-related problems is not significantly 
different from each other. Therefore the null hypothesis, if p-value [Sig. (2-tailed)] is less than 
0.05, is rejected. 
Descriptives
WTPtot
161 124.30 82.043 6.466 111.53 137.07 0 300
102 130.65 93.714 9.279 112.24 149.05 0 367
263 126.76 86.635 5.342 116.24 137.28 0 367
None
Yes
Total
N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum
ANOVA
WTPtot
2516.925 1 2516.925 .334 .564
1963977 261 7524.816
1966494 262
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
Table 5.34 Respondents’ mean willingness to pay with respect to experience with     
medication-related problems (MRP) 
Table 5.35 Compares mean willingness to pay of respondents with respect to experience 
with medication-related problems 
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The p-value (0.564) is greater than 0.05 and therefore the null hypothesis cannot be rejected. It 
can be concluded that prior experience with medication-related problems has no influence on the 
respondents‘ mean willingness to pay. 
5.3.10.2. Regression analysis of medication-related problems on willingness to pay 
Table 5.35 below shows the regression coefficient between the independent variable medication-
related problems (MRPs) and the dependent variable willingness to pay (WTPtot). 
Table 5.35 regression coefficient between medication-related problems and WTPtot 
Dependent variable: WTPtot 
Independent variable: medication-related problem (MRP) 
Predictor Co-efficients Standard Error t-Statistics P-value 
Intercept 124.298 6.837 18.18 0.000 
MRP 6.349 10.977 0.58 0.564 
 
The hypothesis tested is that there is a regression effect of medication-related problems on 
willingness to pay (WTPtot) or alternatively that medication-related problems have an effect on 
WTPtot. The p–value (0.564) is greater than 0.05 and therefore the null hypothesis cannot be 
rejected. It can be concluded that medication-related problems have no effect on WTP. 
Respondents‘ willingness to pay is not influenced by whether or not one had prior experience 
with medication-related problems. 
5.3.10.3. Discussion 
Participants with prior experience of medication-related problems were expected to be willing to 
pay more. It is expected that participants who had experience MRPs are more inclined to 
appreciate pharmacist-interventions to reduce associated risk factors. Contrary to expectations 
there was no evidence to show any influence of experience with medication-related problems on 
WTPtot. In a previous study by Suh (2000), he noted that respondents with prior experience with 
medication-related problems were less willing to pay for pharmacy services than respondents 
with no history of such problems. He suggested that, prior experience of MRPs might have made 
respondents more aware of their allergies and/or clinical conditions and more confident in terms 
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of preventing and handling medication-related problems (Suh, 2000). Respondents in the present 
study might have been indifferent about their willingness to pay, possibly because they might not 
have a good understanding of the consequences of experiencing a medication-related problem, 
thus more education seems necessary to improve awareness. 
5.3.11. The effects of respondents’ medical aid status on willingness to pay 
Figure 5.29 below illustrates the effects on respondents, who had medical aid cover and those 
who did not have any, on willingness to pay. 
 
The results obtained with respect to medical aid cover, were positively skewed. Although 
respondents who were on medical aid were willing to pay more (with a greater upper maximum 
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Figure 5.29 Respondents’ WTP with respect to medical aid cover (n=263) 
Medical Aid cover 
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of approximately R360), some respondents from both categories were not willing to pay 
(minimum willingness to pay of R0.00). 
5.3.11.1. Regression analysis of medical aid cover on willingness to pay 
Table 5.37 below shows the regression coefficient between the independent variable medical aid 
and the dependent variable willingness to pay (WTPtot). 
Table 5.37 Regression coefficient between Medical aid and WTPtot 
Dependent variable: WTPtot 
Independent variable: Medical aid 
Predictor Co-efficients Standard Error t-Statistics P-value 
Intercept 130.019 8.427 15.429 0.000 
Medical aid -5.458 10.907 -0.500 0.617 
 
The p–value (0.617) is greater than 0.05 and therefore the null hypothesis cannot be rejected. It 
can be concluded that medical aid has no effect on willingness to pay, when other factors are 
kept constant. Thus it is evident that respondents‘ willingness to pay is not influenced by whether 
or not one has a medical aid. 
5.3.11.2. Discussion 
Participants with medical aids were expected to be more reluctant to pay as they expect their 
medical aid to cover the proposed pharmacist-interventions on their behalf from their medical 
benefits. Contrary to expectations, there was no evidence of any significant influence, of whether 
or not a respondent had a medical aid, on willingness to pay. Although the present findings were 
inconsistent with findings from another study by Larson (2000), who concluded that respondents 
were more inclined to pay from their insurance benefits, they were consistent with a previous 
study conducted in South Africa (Munyika, 2008). 
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5.3.12. The effects of respondents’ level of satisfaction with pharmacist-provided services on 
willingness to pay 
The box and whisker diagram below illustrates the respondents‘ level of satisfaction of 
pharmacist-provided services with respect to willingness to pay. 
 
The result obtained from the observations depicts a generally positively skewed frequency 
distribution. Across all levels of satisfaction some respondents were not willing to pay, as seen 
by the lower minimum score of R0. The median, mean and inter-quartile ranges increased from 
low levels of satisfaction to high levels of satisfaction, thus showing a general increase in 
willingness to pay from the least satisfied to the most satisfied. 
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Figure 5.30 Respondents’ WTP with respect to level of satisfaction of pharmacist provided 
services (n=263) 
Level of satisfaction 
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However, a few slightly satisfied patients were willing to pay more than other slightly satisfied 
patients as seen by the few out-of-range scores. 
 
 
The respondents‘ mean willingness to pay increased from slightly satisfied (R94.55), to satisfied 
(R112.22) and very satisfied (R155.37). 
5.3.12.1. Analysis of Variance of WTP with respect to levels of satisfaction of pharmacist-
provided services 
 
The null hypothesis is that the level of satisfaction a respondent has does not affect willingness to 
pay, thus the mean amount of WTPtot across all levels of satisfaction is not significantly 
different from each other. 
 
 
Descriptives
WTPtot
40 94.55 83.209 13.157 67.94 121.16 0 367
118 112.22 79.452 7.314 97.74 126.71 0 300
105 155.37 88.006 8.589 138.34 172.40 0 300
263 126.76 86.635 5.342 116.24 137.28 0 367
Slightly
Satisf ied
Very  satisf ied
Total
N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interv al f or
Mean
Minimum Maximum
Multiple Comparisons
Dependent Variable:  WTPtot
LSD
-17.670 15.283 .249 -47.76 12.42
-60.821* 15.520 .000 -91.38 -30.26
17.670 15.283 .249 -12.42 47.76
-43.151* 11.206 .000 -65.22 -21.08
60.821* 15.520 .000 30.26 91.38
43.151* 11.206 .000 21.08 65.22
(J) Satisfaction
Satisf ied
Very  satisf ied
Slightly
Very  satisf ied
Slightly
Satisf ied
(I) Satisfaction
Slightly
Satisf ied
Very  satisf ied
Mean
Dif f erence
(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interv al
The mean dif f erence is signif icant at the .05 level.*. 
Table 5.38: Respondents’ willingness to pay with respect to level of satisfaction with 
pharmacist-provided services 
Table 5.39: Comparisons on mean willingness to pay of levels of satisfaction of pharmacist-
provided serv ces 
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First category: The mean willingness to pay between respondents who were slightly satisfied 
and those who were both satisfied and very satisfied differs significantly (p-values < 0.05). Thus  
it is evident that very satisfied respondents were willing to pay R60.82 more than slightly 
satisfied respondents (category-I–category-j = negative). 
Second category: The mean willingness to pay between respondents who were satisfied  and 
those who were very satisfied  differed significantly (p-values < 0.05), thus very satisfied 
respondents were willing to pay R43.15 more than satisfied respondents.  
5.3.12.2. Regression analysis of satisfaction level on willingness to pay 
Table 5.40 below shows the regression coefficient between the independent variable satisfaction 
and the dependent variable willingness to pay (WTPtot). 
Table 5.40: Regression coefficient between satisfaction level and WTPtot 
Dependent variable: WTPtot 
Independent variable: level of satisfaction 
Predictor Co-efficients Standard Error t-Statistics P-value 
Intercept 18.655 24.453 0.763 0.446 
Satisfaction 33.292 7.361 4.523 0.000 
 
There is a positive relationship between level of satisfaction and the respondents‘ willingness to 
pay (p-value=0.000). Assuming all other factors are held constant, for every unit increase in 
satisfaction, respondents were willing to pay R33.27 more. 
5.3.12.3. Discussion 
It was anticipated that the greater the level of satisfaction of respondents with pharmacist-
provided services the greater the likelihood of willingness to pay. Although most studies did not 
investigate this parameter, the findings were consistent with expectations as respondents were 
willing to pay R33.27 more as their level of satisfaction with provided services increased. 
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5.4. COMBINED REGRESSION EFFECT OF THE INDEPENDENT VARIABLES ON 
WTPtot 
As outlined in Section 4.5.7.5, the independent variables were individually regressed against the 
dependent variables (WTPtot), based on the assumption that all the other influential factors and 
independent variables were constant. However, in reality these variables may occur together and 
hence interfere with each other, consequently producing a combined effect. Thus for purposes of 
inference a second regression, including all the independent variables was done as follows. 
Table 5.41 Combined regression analysis of independent variables on WTPtot 
Dependent variable: WTPtot (n=263) 
Predictor Coefficients Standard Error t-Statistics P-value 
Intercept 69.115 28.186 2.45 0.015 
Age 0.715 0.418 1.71 0.088* 
Income 0.004 0.0009 4.82 0.000** 
Race (non-whites) Dummy/indicator variable 
Whites 27.968 9.951 2.81 0.005** 
Unemployed Dummy/indicator variable 
Employed -80.067 17.996 -4.45 0.000** 
Medical Aid NO Dummy/indicator variable 
 YES -23.047 9.519 -2.42 0.016** 
Co-morbidities NO Dummy/indicator variable 
 YES -0.177 10.118 -0.02 0.986 
Dissatisfied Dummy/indicator variable 
Satisfied 43.150 12.754 3.38 0.001** 
**P<0.05, *P<0.10 
 
 
  
141 
Some independent variables such as gender and geographical location of respondents were found 
to have no effect on willingness to pay (Larsson, 2000; Suh, 2000; Shafie & Haasali, 2010); 
therefore for the purpose of the above regression analysis in Table 5.37, gender and geographical 
location were left out. 
For the purpose of analysis all the qualitative independent variables (race, employment status, 
medical aid status, chronic co-morbidities, and level of satisfaction) were further regrouped into 
mutually-exclusive binary variables where the reference category is denoted by a zero 
representing a dummy or indicator variable and the other denoted by one as the predictor. 
Dummy variables are casually defined as numerical stand-ins for qualitative facts in a regression 
model (Gujarati, 2003). 
The categorical qualitative variables were regrouped as follows: 
Race was grouped into non-Whites and Whites variables; Asian, Black and Coloured 
respondents were represented in the non-Whites variable. In the Employed category; students, 
retired and unemployed respondents and pensioners were represented by the ―Unemployed‖ 
variable, while ―Employed‖ variable represented respondents who were employed full-time, 
part-time and who were self-employed. The level of satisfaction category was divided into 
variables; ―Dissatisfied‖ represented respondents that were not satisfied and slightly satisfied 
with pharmacist-provided services, while the variable ―Satisfied‖ represented those that were 
satisfied and very satisfied. 
Regrouping some of these variables reduces the effect of serial correlation in a regression and 
therefore leads to a better regression output. An example of correlation would be the intra-
relationship within the ―Employed‖ variable. 
A one-year change in respondents‘ age increased willingness to pay by seventy-two cents, with a 
10% level of significance (p-value = 0.088). Thus it is expected that the older a respondent is the 
greater their willingness to pay.This could be understood as the greater the need the more value 
attached to health – hence the older the respondent is the more appreciative they will be  of the 
proposed pharmacist-intervention. 
  
142 
The respondents‘ monthly earnings (income) were all significant in determining their willingness 
to pay. For every unit increase in the respondents‘ earnings, willingness to pay increased by a 
small amount. The present findings were consistent with previous studies (Suh, 2000; Shaafie & 
Haasali, 2010). 
The results show that the white racial group was willing to pay R27.96 more than non-whites. 
The statistical variable was significant at 5%. 
The employed respondents were less willing to pay by a difference of R80.07 than those who 
were unemployed. The statistical variable was significant at 5%. It was logically expected that an 
employed participant should be able to pay more than an unemployed participant. It is likely that 
most employed respondents were covered by medical aid schemes hence the possible 
unwillingness to pay additional amounts for the proposed pharmacist-provided services. Other 
studies did not report any significant influence of employment status on WTP (Suh, 2000, 
Shaafie & Hassali, 2010). 
Respondents with medical aid were less willing to compensate the pharmacists for the proposed 
pharmacist-provided pharmaceutical care intervention out of their own pocket. Respondents 
would rather have their medical aid compensate the pharmacist on their behalf out of their 
monthly premiums. As expected the relationship between being on medical aid and WTPtot was 
negative, and significant at the 5% level of significance. These findings are in line with the 
results of employment status as previously mentioned. 
The greater the level of satisfaction experienced, one is naturally expected to be willing to 
compensate the provider more generously. As expected, respondents‘ level of satisfaction had a 
positive relationship with willingness to pay (p-value = 0.001). As respondents became more 
satisfied with pharmacist-provided care services they were willing to pay the pharmacist R43.15 
more. 
In summary, of the investigated respondents‘ demographic factors the multiple regression 
analysis has shown that the respondents‘ willingness to pay was influenced by their age, 
earnings, racial grouping, employment status, medical aid status and their level of satisfaction 
with pharmacist-provided care services. 
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5.5. MEDICAL AID SCHEMES 
5.5.1. Research population and sample 
South Africa has about 31 open medical schemes and 77 restricted medical schemes totaling 8 
million beneficiaries ( Council for Medical Schemes, 2010). South Africa, according to Statistics 
SA (2009), has a population of 49.9 million (Statistics South Africa, 2010). Less than 17% of the 
population belongs to a medical aid scheme. The five biggest medical aid schemes in SA are 
Discovery, Bonitas, Fedhealth, Medshield and Momentum (InsuranceZA, 2011). 
All 108 registered medical aid schemes (MASs), which were listed in the official website of the 
medical schemes (http://www.medicalschemes.com), were considered in the inclusion of the 
survey. Of the 108 MASs, seventy-seven were restricted to the public and thirty-one were open 
schemes (see Appendix 9). An e-mail, pertaining to the study, was sent to all the medical 
schemes requesting their willingness to participate. 
Of the 77 restricted medical schemes, eighteen declined to participate, fourteen forwarded the 
request to a suitable scheme representative, and 45 did not take part in the study for various 
reasons such as not responding to e-mails and when the researcher followed up telephonically 
they were unavailable. Therefore, no response was obtained from all restricted medical aid 
schemes. 
Of the 31 MASs open to the public, nine declined to participate, fourteen responded positively to 
the initial e-mail request although they were unable to return the completed questionnaire. Only 
eight completed questionnaires were returned. This response resulted in response rate of 25.8% 
(n=33). Table 5.42 provides a summary of recruited potential participants and actual 
respondents. 
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Table 5.42 Summary of recruited potential participants and actual respondents 
Study population details Restricted (MAS, n=77) Open (MAS, n=31) Response Rate 
Schemes that declined 
participating at all 
18 9 0% 
Schemes that responded but 
did not participate 
59 14 0% 
Schemes that responded and 
participated 
0 8 25.8% 
 
5.5.2. Demographic characteristics of medical aid schemes 
Demographic information that was assessed includes total number of members belonging to the 
scheme, percentage of members who are registered on chronic medication benefits, the average 
total monthly premium contributions per principal member, the average number of times the 
member visits the doctor per year for consultation and the pharmacist who fills in their scripts. 
Of the eight (25.8%) open medical aid schemes that responded; four were among the top five 
medical aid schemes registered by the Council of Medical Schemes (CMS) ( Council for Medical 
Schemes, 2010; InsuranceZA, 2011). The eight participating medical schemes reported that they 
had a total of 5.6 million beneficiaries and that their members visit the doctor at least twice a 
year on average, for consultation. 
5.5.3. Respondents’ perception of medical care received by their members from doctors 
Of the eight respondents, seven had the perception that their members were not adequately 
counseled during their doctors‘ consultation about their medical condition and how to use their 
medication properly. They were of the viewpoint that patients are often cycled through the 
doctors‘ consulting rooms in the shortest possible time and further suggested that the doctors 
need to spend more time with patients fulfilling their medical role. 
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According to a study conducted by Ogden and colleagues (2004), patients who were dissatisfied 
with the time they spent with their doctor during consultation were less likely to adhere to 
treatment recommendations (Ogden, et al.2004). Longer consultation hours have been associated 
with higher quality, better therapeutic outcomes and recognition that patient needs are 
individualized, hence require different amount of time for appropriate management (Ogden, et 
al.2004). 
5.5.4.  Respondents’ perception of the importance of pharmaceutical care delivery by 
pharmacists 
As discussed in Section 5.1.17, the delivery of pharmaceutical care (PC) involves several 
activities which may include aspects such as educating the patient about their disease state and 
advising them on how to administer their medications appropriately. Pharmacists may help 
reduce hospital incidents due to mediation-related problems by providing influential services, 
such as screening and monitoring services, Disease State Management (DSM) programs (for 
example asthma, hypertension and hormone replacement therapy), and consequently help 
improve the general quality of patients‘ lives. 
According to a study by Schnipper and colleagues (2006), the role of pharmacists in medication 
review, patient counseling, and telephone follow-ups after discharge were associated with a 
lower rate of preventable adverse drug reactions (ADRs) 30 days after hospital discharge. In 
Finland, pharmacists were reported to have improved the lung function of a group of patients, 
through a pharmacist-directed therapeutic monitoring asthma program (Narhl et al, 2000). In 
Canada, pharmacists helped to decrease a 10-year risk of cardiovascular disease from 17.3% to 
16.4%, through a pharmacist-directed lipid management program (Simpson, 2001). 
In the present study the researcher sought to determine the perceived value of pharmacist 
interventions by third-party payers (SA Medical Aid schemes). On a Likert Scale of 1 to 4, 
respondents were asked to indicate their perceived importance and the influential role the 
pharmacist plays in counseling and providing multiple services such as educating and advising 
the patient amongst other things. A response of 1 indicated a strongly non-influential role, 2-
slightly influential, 3-moderately influential, and 4-strongly influential. A summary of responses 
obtained from all eight medical aid respondents is provided in Table 5.40. 
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Description of influential care service 1 2 3 4 
Educating the patient about their disease state   25.0 75 
Explaining to the patient medication in terms of name, description, 
dosage form, route of administration, dosage frequency, storage, 
scheduling status and duration of therapy. 
12.5 12.5  75 
Providing a generic substitution where possible, and explaining the 
difference from the brand drug. 
   100 
Explaining to the patient how the medication treats their medical 
condition. 
50 50   
Advising patients on how to administer their medications 
appropriately 
   100 
Educating the patient about potential adverse effects and strategies 
to avoid and manage them. 
 12.5 87.5  
Screening and monitoring services    100 
Disease state management programs (for example, asthma, 
hypertension & hormone replacementtherapy) 
37.5 50.0 12.5  
Reducing hospital incidents due to medication-related problems  12.5 12.5 75.0 
Improving the general quality of life of patients   25.0 75.0 
 
Six (75.0%) of the medical aid respondents believed that pharmacists have a strongly influential 
role in educating the patient about their disease states, and have an important role to play in 
making sure that the patient knows about the drug they administering, by providing them with 
the necessary drug information. 
Table 5.43 Respondents’ perceived role played by pharmacists % Response (n=8) 
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All the eight respondents (100%), were of the opinion that it is very important for the pharmacist 
to provide the patient with a cheaper generic alternative where possible, and explain the 
difference with the branded drug product. They also believed that it is either slightly influential 
or not important for pharmacists to explain to the patient how the medication treats their medical 
condition. 
Of the eight respondents, seven (87.5%) were of the perception that it is important for 
pharmacists to educate patients about potential adverse effects and give them strategies to avoid 
and manage them, whilst all of them were quite certain that pharmacists are very influential in 
advising patients on how to administer their medication appropriately and in providing screening 
and monitoring services. 
None of the respondents believed pharmacists have a leading role to play in the provision of 
disease state management programs, and only four of them responded that their role is slightly 
influential. Of the eight respondents, six (75.0%) were of the opinion that pharmacists are very 
instrumental in reducing hospitalization due to medication-related problems. 
Contrary to the belief by most respondents that pharmacists are not influential in providing 
disease state management programs, they all perceived pharmacists as having  essential role to 
play in improving the general quality of life of patients. 
5.5.5. Patients hospitalized due to medication-related problems (MRPs) in South Africa 
Studies have shown that medication-related problems are a significant cause of hospital 
admissions, although mostly common in elderly patients (Wiffen, Gill, Edwards, et al. 2002; 
Mehta, Durrheim, & Blockman, et al.2008; Rogers, Wilson, & Wan, et al. 2009). There is a 
reported correlation between the number of drugs beings administered, and the number in co-
morbidities with the development of medication-related problems (Rogers, Wilson, & Wan, et al. 
2009). 
Respondents were asked to indicate the number of cases they encountered in 2009 in which their 
members were hospitalized due to medication-related problems (MRPs). Of the eight 
respondents, two had no recorded data on the number of patients hospitalized due to MRPs.  
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All the respondents who gave a positive feedback were further requested to provide their own 
opinion on how to resolve medication-related problems and reduce hospitalizations. Table 5.44 
provides a summary of responses obtained. 
Table 5.44 Summary of hospitalized patients due to medication-related problems in 2009 
Respondent 
number 
Number of recorded MRPs in 
the year 2009 
Average MRPs per month 
1 476 40 
2 312 26 
3 228 19 
4 182 15 
5 66 6 
6 63 5 
Total 1327 111 
 
On average, there were about 111 medical aid members per month who were reported to have 
been hospitalized due to medication-related problems in 2009. There seem to be a dearth of 
research and information on medication-related incidents in South Africa. 
 
In order to reduce incidents due to medication-related problems, respondents suggested that 
patients need to understand why and how to use their medication appropriately. They also 
recommended that patients need to be better informed about side effects and when to be 
concerned about them. Respondents also advocated for doctors, pharmacists and other healthcare 
practitioners to work as a team; record full patient history during consultations, ensure the most 
appropriate drug selection is individualized according to unique needs of the patient, consider co-
morbidities before drug selection and monitoring of patient post-intervention. 
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5.5.6. Respondents’ willingness to pay on behalf of medical aid beneficiaries 
Medical aid scheme respondents were given a hypothetical scenario of an ideal pharmacist-care 
service, provided to their medical aid members, which would help reduce the risk associated with 
medication errors. The medial aid respondents were then asked to indicate their willingness to 
pay for the proposed hypothetical services, on behalf of their members, from the medical aid 
benefits. 
Contrary to the willingness to pay indicated by respondents in phase-one of the study involving 
patients, all the eight respondents (MAS participants) indicated that they were not willing to pay 
anything over and above the dispensing fee stipulated by the Medicine Control Council. They 
were of the general opinion that it is the pharmacists‘ responsibility to counsel and educate the 
patients about appropriate use of medication, irrespective of whether they are reimbursed or not. 
Although all the medical aid scheme participants indicated their unwillingness to pay for 
pharmaceutical care interventions provided by the pharmacists in South Africa, they strongly 
believe that the pharmacist is an influential member in the healthcare sector especially where 
rational medicine use is concerned. 
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6. CHAPTER SIX: CONCLUSION, LIMITATIONS AND RECOMMENDATIONS 
 
6.1. CONCLUSION 
Studies have shown that pharmacists can play a vital role in reducing medication-related 
morbidity and mortality, and help to improve therapeutic outcomes and ultimately improve the 
patients quality of life (Suh, 2000; Larson, 2000; Barner & Branvold, 2005). Despite all the cited 
physical, attitudinal and economic barriers pharmacists may face, it is important for them to 
adopt a pharmaceutical care practice model for the survival of the profession. 
In order for pharmacists to adopt the pharmaceutical care approach, they need to find means to 
overcome the barriers. Pharmacists need to free themselves from their traditional role of mere 
dispensing or supply of medications and focus on developing advanced counseling skills, clinical 
knowledge pertaining to disease states and proper use of drugs (Roxy & Shroute, 2006). Possibly 
pharmacists need to invest in more technical pharmacist assistants to overcome the human 
resource shortages they may have (Awad, Al-Ebrahim, & Eman, 2006). To enable professional 
re-modeling, pharmaceutical societies and associations, government health institutions and 
educational institutions should participate in the continuous development of pharmacists‘ 
knowledge and advanced skills (Awad, Al-Ebrahim, & Eman, 2006). 
Although third-party payers (medical aid companies) were not willing to compensate 
pharmacists for pharmaceutical care intervention, findings in this study suggest that both the 
third-party payers and patients value the services provided by pharmacists. 
It has been suggested that one of the biggest barriers to implementation and provision of 
pharmaceutical care that pharmacists face is obtaining appropriate reimbursement (Babiker, 
2008). Many pharmacists also have the impression that patients are not willing to pay for 
pharmacist provided care services (Larson, 2000). A substantial proportion of respondents in this 
study were willing to pay the pharmacist for interventions directed towards reducing risk of 
medication-related problems. The fact that respondents indicated they would be willing to pay 
for a hypothetical service does not mean that they will do so in real life (Shafie & Hassali, 2010). 
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However, this willingness to pay could be seen as a starting point and may be an indicator that 
the demand by patients for the proposed services will be appreciated by third-party payers and 
decision makers. Thus, in light of the MASs responses, pharmacists must look to the patient for 
payment. 
Reimbursement or no reimbursement, pharmacists need to convey the message that they are 
willing providers of healthcare to patients, other healthcare professionals, government officials, 
third-party payers and healthcare administrators (Shu Chuen Li, 2003). It should therefore be 
their objective to market themselves, educate the general public about their role in modern 
healthcare and quantify the economic benefits of pharmaceutical care interventions (Crealey, 
McElnay, & Madden, 2002). 
However some benefits are difficult to measure and quantify - especially in monetary terms 
(Bootman, Townsend, & McGhan, 1998). In this study, the utility (meaning usefulness) of 
pharmacist-provided care services for participants, by reducing risk of medication-related 
problems, was measured through a willingness-to-pay approach. 
In a willingness-to-pay approach the utility an individual gains from an intervention is valued as 
the maximum amount they would be willing to pay for it (Cookson, 2003). Using a Contingency 
Valuation Method (CVM), this study sought to determine the participants‘ willingness to pay for 
hypothetical pharmacist interventions, either out-of-pocket or through their medical aid and 
additionally to determine some of the factors which might influence WTP. 
Findings in the present study were similar to findings in other studies (Larson, 2000; Suh, 2000; 
Barner & Branvold, 2005; Munyikwa, 2009), where the majority of patients were willing to pay 
for proposed pharmacist interventions. WTP, for pharmacist-services, was influenced by 
respondents‘ age, level of education, employment status, income, co-morbidities, and the level of 
satisfaction they had with the provided pharmaceutical care services. 
The patients‘ willingness to pay (WTP) for pharmacist-provided services in South Africa was 
measured for three different hypothetical risk reduction levels of medication-related problems 
(MRPs). The hypothetical risk reduction of MRPs through pharmacist interventions was varied 
from 30%, to 60% and 90%. The respondents‘ mean willingness to pay (WTPtot), for risk 
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reduction of MRPs at the three levels, was calculated and utilized to ascertain the 
aforementioned relationships between WTPtot and the independent variables. 
 
Results have shown that 88.6% (n=263) respondents were willing to pay on average R126.76 
from their own pockets in-order to avoid risk of medication-related problems through pharmacist 
interventions. These findings were consistent with a similar study by Munyikwa (2008) where it 
is reported that 94.7% of respondents were willing to pay for pharmacist-provided intervention. 
The maximum amount the respondents were willing to pay out of their own pockets was R367. 
Previous studies have shown that respondents were willing to pay varying amounts of money for 
pharmacist-provided interventions; and the present findings are consistent with those studies. 
In other studies on WTP for different pharmacist-provided services such as hormone-
replacement therapy, asthma and pharmacist-assisted therapy, the amount patients were willing 
to pay varied. A study was undertaken by Suh (2000), in America, which included 316 
respondents whose mean WTP out-of-pocket expenses for pharmacy services ranged from $4.02 
to $5.48 per prescription and from $28.79 to $36.29 for medical aid premiums. In a similar study 
in the USA consisting of 2500 adult participants it was found that the majority of the respondents 
who were receiving pharmaceutical care services were willing to pay the pharmacist an average 
of $13 for a once-off consultation (Larson, 2000). 
Respondents‘ WTP increased as the risk associated with medication-related problems was 
reduced, due to pharmaceutical care interventions. As the risk associated with MRPs was varied 
the willingness to pay also varied significantly: 50% (n=263) were willing to pay at least R100 
for a risk reduction of 30%; R120 for a 60% reduction and approximately R150 for a greater than 
90% risk reduction. 
Unlike most studies on willingness to pay for pharmacist-provided care services (Suh, 2000; 
Larson, 2000; Donaldson, 2000; Cookson, 2003; Munyikwa, 2008; Shafie & Haasali, 2010), the 
present study sought to establish the perceived value of the pharmacists‘ role in patient care, by 
third-party payers (SA Medical Aid providers) and their WTP for pharmacist-provided services 
(such as DSM) on behalf of members. Although the response rate from medical aid 
representatives was very low (25.8% n = 31), a significant response was obtained from the top 
four schemes in South Africa. 
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Findings indicate that all the participating medical aid respondents felt that pharmacists should 
not be paid for any pharmacists-provided care services, as the pharmacist already charge a 
professional fee. They believed the professional fees already charged by pharmacists should be 
sufficient to cover all the costs incurred in providing any pharmaceutical care service. Despite 
third-party payers‘ unwillingness to pay, they perceived pharmacists as very influential 
healthcare providers and as having a significant role to play in reducing medication-related 
problems and improving therapeutic outcomes, as well as improving patients‘ quality of life. 
 
Any inferences and generalizations in this study which include the whole South African 
population, based on the presented findings, should be dealt with cautiously as the study sample 
is very small. It is sincerely hoped that the findings do provide helpful pointers to pharmacists, 
the South African Pharmacy Council (SAPC), third-party payers (SA Medical Aid schemes), 
South African Universities and any other interested stakeholders. However, any final 
deliberations of these findings are in the hands of South Africa‘s decision-makers. 
6.2. Significance of the study 
The focus of the study has been to assess the patients‘ WTP and their perception towards 
pharmacist-provided care services in South Africa. The study is one of a few that utilizes the 
contingent valuation method (CVM) to measure healthcare benefits. 
Pharmacists in South Africa should be better able to determine consumer-demands for 
pharmaceutical care and levels of payment necessary for these services. The study was also able 
to provide information on specific variables that influenced patients‘ WTP. This information, it 
is hoped, should help pharmacists target specific individual‘s needs, and tailor programs to meet 
those needs. 
This study may encourage and increase the development of patient-focused programs such as 
disease state management (DSM), which could result in better patient management of their 
disease states. Although these services may result in better patient outcomes, they would not only 
benefit the patient but possibly provide a positive reflection on the importance of the pharmacist 
in delivering quality healthcare. Consequently, positive changes in healthcare outcomes due to 
pharmacist-provided care services would be beneficial to third-party payers such as SA Medical 
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Aid schemes and influence them to become more willing to compensate pharmacists for 
providing care services to their members. 
Lastly, it is hoped that the findings of this study may be considered as evidence to South African 
Medical Aid schemes that patients need, and are willing to pay for, pharmacist-provided care 
services. 
6.3. Limitations of the study 
A number of limitations need to be addressed to place the results of this study into perspective. 
As explained in Section 3.3.2.3, one of the limitations of this study relates to measurement bias 
in WTP approach. The contingent valuation approach has been subject to controversy in 
adequately determining consumers‘ willingness to pay, one of the major problems with the use 
of CVM is hypothetical bias (Journal of Pharmaceutical Association, 2000; Suh, 2000). The 
respondents were asked their maximum WTP for pharmaceutical care services and were given 
hypothetical scenarios that payment be made from their own expenses or through medical aid 
benefits. However, respondents may have been unfamiliar with assigning monetary value to 
pharmacist-provided care services, as they have always been traditionally free, thus determining 
their true utility on unfamiliar hypothetical goods is uncertain. 
Although a stratified sampling method was employed very low participation in some provinces 
limits the generalization of the findings to the whole South African population. Most respondents 
were chosen from the Gauteng province which is highly urbanized and is a high income 
province; this might not reflect the other South African provinces with lower income populations 
and by comparison have few respondents.  
Phase two of the study was also meant to analyze data statistically but, due to a relatively low 
response rate, it was adjusted to 25.8% and only descriptive statistical methods could be 
employed. The low response rate could possibly be attributed to the way large organizations, 
such as medical aid schemes, operate. Intermediaries, such as secretaries, make it difficult to 
contact principal officers for telephonic interviews. 
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6.4. Recommendations 
With or without reimbursement, an added responsibility is being placed on upon pharmacists to 
initiate and facilitate the implementation of cognitive pharmaceutical care services in South 
Africa. There is a serious lack of pharmacoeconomic studies in South Africa in relation to the 
costs and benefits of providing pharmaceutical care services to all South Africans. The present 
study has shown there is a need for pharmacist interventions.   
Future studies may be able to quantify the cost-effectiveness of implementing cognitive 
pharmaceutical care services in the South African context. It is therefore recommended that 
further pharmacoeconomic studies quantifying cost of implementation be conducted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
155 
REFERENCE LIST 
 
Academy of Managed Care Pharmacy. (2008, February 16). Advising an Collaborative Drug 
Therapy Management. Retrieved October 04, 2010, from Academy of Managed Care Pharmacy: 
http://www.amc.org/workarea/download.asset.aspx?id=9654 
Africa, S. S. (2009, July 27). Statistic South Africa. Retrieved January 02, 2012, from Statistical 
release (P0302): Mid-year population estimates: 
http://www.statssa.gov.za/publications/P0302/P03022009.pdf 
Al Shaqua, M., & Zairi, M. (2001). Pharmaceutical care management: A modern approach to 
providing seamless and intergrated health care. International Journal of Health Care Quality 
Assurance, 14:282-301. 
Al-Arifi, M. N., Al-Dhuwaili, A. A., & Gubara, O. A. (2007). Saudi Pharmaceutical Journal, 
15: 146-159. 
American Society of Hospital Pharmacists. (1993). ASHP Statement of Pharmaceutical Care. 
American Journal of Hospital Pharmacists, 50:1720-3. 
Anderson, S. (2002). The state of the world‘s pharmacy: a portrait of the pharmacy profession. 
Journal of Iinterprofessional Care, 391-4. 
Anonymous. (2000). Patient pay off in pharmaceutical care. America's Pharmacist, 122(2):43-
46. 
Anonymous. (1997). Physcians Pharmacists. Int Pharm J 11, 70-71. 
Antonius, R. (2003). Interpreting Quantitative Data with SPSS. London: SAGE Publications. 
Association of Chartered Certified Accountants. (2009). Accuntant in Business. London: BPP 
Learning Media. 
Awad, A., Al-Ebrahim, S., & Eman, A. (2006). Pharmaceutical Care Services in Hospitals of 
Kuwait. J Pharm Pharmaceut Sci, 9 (2): 149-157. 
Azhar, S., Hassali, M. A., & al, e. (2009). The role of pharmacists in developing countries: the 
current scenario in Pakistan. Human Resources for Health, 7:1-6. 
Babiker, G. A. (2008). An Explorative study on Pharmaceutical Care Practice fro the perspective 
of Pharmacists in Malaysia. University of Sains Malaysia, Masters Dissertation. 
Barner, J. C., & Branvold, A. (2005). Patients' willingness to pay for pharmacist-provided 
menopause and hormone replacement therapy consultations. Soc. Admin. Pharm., (1): 77-100. 
  
156 
Barner, J. C. (2004). Patients' Wllingness to Pay for diabetes disease state management 
programs. Journal of Managed Pharmaceutical Care, 1: 23-25. 
Barner, J., Manson, H., & Murray, M. (1999). Assessment of asthma patients' willingness to pay 
for and give time to an asthma self-management program. Clinical therapeutics, 21(5):878-894. 
Benrimoj, S. I, & Langford, J. H. (2000). Economic impact of increased clinical intervention 
rates in community pharmacy: a randomised trial of the effect of education and a professional 
allowance. Pharmacoeconomics, 18: 459-68. 
Berenguer, B., La Casa, C., de la Matta, M., & Martin-Calero, M. (2004). Pharmaceutical Care: 
Past, Present and Future. Current Pharmaceutical Design, 10: 3931-3946. 
Blumenschein, K., & Freeman, P. (2004). Consumer's Willingness to Pay for Pharmacist Care 
Services in Community Pharmacies. Executive Summary: NCPA Research Award, 1-13. 
Bootman, J., Townsend, R., & McGhan, W. (1998). Cost-Utility Analysis. In J. Bootman, R. 
Townsend, & W. McGhan, Principles of Pharmacoeconomics (p. 119). Harvey Whitney Books . 
Bootman, J., Townsend, R., & McGhan, W. (1998). Cost-Utility Analysis. In J. Bootman, R. 
Townsend, & W. McGhan, Pharmacoeconomics (pp. 113-115). Harvey Whitney Books 
Company. 
Bootman, L. J., Townsend, R. J., & McGhan, W. F. (1998). Principles of Pharmacoeconomics. 
Cincinnati: Harvey Whitney Books Company. 
Carter, B., & Barnett, D. (1996). How many of us provide pharmaceutical care. 
Pharmacotherapy, 16:965-967. 
Christenten, D., & Hansen, R. (1993). Charecteristics of pharmacies and pharmacists associated 
with the provision of cognitive services in the community setting.  J Am Pharm Assoc., 39:640-
649. 
Cookson, R. (2003). Willingnes to pay methods in healthcare: a sceptical view. Health 
Economics, 12: 891-894. 
Council for Medical Schemes. (2010, October 22). Medical Schemes. Retrieved October 
Monday, 2010, from Council of Medical Scheme: 
http://www.medicalschemes.com/MedicalSchemes.aspx 
Commonwealth Pharmacy Association. (2005, April 25). Africa Malaria Day. Retrieved October 
22, 2010, from Commonwealth Pharmacy Association: 
http://www.commonwealthpharmacy.org/africa-malaria-day-2005 
Crealey, G. E., McElnay, J. C., & Maguire, T. A. (1998). Costs and effects associated with a 
community pharmacy-based smoking-cessation programme. Pharmacoeconomics, 14: 323-33 
  
157 
 
De Santis, G., Harvey, K. J., & Howard, D. (1994). Improving the quality of antibiotic 
prescription patterns in general practice: the role of educational intervention. Med J Aust; 160: 
502-5. 
De Vos, A. S. (2002). For the Social Sciences and Human Services Professionals. In A. S. De 
Vos, Research at Grass Roots (pp. 1-49). Pretoria: J L Van Schaik. 
Donald, C. (2000). Eliciting patients' value by use of willingness to pay:letting theory drive the 
method. Health Expectations , 4:180-188. 
Drummond, M. F. (2008). Introduction to Pharmacoeconomics. EJHP Practice, 17-19. 
Encyclopædia Britannica. (2010). Science & Technology : correlation coefficient. Retrieved 
November 16, 2010, from Encyclopædia Britannica: 
http://www.britannica.com/EBchecked/topic/138639/correlation-coefficient 
Fleurence, R. (2003). An Introduction to Health Economics. The Pharmaceutical Journal, 679-
681. 
Foppe van Mil, J. W., & Schulz, M. (2006). A Review of Pharmaceutical Care in Community 
Pharmacy in Europe. Harvard Health Policy Review, 7:155-168. 
Frances, O. F. S. (2008). Adressing the workforce crisis: the professional aspiration of pharmacy 
students. Pharm World Sci, 30(5):577-583. 
Garratt, A., & Fitzpatrick, R. (2003). Quality of Life measurement: bibliographica study of 
patient assessed health outcome measures. British Medical Journal, 324. 
Gilberts, L. (2001). To diagnose, prescribe and dispense: Whose right is it? Current Sociology, 
97-118. 
Gilberts, L. (1998). Dispensing doctors and prescribing pharmacists: A South African 
perspective. Social Science & Medicine, 46: 83-95 . 
Gillespie, J. L., & Rossiter, L. F. (2003). Disease Management . Health outcomes, 346-360. 
Gonzalez-Martin, G., Joo, I., & Sanchez, I. (2003). Evaluation of the impact of a pharmaceutical 
care program in children with asthma. Patient Educating and Counselling, 49:13-8. 
Gray, A. (2009). Medicine pricing interventions. The South African expert. South African 
Medical Review, 2: 15-19. 
Gray, A., & Smit, J. (1998). Teaching Pharmaceutical Care principles for PHC. Medical 
Teacher, Vol. , 20, No. 5:460-463. 
Gujarati, D. N. (2003). Basic Econometrics. New York: Gary Burke. 
  
158 
Hammarlund, E. R., Ostrom, J. R., & Kethley, A. J. (1985). The effects of drug counseling and 
othereducational strategies on drug utilization of the elderly. Med Care, 23:165-70. 
Hanlon, J. T., Weinberger, M., & Samsa, G. P. (1996). A randomized, controlled trial of a 
clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with 
polypharmacy.Am J Med, 100: 428-37. 
Hailemeskel, B. (2001). Establishing a herbal counseling center in a community pharmacy. 
America's Pharmacist , 123(8): 19-22. 
Haycox, A., Boland, A., & Walley, T. (2004). Approaches to Pharmacoeconomic analysis. In A. 
Haycox, A. Boland, & T. Walley, Pharmacoeconomics (pp. 3-12, 107-112). Churchill 
Livingston: 2004. 
Heple, C., & Strand, L. (1990). Opportunities and responsibilities in pharmaceutical care. Am. J. 
Hosp. Pharmacists, 47:533-43. 
Higby, G. J. (1990). Evolution of pharmacy in Remington's pharmaceutical sciences. In G. J. 
Higby, The Science and practice of pharmacy (pp. 8-19).18
th
 ed Easton(PA): Mack Publishing 
Company. 
Hill, P., & Dowse, R. (2007). Cognitive pharmaceutical services that reduce risk of medication 
related problems. American Pharmaceutical Association, 15:201-208. 
InsuranceZA. (2011, November 10). About Medical Aids. Retrieved January 05, 2012, from 
InsuranceZA: http://www.insurance.za.org/medical-aid.htm 
Investopedia ULC. (2010, November). Investopedia News and Articles. Retrieved November 12, 
2010, from Investopedia: http://www.investopedia.com/terms/a/anova.asp 
Keller, G., & Warrack, B. (2003). Statistics for Management and Economics. Pacific Grove: 
Thompson Brooks/Cole. 
King, R. C., & Fomundam, H. N. (2010). Remodeling pharmaceutical care in Sub-Saharan 
Africa (SSA) amidst human resources challenges and the HIV/AIDS pandemic. International 
Journal of  Health Planning and Management, 25: 30–48. 
Krska, J., & Veith, G. (2001). Providing pharmaceutical care: The views of Scottish pharmacists. 
Pharmaceutical Journal, 267:549-55. 
Kwa-Zulu Natal Provincial Government. (2010, March 30). South African Government Info. 
Retrieved November 26, 2010, from South African Government Info: 
http://www.info.gov.za/speech/DynamicAction?pageid=461&sid=8846&tid=8863 
  
159 
Larson, R. (2000). Patients' Willingness to Pay for Pharmaceutical Care. J Am Pharm Assoc, 
40(5):618-624. 
Lourie, N., & Robertson, N. (1993). Barriers to pharmaceutical care in the managed care setting. 
Am J Pharm, 50:1614-7. 
Lowe, R. F., & Montagu, D. (2009). Legislation, regulation, and consolidation in the retail 
pharmacy sector in low-income countries. Southern Med Review, 2:35-44. 
Maine, L., & Pathak, D. (1996). Measuring Outcomes in Pharmaceutical care In: Health 
Outcomes and Pharmaceutical Care. Binghamton New York: Pharmaceutical Product Press. 
Mannase, H. J. (1989). Medication use in an impefect world: drug misadventuring an issue of 
public policy part1. Am J Hosp Pharm, 46: 929-44. 
Marra, L. A., Cibere, J., Tsuyuki, R. T., & al, e. (2007). Improving osteoarthritis detection in the 
community: Pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis 
Rheum. , 57(7): 1238-1244. 
Martín-Calero, M., Berenguer, B., La Casa, C., &de la Matta, M. (2004). Structural Process and 
Implementation Programs of Pharmaceutical Care in Different Countries. Current 
Pharmaceutical Design, 10:3969-3985. 
May, R. (1993). Barriers to pharmaceutical care in acute setting. Am J Hosp Pharm, 50:1608-11. 
McGhan, W., Rowland, C., & Bootman, J. (1978). Cost-Benefit and cost-effective: 
methodologies for evaluating innovative pharmaceutical services. Am J Hosp Pharm, 35:133-40. 
McKenney, J., & Harrison, W. (1976). Drug-related hospital admissions. Am J Hosp Pharm, 33: 
792-95. 
Mehta, U. C. (2011). The devastating consequences of not thinking about adverse drug reactions. 
Pharmacovigilance, 29:247-251. 
Munroe, W. P., Kunz, K., & Dalmady-Israel, C. (1997). Economic evaluation of pharmacist 
involvement in disease management in a community pharmacy setting. Clin Ther, 19: 113-23 
Munyikwa, E. (2008). Patients' Willingness to Pay for pharmacists provided asthma care 
services. Neslson Mandela Metropolitan University Masters Dissertation. 
Nahata, M. C. (2000). Pharmaceutical care Research and Pharmacy practice chair report for 
1999/2000. Research and Graduate Affairs. American Journal of Pharmaceutical Education, 64. 
  
160 
Narhi, U., Airaksinen, M., & Tanskanen P. (2000). Therapeutic outcomes monitoring by 
community pharmacists for improving clinical outcomes in asthma. J Clin Pharm Ther, 25:83-
177. 
Nord, E. (1992). Methods of quality adjustment of life years. Soc Sci Med, 34:559-569. 
Norwood, G., Sleath, B., & Caiola, S. (1998). Cost of Implementing pharmaceutical care in 
community pharmacies. J Am Pharm Assoc, 38:755-61. 
O'Brien, B., Torrance, G., & Streiner, D. (1995). Assessing the economic value of a new 
antidepressant: A willingness to pay approach. Pharmacoeconomics, 8:34-35. 
Oparah, A. C., & Eferakeya, A. E. (2005). Attitude of Nigerian pharmacists towards Pharmacy  
Pearson, G. J. (April 24, 2007). Evolution in the practice of pharmacy—not a revolution! . 
Canadian Medical Association Journal, 1295-1296. 
Pharmaceutical Society of South Africa. (2010, February). PSSA. Retrieved February 16, 2010, 
from Pharmaceutical Society of South Africa: 
http://www.pssa.org.za/index.php?option=com_content&task=view&id=14&ltemid=45 
Pioneer, A. P. (1997). A Pharmacy pioneer. Int Pharm J, 69. 
Piorier, S., & Gariepy, Y. (1996). Compensation in Canada for resolving drug-related problems.  
J Am Pharm Assoc, 117-122. 
Raisch, D. (1993). Barriers to providing cognitive services. Am Pharm, NS33(12):54-8. 
Republic of South Africa. (2004). Pharmacy Act: Rules and Regulations: Services for which a 
pharmacist may levy a fee and guidelines for levying such a fee or fees. Gazette 26904, Notice 
106.   
Republic of South Africa. (2007). Pharmacy Act: Rules and Regulations. Services for which 
pharmacists may levy fees and guidelines for levying such fees. Gazette 29643. 
Read, R., W., & Krska, J. (1998). Targeted medication review: patients in the community with 
chronic pain. Int J Pharm Pract, 6: 216-22 
Rexy, J., & Shruti, S. (2006). Pharmacists: To Move Forward with Principles and the Practice of 
Pharmaceutical Care. JASA , 41-43. 
Rossi, P. H., Wright, J. D., & Anderson, A. B. (1983). Handbook of Survey Research. Academic  
Press. Inc 
 
  
161 
Roughead, L., Semple, S., & Vitry, A. ( 2002). The value of Pharmacist Professional Services in 
the community setting. A systematic review of the literature 1990-2002. Adelaide: University 
South of Australia, 120-135. 
Rovers, J., Currie, J., Hagel, H., McDonough, R., & Sobotka, J. (1998). A Pratical Guide to 
Pharmaceutical Care. Am. Pharm. Assoc. 
SA-Info Reporter. (2010, November 26). Education in South Africa. Retrieved November 
Friday, 2010, from South Africa.Info:http://www.southafrica.info/about/education/education.htm 
SAinfo Reporter. (2010, December 17). South Africa.Info. Retrieved December 17, 2010, from 
South Africa Info: http://www.southafrica.info/about/health/health.htm 
Sakthong, P. (2007). Comparative analysis of pharmaceutical care and traditional dispensing role 
of pharmacy. Thailand Journal of Pharmaceutical Sciences, 31: 100-104. 
Schemes, C. f. (2010, October 4). Medical Schemes. Retrieved November 15, 2010, from 
Council for Medical Schemes: http://www.medicalschemes.com/MedicalSchemes.aspx 
Schneider, J., & Nickman, N. (1994). Assessment of pharmaceutical care needs in an ambulatory 
setting. Hosp Pharm, 29: 238-42. 
Shafie, A. A., & Hassali, M. A. (2010). Willingness to pay for a pharmacist's dispensing service: 
a cross-sectional pilot study in the state of Penang, Malaysia. Pharmacy Practice, 8(2): 116-121. 
Shepherd, M. (1999). Pharmaceutical Care: adding value to the future. Am Pharm, NS31:303-8. 
Shu Chuen Li. (2003). An introduction to pharmacoeconomic evaluation in rheumatology. 
APLAR Journal of Rheumatology, 6: 192–200. 
Shu Chuen Li, L. (2003). An Overview of Community Pharmacist Interventions: Assessing 
Cost-effectiveness and Patients' Willingness to pay. Manage Health Outcomes, 11:95-106. 
Simpson, D. (1997). Pharamceutical Care: The Minnesota Model. The Pharamceutical Journal, 
258:899-904. 
Smith, D., Fasset, W., & Christensen. (1999). Washington state CARE project: downstream cost 
changes associated with provision of cogntive services by pharmacists. J Am Pharm Assoc, 
39:650-657. 
Smith, W., Ray, M., & Shannon, D. (2002). Physicians' expectations of Pharmacists . Am J 
Health Syst Pharm, 59:50-7. 
Statistics South Africa. (2010, November 23). Gross Domestic Product. Retrieved November 24, 
2010, from Statistics South Africa: 
http://www.statssa.gov.za/publications/P0441/P04413rdQuarter2010.pdf 
  
162 
Statistics South Africa. (2006). Income and expenditure of households. Retrieved November 24, 
2010, from statistic South Africa: http://www.statssa.gov.za/ies/Pamphlet.pdf 
Statistics South Africa. (2010, July 14). Statistical Release. Retrieved November 24, 2010, from 
Statistics South Africa: http://www.statssa.gov.za/publications/P0302/P03022010.pdf 
Strand, L., & Cipolle, R. (2004). The Impact of Pharmaceutical Care Practice on the Practitioner 
and the Patient on the Ambulatory Practice Setting:Twenty-Five years of experience. Current 
Pharmaceutical Design , 10:3987-4001. 
Strand, L., & Hepler, C. (1997). Pharmaceutical Care: The Minessota Model. The 
Pharmaceutical Journal, 258:899-904. 
Studenmund, A. (2000). Using Econometrics: A Practical Guide. California: Addison Wesley 
Longman. 
Suh, D. (2000). Consumers' Willingness to pay for Pharmacy Services that reduce Risk of 
Medication-Related Problems. J Am Pharm Assoc, 40(6):818-827. 
Summers, K. H., (1996). The ‗rebirth‘ of cognitive services. In: Smith MC, Wertheimer AI, 
editors. Social and behavioral aspects of pharmaceutical care. Binghamton (NY): Haworth Press, 
675-714 
Swift, B. (1993). Barriers to pharmaceutical care in the home care setting. Am J Hosp Pharm, 
50:1614-7. 
Sykes, A. O. (2008). An Introduction to Regression Analysis. Chicago Working Paper in Law & 
Economics, 1-33. 
Terre Blanche, M., & Durrheim, K. (1999). Research in Practice. Cape Town: The University of 
Cape Town Press. 
The Free Market Foundation of Southern Africa. (2005). Comments on an increase in the Single 
Exit Price of medicines. Health Policy Unit, 1-5. 
Thiedei, M., & McIntyrei, D. (2007). Health Care Financing and Expenditure. Health Economics 
Unit, University of Cape Town, 35-46. 
TNS Research surveys. (2010, July 27). Bizcommunity.com. Retrieved November 24, 2010, from 
Bizcommunity.com: http://www.biz-community.com/Article/196/19/49191.html 
Townsend, R. (1986). Post marketing drug research and development: an industry clinical 
pharmacist's prspective. Am J Pharm Educ, 50:480-2. 
Townsend, R. (1987). Postmarketing drug research and development. Drug Intell Clin Pharm, 
134-6. 
  
163 
Tustin, Ligthelm, Martins, & Wyk, V. (2005). Marketing Research in Practice. Pretoria, 
SouthAfrica: Unisa Press. 
United States Department of Agriculture (USDA). (2009, May). Willingness-to-Pay Approach. 
Retrieved December Thursday, 2010, from Economic Research: 
http://www.ers.usda.gov/publications/aer784/aer784e.pdf 
Van Amburgh, J. A., Waite, N. M., &Hobson, E. H. (2001). Improved influenza vaccination 
rates in a rural population as a result of a pharmacist-managed immunization campaign. 
Pharmacotherapy, 21: 1115-22 
Venturini, F., & Johnson, K. (2002). Introduction to Pharmacoeconomic Principles and 
Application in Pharmacy Practice. Carlifornia Journal of Health-Systems Pharmacy, 6-14. 
Walley, T., Haycox, A., & Boland, A. (2004). Pharmacoeconomics. Philadelphia: Churchill 
Livingstone. 
Wessels, F., Rheeder, P.  2003.  Pharmacoeconomics:  the value argument behind  
medicine (Training workshop presentation, August 21, Johannesburg, South Africa).   
Unpublished 
 
Wikimedia foundation. (2010, Novemebr Tuesday). Retrieved November 16, 2010, from 
Wikipedia The Free Encyclopedia: http://en.wikipedia.org/wiki/Analysis_of_variance. 
Zermansky, A. G., Petty, D. R., & Raynor, D. K. (2001).Randomised controlled trial of clinical 
medication review by a pharmacist of elderly patients receiving repeat prescriptions in general 
practice. British Medical Journal, 323: 1340-3. 
 
  
 
 
 
 
 
 
 
 
 
 
  
164 
 
PERMISSION TO SUBMIT A TREATISE/DISSERTATION/THESIS 
FOR EXAMINATION 
Please type or complete in black ink 
FACULTY:  ____Health Sciences               __________________________________ 
SCHOOL/DEPARTMENT: ____Pharmacy__________________________________ 
I, (surname and initials of supervisor/promoter) ____Sue Burton__________________ 
and (surname and initials of co-supervisor/co-promoter) _________________________ 
the supervisor/promoter and co-supervisor/co-promoter respectively for (surname and initials of candidate) 
____________Irvine Tawanda Mushunje 
(student number) __204009553__________a candidate for the (full description of qualification) 
___Magister Pharmaciae_______________________________ 
with a treatise/dissertation/thesis entitled (full title of treatise/dissertation/thesis): 
_Willingness to pay for pharmacist-provided services directed towards reducing risks of medication-related problems 
hereby certify that we give the candidate permission to submit his/her treatise/ dissertation/ thesis for examination._
_   10/01/2012 
 
SUPERVISOR / PROMOTER     DATE 
 
________________________    _________________ 
CO-SUPERVISOR / CO-PROMOTER 
 
 
APPENDIX 1: PERMISSION TO SUBMIT A TREATISE 
APPENDIX 2: LETTER OF APPROVAL FROM ETHICS COMMITTEE 
  
165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX 3: COVER LETTER TO THE PATIENT 
  
166 
           Department of Pharmacy 
         Faculty of Health Sciences 
 Tel: 0027-41-504-2128 
 30-January-2010 
Dear Patient, 
Willingness to Pay for Pharmacist Provided 
Services directed towards reducing risks of Medication Related Problems 
 
Thank you very much for your desire to sacrifice your valuable time to participate in this research study. In order to 
fulfill the requirements for the Master‘s degree in Pharmacy, at the Nelson Mandela Metropolitan University, I am 
conducting an investigation into the patients‘ willingness to pay for pharmacist provided services so as to reduce 
medication related problems.  The objectives of this study are: to ascertain the perceived value of the pharmacist 
provided services by patients in South Africa, to determine factors that influence willingness to pay (WTP), such as 
patient‘s financial status, gender, race, age and others, as well as making recommendations to South African 
Pharmacy Council or society (including any other interested parties) on the development and viability of disease 
state management programes.  
In order for you to participate, you will be required to sign the consent form and provide the recruiting pharmacist 
with your telephonic details and you will be contacted by the researcher at a time convenient to you to fill in the 
questionnaire.  
 Your assistance in completing this questionnaire will be highly appreciated. Your response will be anonymous, so 
confidentiality is assured. The questionnaire should only take 15 minutes of your precious time. 
 Please do not hesitate to contact the researcher below should you require any more information on this survey. 
Yours sincerely, 
Irvine Tawanda Mushunje                   Mrs. Sue Burton 
Researcher      Supervisor 
Tel: 072-402-8234     Tel: 041-5044212 
Fax: 011 480 5981     Email: susan.burton@nmmu.ac.za 
Email: vinnyceutics@gmail.com 
 
 
 
APPENDIX 4: COVER LETTER TO THE PHARMACIST 
  
167 
           Department of Pharmacy 
 Faculty of Health Sciences 
 Tel: 0027-41-504-2128 
 30-January-2010 
Dear Pharmacist, 
Willingness to Pay for Pharmacist Provided 
Services directed towards reducing risks of Medication Related Problems 
 
Thank you very much for your willingness to sacrifice your valuable time to participate in this research study. In 
order to fulfill the requirements for the Master‘s degree in Pharmacy, at the Nelson Mandela Metropolitan 
University, I am conducting an investigation into the patients‘ willingness to pay for pharmacist provided services 
aimed at reducing medication related problems.  The objectives of this study are: to ascertain the perceived value of 
the pharmacist provided services by patients in South Africa, to determine factors that influence willingness to pay 
(WTP), such as patient‘s financial status, gender, race, age and others, as well as making recommendations to South 
African Pharmacy Council or society (including any other interested parties) on the development and viability of 
disease state management programes.  
The pharmacy profession in SA has faced a lot of challenges in the past few years, following the implementation of 
Single Exit Pricing (SEP) system. For survival, the profession has to look into levying a fee for the already provided 
pharmaceutical care services as well as pioneering disease state management programs in pharmacies, to improve 
patient care and create revenue for the pharmacist. The study is being conducted nationally to ascertain the demand 
for these services in South Africa and the patients‘ willingness to pay for them, as well as the third party payers‘ 
willingness to remunerate the pharmacist on behalf of the patient. We hope the study will also serve as a guideline to 
the South African Pharmacy Council in formulating the much needed professional fee charge. 
Your assistance is greatly appreciated in recruiting at least ten patients in your pharmacy based on the following 
inclusion criteria: 
 patients must be patrons to the pharmacy, at least have had two or more of their acute or chronic 
prescriptions filled at this pharmacy, 
 patients must be above the age of 21, and 
 patients must be able to read and write and understand English. 
The selected patients should be given the study research package which includes the patient cover letter, consent 
form and the questionnaire.  We would gratefully appreciate if you could explain to the patient what the study is all 
about beforehand. 
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 We kindly request you to collect and record all the recruited patients‘ details in the provided patient recruitment 
sheet. The study will be conducted telephonically, thus it is imperative that you record the patient‘s research code 
number, telephone numbers and the convenient time to call them. Patients should be encouraged to familiarize 
themselves with the questionnaire beforehand.  
If you would like any further information about the study please do not hesitate to contact the researcher. Your co-
operation is greatly appreciated.  
Yours sincerely 
Irvine Tawanda  Mushunje    Mrs. Sue Burton 
Researcher      Supervisor 
Tel: 072-402-8234     Tel: 041-5044212 
Fax: 011 480 5981     Email: susan.burton@nmmu.ac.za 
Email: vinnyceutics@gmail.com 
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Title of the research project 
 
Willingness to Pay for Pharmacist Provided 
Services directed towards reducing risks of Medication Related Problems 
 
Principal researcher Irvine Tawanda Mushunje 
Address 
 
 
Postal Code 
c/o Department of Pharmacy 
P O Box 77000 
Nelson Mandela Metropolitan University 
Port Elizabeth. 6031 
Contact telephone number 011 480 5698 
 
A. DECLARATION BY OR ON BEHALF OF PARTICIPANT 
 (Person legally competent to give consent on behalf of the participant) 
 
Initial 
 
I, the participant and the undersigned  
 
Research code/name 
 
(full names)   
 
 
B.1 I HEREBY CONFIRM AS FOLLOWS:  
I, the participant, was invited to participate in the above-mentioned research project that is being  
undertaken by 
of the Department of pharmacy in the Faculty of health sciences, of the Nelson Mandela Metropolitan University. 
2. The following aspects have been explained to me, the participant: 
Aim:  Willingness to Pay for Pharmacist Provided 
Services directed towards reducing risks of Medication Related Problems 
 The information will be used to/for: 
 To help demonstrate to the South African Pharmacy Council the extent to which patients are willing to pay 
for pharmacist provided services. 
 
 
 2.1 Risks: There are no risks associated with the respondents to this questionnaire.  All information supplied 
will be treated with the strictest of confidence.  No name will be attached to the questionnaire. 
 
2.2 Confidentiality:  My identity will not be revealed in any discussion, description or scientific 
 publications by the investigator.  All the questionnaires are coded to facilitate recording but no name will be 
written on the questionnaire.  All feedback will be anonymous with no association to an individual. 
 
2.3            Access to findings: 
Would you like to get a copy of the findings of this study, do not hesitate to indicate this so that you can make contact 
 
Irvine TawandaMushunje 
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with the researcher at the completion of the study.  The results will be presented at various conferences and symposia 
in South Africa. 
2.4 Voluntary participation/refusal/discontinuation: 
                  My participation is voluntary 
 My decision whether or not to participate will in no way affect my present or future 
 care/employment/lifestyle 
 
 2.5 (a). I was given the opportunity to ask questions and all these questions were answered satisfactorily. 
      (b).No pressure was exerted on me to consent to participation and I understand that I may withdraw at any stage 
without penalization. 
      (c).Participation in this study will not result in any additional cost to myself. 
 
 
 
C. I HEREBY VOLUNTARILY CONSENT TO PARTICIPATE IN THE ABOVE-MENTIONED 
 PROJECT  
 
  
 
 
 
D. IMPORTANT MESSAGE TO PARTICIPANT 
Dear participant 
 
Thank you for your participation in this study.  Should, at any time during the study: 
- an emergency arise as a result of the research, or 
- you require any further information with regard to the study  
  
 
 
 
 
 
 
 Questionnaire 1 (Administrator)…………………… 
YES NO 
YES NO 
Signed/confirmed at 200 ON 
Signature of applicant 
Signature of witness 
Kindly contact Irvine Tawanda Mushunje 
at 072 402 8234 
APPENDIX 6: QUESTIONNAIRE ONE (Research Process Phase-1) 
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Please provide the following information regarding yourself. 
SECTION A: DEMOGRAPHICS  
 
Please respond by ticking in the appropriate box. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. What is your occupation? ……………………………………………………………………….  
7. How many people live in your house hold?  
 
1. How old are you? 21-30 
2.  What is your gender? 
3.  What is your racial group? White Coloured Asian 
If other (please specify): 
Black 
 
4.  What is your highest level of  
education? 
 
Pre-Matriculate 
Matriculate 
College Qualification  
Other (please specify):  
Undergraduate 
Graduate 
Post-graduate 
Unemployed 
Self-Employed 
Student 
Other (please specify):  
Employed (full time) 
Employed (part-time) 
Pensioner/Retired 
5.  What is your current 
employment status?  
31-40 
 
 
41-50 
51-60 
 
 
61-70 
71-80 
 
 
81+  
         Female Male   
  Adults Children < 18 
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10. How much would you be willing to pay for the following? 
 
a) A new car        c) Membership at a fitness club 
 
b)  A night out with friends      d) A week’s vacation 
 
11. How many hours in a week do you spend on the following? 
 
a) Income generating activities (this includes full and part time work, time at university or 
study time for students) 
 
b) Recreational activities (this is your leisure time, and includes sporting activities, societies, 
basic social activities) 
 
c) Family (this is time you specially set aside for your family.)  
d) Spiritual or religious activities   
 
12. Are you on any medical aid or hospital plan?                    
13. If yes to Question 13 above, please answer the following question below? 
a)  If yes, which medical aid do you belong to?    
b)   What hospital plan do you have?                                                       
8.  What is your total monthly household 
income (R)? 
9. What is your average monthly household expenditure on food and groceries(R)? 
500-750 
  751-1000 
1001-1250 
1251-1500 
1501-1750 
1751-2000 
More than 
      3000 
2001-2250 
2251-2500 
2501-2750 
2751-3000 
<2000 
2001 - 5001 
 
 
5001- 10000 
10001-15000 
 
 
 15001 - 20000 
>20001 
 
 
R 
R 
R 
R 
Hrs 
YES NO 
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c)   What is your monthly medical aid premium? 
Employer’ contribution R 
Self-contribution R 
 
14. Do you suffer from any chronic condition?    
15. If yes to question 14 above, please specify the condition, appropriate date of diagnosis and the 
medication being used to manage it;  
Chronic Disease Date of diagnosis Medication being used to manage condition 
   
   
   
   
   
   
 
SECTION B: DOCTOR’S CONSULTATION 
16. On average how many times do you visit a doctor for consultation, in a year? 
 
17. Thinking about your last visit to the doctor, did he/she ask any information 
concerning: 
YES NO 
a) the  presence of any allergies,   
b) other medical conditions you might have,   
c) any other current prescription medications you might be taking or over the counter?   
 
 
 
YES NO 
YES NO 
18. During consultation, did the doctor explain clearly the following? 
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a) the nature of your condition    
b) the diagnosis   
c) reasons for the prescribed medicines   
d) how the medication is expected to work   
e) how the medication is administered   
f) and, any possible side effects   
19. Where you given a chance to ask questions, if you had any 
 
 
SECTION C: COGNITIVE PHARMACEUTICAL CARE SERVICES (CPCS) 
20. Is this your pharmacy of choice, for getting your monthly medicines?  
 
21. If yes to question 20 above, on average how many times do you visit the pharmacy in a month? 
 
22. Are you aware that the pharmacy keeps record of all your past and present medication records 
obtained from them? 
23. How many other pharmacies do you use to get both your acute and chronic prescribed medications? 
Please indicate number  
 
Thinking about your last time you got prescription medication from a pharmacist, please 
answer questions, 24 and 25 below;   
 
 
YES NO 
a) the  presence of any allergies,   
YES NO 
YES 
                            times 
NO 
 
YES NO 
24. Did the pharmacist ask any information concerning the following? 
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b) other medical conditions you might have,   
c) any other current prescription medications you might be taking or over the counter?   
 
YES NO 
a) the different types of the medication dispensed, as well as their function   
b) the appropriate use of the medications   
c) how the medication is administered   
d) how the medication is expected to work   
e) and, any possible side effects   
 
26. Where you given a chance to ask questions, if you had any? 
 
27. When you have received prescription medications from a pharmacist, have you ever been aware of 
the pharmacist needing to communicating with your doctor, if need be? 
 
28. If yes to question 28, have you ever been given feedback by your pharmacist,with regards to the 
communication with the prescribing doctor about your prescription? 
 
29. Where you given a chance to ask questions, if you had any? 
  
30. How satisfied were you with the pharmaceutical care service provided by the pharmacist? 
Please indicate your response by placing a tick in any one of the boxes shown below 
 
 
31. Do you think it is important for pharmacists to spend their time counseling patients and providing 
pharmaceutical care? 
Please indicate your response by placing a tick in any one of the boxes shown below 
NO 
1 Dissatisfied 
YES 
25. When giving you your medication, did the pharmacist explain clearly the following? 
YES NO 
3 Satisfied 4 Very Satisfied 
1 Not important 2 Slightly important 3 Important 4 Very important 
YES NO 
YES NO 
2 Slightly Satisfied 
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32. What is the longest time you have spent before, consulting with a pharmacist?  
 
33. What is the average time you have spent before, consulting with a pharmacist?  
 
34. In your own opinion, how many minutes do you think a pharmacist should spend in a counseling 
session with you, on average? 
 
 
 
When a prescription drug is given to a patient, medication-related problems may result. 
Medication-related problems may include untreated indications, improper drug selection, 
doses too low, overdose, adverse drug reactions and medication interactions. 
35. Have you or any member of your family ever experienced a medication related problem before? 
 
36. If YES to question 37 above, who did you discuss the medication related problem with? 
Please indicate your response by placing a tick in any one of the boxes shown below 
 Pharmacist  Medical doctor  Nurse 
 All the above  Other (Specify) 
 
37. In your opinion, who is the right person to manage your medication therapy? 
…………………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………………
……………………………………………… 
SECTION D: WILLINGNESS TO PAY  
 
Minutes 
YES NO 
“Imagine that when you submit your prescription, the pharmacist would spend a certain amount of private time 
with you discussing your medications in an effort to reduce the potential for medication-related problems.” 
During the consultation, assume the pharmacist’s counseling services would include the following: 
 Reviewing all your previous and current medications you are taking 
 Linking each current medication to its appropriate indication 
Minutes 
Minutes 
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Please answer the following questions with reference to the above scenario. 
38.  How much will you be willing to pay the pharmacist, for providing the above mentioned services 
given that, it would decrease the risk associated with medication-related problems by a given 
percentage? 
Risk reduction of 
Medication-Related 
Problems (MRP) 
Willingness To Pay/ZAR                    
(Out  of pocket) 
How much do you think your 
medical aid should pay?  /(ZAR) 
30%   
60%   
>90%   
 
 
 
Any other comment you would like to add? 
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Thank you very much for your desire to sacrifice your valuable time to 
participate in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Questionnaire 2 (Specific to medical aid respondents) 
APPENDIX 7: QUESTIONNAIRE TWO (Research Process Phase-2) 
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Section A: Demographics  
 
Name of Company:…………………………………          Date:……………………………. 
1. Approximately how many members do you have?  
2. What percentage of your members are on day to day benefit plan or have a MSA benefit  
3.Approximately, how many members do you have who are registered on chronic medication benefit?  
4. What is the average total monthly premium contribution per member, including all the dependents on 
the plan? 
 
5. On average how many times does the member visit a doctor for consultation, on a monthly basis?  
6. On average how many times does the member visit a pharmacy on a monthly basis?  
 
SECTION B: DOCTOR’S CONSULTATION 
 
YES NO 
a. their medical condition,   
b. how to use their medications appropriately?   
 
8.  If no, what do you propose should be done to inform the patients? 
 
 
 
 
9. Do you have any members who have been hospitalized due to medication related problems (for 
example adverse drug reactions)? YES NO 
7. Generally during doctor‘s consultationsdo you think your members are adequately counseled on; 
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10. If yes to question 9 above, please specify approximate number of hospitalization cases on 
monthly bases?  
11.  In your own opinion, what do you think could be done to reduce the number of hospitalization 
cases due medication related problems?  
 
 
 
 
SECTION C: Cognitive Pharmaceutical Care Services (CPCs) 
 
 
 
 1 2 3 4 
Educating the patient about their disease state     
Advising patients on how to administer their medications appropriately     
Screening and monitoring services     
Disease state management programes (e.g. asthma, hypertension, hormone replacement therapy)     
Reducing hospital incidents due to medication related problems     
Improving the general quality of life of patients     
 
 
13. On a scale of 1 to 4, during consultation how important is it for a pharmacist to explain and 
discuss the following information with a patient; 
KEY 
KEY 
1 Strongly non-influential 
 
2 Slightly influential 
 
3 Moderately influential 
 
4 Strongly influential 
 
 12. On a scale of 1 to 4, what role do youthink the pharmacist plays in the following? 
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 1 2 3 4 
The medication in terms of name, description, dosage form, route of administration, dosage 
frequency, storage, scheduling status and duration of therapy 
    
Generic substitution and the difference from the brand drug     
How the medication treats their medical condition      
Potential adverse effects and strategies to avoid or manage them     
How the effects of the medication will be monitored      
 
SECTION D: Willingness to pay (WTP) 
When a prescription drug is given to a patient, medication-related problem may result. Medication-related 
problems may include, untreated indications, improper drug selection, sub-therapeutic dosage, overdose, 
adverse drug reactions, medication interaction or medication use without indication 
 
 
 
 
 
 
 
14. How many minutes,on average, do you think the pharmacist should spend counseling the patient? 
 
15. How much do you think your company should be willing to pay the pharmacist, on behalf of the 
patient, if the services provided would decrease the risk associated with medication-related 
problems by a given percentage? 
“Imagine that when a patient submits a prescription, the pharmacist would spend a certain amount of private time with the patient 
discussing their medications in an effort to reduce the potential for medication-related problems.” 
During the consultation, assume the pharmacist‘s counseling services would include the following: 
 Reviewing all your previous and current medications you are taking 
 Linking each current medication to its appropriate indication 
 An explanation of:  
 The medication in terms of name, description, dosage form, route of administration, dosage frequency, 
scheduling, and duration of therapy 
 How the medication treats your medication condition 
 Potential adverse effects and strategies to avoid or manage them 
 How the effect of the medication will be monitored 
 And, communicating with your doctor if necessary. 
“Assuming that there is willingness to pay for a full comprehensive pharmaceutical care service offered by the pharmacist as 
depicted by the hypothetical scenario above, please answer the following questions.” 
1 Not important 
 
2 Slightly important 
 
3 Important 
 
4 Very important 
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Risk reduction of Medication-Related Problems 
(MRP) 
Willingness To Pay/ZAR                   
30%  
60%  
>90%  
 
 
Any other comment you would like to add?  
 
 
 
 
 
 
 
Thank you very much for your desire to sacrifice your valuable time to participate in this study. 
 
 
 
 
 
 
APPENDIX 8:DATA COLLECTION TOOL 
 
Standard patient recruitment sheet: 
  
183 
Pharmacy details 
Name of the pharmacy  
Pharmacy Address  
 
Telephone number  
Fax  number  
Pharmacist name   
 
Respondents recruitment list 
Date of 
recruitment 
Name of patient / Patient’s 
recruitment code number 
Patient’s  contact 
numbers 
Interview appointment 
Date Time 
     
     
     
     
     
     
     
     
     
     
 
Medical Aid respondents’ recruitment sheet: 
 
Respondents recruitment list 
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Name of Medical aid 
company 
Contact numbers Respondent’s code number/ 
email address 
Interview appointment 
Date Time 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
 
 
 
 
Respondents recruitment list 
APPENDIX 9: MEDICAL AID LIST 
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Name of Medical aid 
company 
Respondent’s email address Respondent’s contact 
number 
 
1 AECI MEDICAL AID SOCIETY louisw@aeci.co.za (011)-510-2717 Restricted  
2 AFRISAM SA MEDICAL 
SCHEME 
 (011)-767-7242 Restricted  
3 AFROX MEDICAL AID SOCIETY michael.rowell@afrox.linde.com (011)-703-3010 Restricted  
4 ALLIANCE MIDMED MEDICAL 
SCHEME 
hartzenberg.johan@columbus.co.za (086)-000-2101 Restricted  
5 ALTRON MEDICAL AID 
SCHEME 
rsedlmaier@altron.com (011)-290-6200 Restricted  
6 ANGLO MEDICAL SCHEME fiona.robertson@angloamerican.co.za (011)-638-5471 Restricted  
7 ANGLOVAAL GROUP MEDICAL 
SCHEME 
vivienc@avi.co.za (086)-010-0693 Restricted  
8 BANKMED LMcDonald@bankmed.co.za (080)-022-65633 Restricted  
9 BARLOWORLD MEDICAL 
SCHEME 
jpmurphy@barloworld.com (011)-510-2000 Restricted  
10 BMW EMPLOYEES MEDICAL 
AID SOCIETY 
anthony.kelbrick@bmw.co.za (086)-000-2107 Restricted  
11 BP MEDICAL AID SOCIETY ilse.hartlief@za.bp.com 021-4804610 Restricted  
12 BUILDING & CONSTRUCTION 
INDUSTRY MEDICAL AID 
FUND 
halroux@iafrica.com (11)-208-1000 Restricted  
13 BUILT ENVIRONMENT 
PROFESSIONAL 
ASSOCIATIONS MEDICAL 
SCHEME (BEPMED) 
 031-5734000 Restricted  
14 CHARTERED ACCOUNTANTS 
(SA) MEDICAL AID FUND 
(CAMAF) 
Bruce.Dickson@camaf.co.za 011-7078400 Restricted  
15 CLICKS GROUP MEDICAL 
SCHEME 
 021-4601202 Restricted  
16 DE BEERS BENEFIT SOCIETY leon.coetzee@dbpf.co.za (053)-807-3111 Restricted  
17 EDCON MEDICAL AID SCHEME MMoodley@edcon.co.za (011)-495-6707 Restricted  
 
18 ENGEN MEDICAL BENEFIT 
FUND 
nazeem.salie@engenoil.com (021)-480-4796 Restricted  
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19 EYETHUMED MEDICAL SCHEME anthony@fundsadmin.co.za (086)-050-2502 Restricted  
20 FISHING INDUSTRY MEDICAL 
SCHEME (FISH-MED) 
alidas@ij.co.za 021-4029927 Restricted  
21 FOOD WORKERS MEDICAL 
BENEFIT FUND 
appollis@foodmed.co.za 021-9303550 Restricted  
22 FOSCHINI GROUP MEDICAL AID 
SCHEME 
 (021)-480-5064 Restricted  
23 GOLD FIELDS MEDICAL 
SCHEME 
elias.mabena@goldfields.co.za (041)-395-4400 Restricted  
24 GOLDEN ARROWS EMPLOYEES 
MEDICAL BENEFIT FUND 
mariehettelouwsma@gabs.co.za (021)-937-8800 Restricted  
25 GOVERNMENT EMPLOYEES 
MEDICAL SCHEME (GEMS) 
eugene@gems.gov.za (012)-362-6321 Restricted  
26 GRINTEK ELECTRONICS 
MEDICAL AID SCHEME 
hein.morkel@za.saabgroup.com (011)-208-1000 Restricted  
27 IBM (SA) MEDICAL SCHEME halroux@iafrica.com (086)-010-0418 Restricted  
28 IMPALA MEDICAL PLAN johan.dewaal@implats.co.za 014-5697597 Restricted  
29 IMPERIAL GROUP MEDICAL 
SCHEME 
johan@cedareb.co.za (011)-821-5503 Restricted  
30 LA-HEALTH MEDICAL SCHEME adekoker@lahealth.co.za (021)-555-4727 Restricted  
31 LIBCARE MEDICAL SCHEME tracey.unser@libcare.co.za (080)-012-2273 Restricted  
32 LONMIN MEDICAL SCHEME Sifiso.Sibeko@lonmin.com (086)-010-4883 Restricted  
33 MALCOR MEDICAL SCHEME droseveare@allcare.co.za (011)-372-1500 Restricted  
34 MASSMART HEALTH PLAN jhawksl@massmart.co.za (086)-000-2117 Restricted  
35 MBMED MEDICAL AID FUND neville.walton@daimler.com (011)-510-2000 Restricted  
36 MEDIPOS MEDICAL SCHEME Francina.Mosoeu@postoffice.co.z
a 
(086)-010-0078 Restricted  
37 METROCARE  fkotze@metcash.co.za (086)-000-2123 Restricted  
38 METROPOLITAN MEDICAL 
SCHEME 
rodutoit@metropolitan.co.za (086)-188-8104 Restricted  
39 MINEMED MEDICAL SCHEME pat.kmohale@harmony.co.za (041)-395-4400 Restricted  
40 MOREMED MEDICAL SCHEME  (086)-010-1103 Restricted  
41 MOTOHEALTH CARE murida.khan@motohealthcare.org (086)-132-9800 Restricted  
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42 NAMPAK (SA) MEDICAL 
SCHEME 
sue.steyn@za.nampak.com 011-7196300 Restricted  
43 NASPERS MEDICAL FUND jlouw@media24.co.za (021)-406-3186 Restricted  
44 NEDGROUP MEDICAL AID 
SCHEME 
julial@nedbank.co.za (021)-412-3814 Restricted  
45 NETCARE MEDICAL SCHEME craig.taylor@netcare.co.za (031)-573-4000 Restricted  
46 OLD MUTUAL STAFF MEDICAL 
AID FUND 
FReynolds@oldmutual.com (021)-509-7036 Restricted  
47 PARMED MEDICAL AID SCHEME dawnd@xsinet.co.za (086)-000-2126 Restricted  
48 PG BISON MEDICAL AID 
SOCIETY 
HALROUX@IAFRICA.COM 011-2906200 Restricted  
49 PG GROUP MEDICAL SCHEME llongley@pg.co.za (11)-417-5800 Restricted  
50 PICK N PAY MEDICAL SCHEME avisser@pnp.co.za (080)-000-4389 Restricted  
51 PLATINUM HEALTH Wmboniso@angloplat.com (014)-591-3069 Restricted  
52 PROFMED grahama@profmed.co.za (011)-628-8904 Restricted  
53 QUANTUM MEDICAL AID 
SOCIETY 
wissler@mweb.co.za (086)-010-2958 Restricted  
54 RAND WATER MEDICAL 
SCHEME 
mnyembe@randwater.co.za (011)-682-0560 Restricted  
55 REMEDI MEDICAL AID SCHEME bushjep@intekom.co.za 0860-102472 Restricted  
56    Restricted  
57 RETAIL MEDICAL SCHEME msmith@shoprite.co.za (021)-980-4465 Restricted  
58 RHODES UNIVERSITY MEDICAL 
SCHEME 
r.marriner@ru.ac.za (041)-395-4476 Restricted  
59 S A BREWERIES MEDICAL AID 
SOCIETY 
Belinda.Phillips@za.sabmiller.co
m 
(086)-000-2133 Restricted  
60 SABC MEDICAL AID SCHEME anthony@fundsadmin.co.za (086)-000-2136 Restricted  
61 SAMWUMED neiln@samwumed.org 021-6979000 Restricted  
62 SAPPI MEDICAL AID SCHEME principalofficer@polmed.co.za (086)-010-1280 Restricted  
63 SASOLMED freddy.beukes@sasol.com (086)-000-2134 Restricted  
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64 SEDMED sau.sedmed@adventist.org.za 051-4478271 Restricted  
65 SIEMENS MEDICAL SCHEME Anne.petricevic@siemens.com (011)-671-2000 Restricted  
66 SOUTH AFRICAN POLICE 
SERVICE MEDICAL SCHEME 
(POLMED) 
principalofficer@polmed.co.za (012)-431-0239 Restricted  
67 STOCKSMED   (086)-000-2137 Restricted  
68 TIGER BRANDS MEDICAL 
SCHEME 
andre.koekemoer@tigerbrands.co
m 
011-2081000 Restricted  
69 TRANSMED MEDICAL FUND pwassermann@transmedfund.co.z
a 
011-4033358 Restricted  
70 TSOGO SUN GROUP MEDICAL 
SCHEME 
aland@tsogosungroup.com (086)-010-0421 Restricted  
71 UMED  (012)-667-8008 Restricted  
72 UMVUZO HEALTH MEDICAL 
SCHEME 
oosieo@umvuzohealth.co.za 012-8450000 Restricted  
73 UNIVERSITY OF KWA-ZULU 
NATAL MEDICAL SCHEME 
philippa.hempson@gmail.com (031)-260-1007 Restricted  
74 UNIVERSITY OF THE 
WITWATERSRAND STAFF 
MEDICAL AID SCHEME 
michaeldb@wbs.co.za 086000-2140 Restricted  
75 WITBANK COALFIELDS 
MEDICAL AID SCHEME 
hdejager@wcmas.co.za 013-6561407 Restricted  
76 WOOLTRU HEALTHCARE FUND keith@wbs-funds.co.za (21)-480-4849 Restricted  
77 XSTRATA MEDICAL AID 
SCHEME 
mretief@xstrata.co.za (086)-000-2141 Restricted  
78 BESTMED MEDICAL SCHEME drieslg@bestmed.co.za (012)-339-9800 Open  
79 BONITAS MEDICAL FUND bonitas@medscheme.co.za 011-5102000 Open  
80 CAPE MEDICAL PLAN principal@cmp.co.za 021-9378300 Open  
81 COMMUNITY MEDICAL AID 
SCHEME (COMMED) 
thabisilem@allcare.co.za (011)-290-6338 Open  
82 COMPCARE WELLNESS 
MEDICAL SCHEME 
halroux@iafrica.com (11)-208-1000 Open  
83 DISCOVERY HEALTH MEDICAL 
SCHEME 
miltons@discovery.co.za (011)-529-1533 Open  
84 FEDHEALTH MEDICAL SCHEME peter@fedhealth.co.za (086)-000-2153 Open  
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85 GEN-HEALTH MEDICAL 
SCHEME 
 (011)-353-0333 Open  
86 GENESIS MEDICAL SCHEME dvandermerwe@gmed.co.za (21)-442-9900 Open  
87 GOOD HOPE MEDICAL AID 
SOCIETY 
 (011)-208-1000 Open  
88 HOSMED MEDICAL AID SCHEME ceo@hosmedical.co.za (011)-895-8882 Open  
89 INGWE HEALTH PLAN  (086)-010-2493 Open  
90 KEYHEALTH barry.kruger@keymed.co.za (086)-067-1050 Open  
91 LIBERTY MEDICAL SCHEME epo@lhms.co.za (086)-000-2163 Open  
92 MEDIHELP arijnen@medihelp.co.za 012-3342000 Open  
93 MEDIMED MEDICAL SCHEME swynn@ccsabco.co.za (041)-395-4400 Open  
94 MEDSHIELD MEDICAL SCHEME duduzak@medshield.co.za (086)-000-2120 Open  
95 MOMENTUM HEALTH toniv@momentumhealth.co.za (086)-011-7859 Open  
96 NATIONAL INDEPENDENT 
MEDICAL AID SOCIETY (NIMAS) 
nimas@ispace.co.za 031-2517500 Open  
97 OXYGEN MEDICAL SCHEME  (021)-532-6800 Open  
98 PHAROS MEDICAL PLAN principalofficer@pharosmp.co.za (031)-267-5000 Open  
99 PRO SANO MEDICAL SCHEME aglaakm@prosano.co.za 021-9174440 Open  
100 PROTEA MEDICAL AID SOCIETY  (021)-552-7111 Open  
101 PUREHEALTH MEDICAL 
SCHEME 
 (086)-010-9393 Open  
102 RESOLUTION HEALTH MEDICAL 
SCHEME 
marka@resohealth.co.za 0861-7916425 Open  
103 SELFMED MEDICAL SCHEME nicolew@selfmed.co.za 021-9432300 Open  
104 SIZWE MEDICAL FUND mel.pohler@sizwe.co.za (11)-353-0000 Open  
105 SPECTRAMED rincipal.officer@spectramed.co.z
a 
(011)-582-0000 Open  
106 SUREMED HEALTH paiea@netactive.co.za (086)-008-0888 Open  
107 THEBEMED mamafhas@tybhealth.co.za 011-5448899 Open  
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108 TOPMED MEDICAL SCHEME john58@telkomsa.net 031-5734000 Open  
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APPENDIX 10: LETTER TO THE MEDICAL AID RESPONDENT 
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Faculty of Health Sciences  
Tel: 0027-41-504-2128  
25-May-2010  
 
Dear Sir/Madam,  
 
 
Willingness to Pay for Pharmacist Provided 
Services directed towards reducing risks of Medication Related Problems 
 
 
Thank you very much for your willingness to sacrifice your valuable time to participate in this research study. In 
order to fulfill the requirements for the Masters degree in Pharmacy, at the Nelson Mandela Metropolitan 
University, I am conducting an investigation into the patients‘ willingness to pay for pharmacist provided services 
aimed at reducing medication related problems. The objectives of this study are: to ascertain the perceived value of 
the pharmacist provided services by patients in South Africa, to determine factors that influence willingness to pay 
(WTP), such as patient‘s financial status, gender, race, age and others, as well as making recommendations to South 
African Pharmacy Council or society (including any other interested parties) on the development and viability of 
disease state management programes.  
 
The pharmacy profession in SA has faced a lot of challenges in the past few years, following the implementation of 
Single Exit Pricing (SEP) system. For survival, the profession has to look into levying a fee for the already provided 
pharmaceutical care services as well as pioneering disease state management programs in pharmacies, to improve 
patient care and create revenue for the pharmacist. The study is being conducted nationally to ascertain the demand 
for these services in South Africa and the patients‘ willingness to pay for them, as well as the third party payers‘ 
willingness to remunerate the pharmacist on behalf of the patient. We hope the study will also serve as a guideline to 
the South African Pharmacy Council, in formulating the much needed professional fee charge.  
 
Attached herewith, is a short questionnaire for your attention. Your assistance in completing this questionnaire will 
be highly appreciated. Your response will be anonymous, so confidentiality is assured. The questionnaire should 
only take 10-15 minutes of your precious time.  
Once completed I kindly request you to e-mail it back to the researcher at vinnyceutics@gmail.com , as shown 
below.  
 
Please do not hesitate to contact the researcher below should you require any more information on this survey.  
 
Yours sincerely 
Irvine Tawanda Mushunje                   Mrs. Sue Burton 
Researcher      Supervisor 
Tel: 072-402-8234     Tel: 041-5044212 
Fax: 011 480 5981     Email: susan.burton@nmmu.ac.za 
Email: vinnyceutics@gmail.com 
 
